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1 Introduction

Background 
Alkenylbenzenes are common components of spices and herbs such as tarragon, basil, 
fennel, mace, allspice, star anise and anise and their essential oils. Major examples of 
alkenylbenzenes are the compounds estragole (1-allyl-4-methoxybenzene) (Figure 1A) 
and methyleugenol (1-allyl-3,4-dimethoxybenzene) (Smith et al., 2002)(Figure 1B). 
At high dose levels estragole and methyleugenol and their 1′-hydroxy metabolites 
can induce hepatic tumours in mice (Miller et al., 1983). In 2000, the National Toxicology 
Program (NTP) has further investigated the carcinogenicity of methyleugenol and 
concluded that methyleugenol is carcinogenic in both rats and mice (NTP, 2000). 
Based on the rodent studies with estragole, methyleugenol and structurally related 
alkenylbenzenes the hepatocarcinogenicity of alkenylbenzenes is ascribed to their 
bioactivation by cytochrome P450 enzymes leading to the formation of the proximate 
carcinogen 1′-hydroxy metabolite (Figure 2) (Miller et al., 1983; Phillips et al., 1984; 
Randerath et al., 1984; Smith et al., 2002). Further bioactivation of the 1′-hydroxy 
metabolite requires the involvement of sulfotransferases (SULTs) which convert the 1′-
hydroxy metabolite to the ultimate carcinogenic 1′-sulfooxy metabolite (Figure 2). The 
1′-sulfooxy metabolite is unstable and covalently bind via presumed reactive carbocation 
intermediate to different endogenous nucleophiles including DNA (Phillips et al., 1981, 
1984; Boberg et al., 1983; Miller et al., 1983; Randerath et al., 1984; Fennell et al., 1985; 
Wiseman et al., 1987; Smith et al., 2002). Because of their genotoxicity the addition 
of estragole and methyleugenol as pure substances in foodstuffs has been prohibited 
within the European Union since September 2008 (European Commission, 2008). 
A significant difficulty in evaluating the metabolic and toxicological data for 
alkenylbenzenes is that human exposure to these substances results from exposure 
to a complex mixture of food, spice, and spice oil constituents which may influence 
the biochemical fate and toxicological risk of the alkenylbenzenes. For example, a 
methanolic extract of basil has been shown to inhibit the formation of estragole DNA 
adducts in human HepG2 cells exposed to the proximate carcinogen 1′-hydroxyestragole 
(Jeurissen et al., 2008). This inhibition occurred at the level of SULT-mediated 
bioactivation of 1′-hydroxyestragole into 1′-sulfooxyestragole (Jeurissen et al., 2008). 
The objective of this PhD research was to identify the SULT inhibitor(s) present in 
the basil extract able to inhibit the estragole DNA adduct formation and to identify 
the presence of other SULT inhibitors in a series of alkenylbenzene-containing herbs 
and spices. An additional objective was to predict the potential reduction in estragole 
Figure 1. Chemical structures of the alkenylbenzenes A) estragole and B) methyleugenol.
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and methyleugenol bioactivation when these compounds are consumed with either 
a single SULT inhibitor or a mixture of SULT inhibitors at relevant dose levels of the 
alkenylbenzene and the SULT inhibitor(s). An integrated approach of in vitro, in vivo 
and physiologically based biokinetic (PBBK) models was applied to investigate how 
the SULT inhibition influences the bioactivation and thus potentially also the toxicity 
and risk assessment of alkenylbenzenes.  
Figure 2.  Bioactivation and detoxification pathways of estragole which are also representative 
for methyleugenol.
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Exposure to alkenylbenzenes
Even though alkenylbenzenes are present in many foods at low levels, including for 
example oranges, bananas and grapefruit juice, intake of alkenylbenzenes occurs 
primarily from herbs, spices and their essential oils (Smith et al., 2002). The intake of 
estragole occurs for example primarily from consumption of foods containing sweet 
basil, fennel and anise or their essential oils whereas intake of methyleugenol occurs 
primarily from nutmeg, allspice, sweet basil, and fennel (Smith et al., 2002). 
Among different alkenylbenzenes, only estragole and methyleugenol are used as 
flavouring agents intentionally added as pure compounds to compounded flavours. 
This use is limited to the USA, but annual production volumes are low (491 kg per year 
for estragole and 77 kg per year for methyleugenol) (Gavin et al., 2008). Realistic daily 
intake levels of estragole have been estimated to range between 0.01 mg/kg bw/day 
(Smith et al., 2002) and 0.07 mg/kg bw/day (SCF, 2001a). Realistic daily intake levels of 
methyleugenol have been estimated to range from 0.014 mg/kg bw/day (Smith et al., 
2002) to 0.217 mg/kg bw/day (SCF, 2001b). The intake estimates of the SCF for estragole 
and methyleugenol were based on theoretical maximum use levels of the two compounds 
as flavouring substances in various food categories and consumption data for these food 
categories (SCF, 2001a, b). The intake estimation of the Flavour Extract Manufacturers 
Association (FEMA) of the United States was based on production volume data for herbs 
and their essential oils and for the pure compounds to be used as flavouring substances 
(Smith et al., 2002). Given that at present in the European Union addition of estragole and 
methyleugenol as pure compounds to individual food categories is no longer allowed, 
the intake estimates from Smith et al. (2002) resulting mainly from herbs and spices may 
represent more accurate estimates for the current levels of dietary human intake.
In addition to the average daily intake, some specialized eating groups may 
experience higher exposure levels. For example, people frequently consuming pesto 
ingest some of the highest levels of methyleugenol. Thus although normal exposure 
to methyleugenol may be in the order of 0.001-0.01 mg/kg bw/day, exposures of at 
least 10 times higher may be experienced by this group (Smith et al., 2002).
Absorption, distribution, metabolism and excretion 
In vivo studies with rodents and humans indicate that upon oral intake estragole and 
methyleugenol are rapidly and completely absorbed and that they are predominantly 
metabolised in the liver (Sutton et al., 1985; Anthony et al., 1987; Sangster et al., 1987; 
Johnson et al., 2000; Smith et al., 2002; Schecter et al., 2004). In rats, both estragole and 
methyleugenol are rapidly cleared from the system within 24 h (Solheim and Scheline, 
1973; Anthony et al., 1987). In two human subjects given a 100 µg dose of 14C-methoxy 
labelled estragole by gelatin capsule, approximately 70% of the dose was recovered 
within 48 h (Sangster et al., 1987). Also, in an experiment with human volunteers 
who consumed estragole by drinking fennel tea, containing 3.5 mg of estragole, no 
estragole was detectable in plasma or urine samples pointing at a very fast distribution 
and complete metabolism in the body. After 0.75 h, less than 0.1% of the estragole dose 
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could be detected as conjugated 1’-hydroxyestragole in plasma whereas in the urine 
0.27% of the estragole dose was detected as conjugated 1’-hydroxyestragole. Excretion 
happened very quickly, and after 10 h, no metabolite was detectable in the urine (Zeller 
et al., 2009). Methyleugenol has been detected in the plasma of humans not specifically 
exposed (Schecter et al., 2004), indicating that methyleugenol and probably other 
alkenylbenzene derivatives are absorbed from the diet. 
The principal metabolic pathways for alkenylbenzene derivatives have been 
established based on studies in rats, mice and humans and Figure 2 presents 
an overview of estragole metabolism. This overview is also representative for 
methyleugenol as well as for other alkenylbenzene derivatives. O-demethylation of 
estragole or methyleugenol results in phenolic derivatives, which may be excreted as 
sulfonate or glucuronic acid conjugate (Solheim and Scheline, 1973; Anthony et al., 
1987). Epoxidation of the side chain yields a 2′,3′-epoxide. This epoxide has been 
shown to be able to form DNA adducts in vitro, but these adducts are not found 
in vivo. This has been ascribed to the rapid detoxification of the 2’,3’-epoxide by 
epoxide hydrolases and/or glutathione-S-transferases in vivo (Solheim and Scheline, 
1976; Luo et al., 1992; Luo and Guenthner, 1995; NTP, 2000; Guenthner and Luo, 
2001). Bioactivation of estragole proceeds by cytochrome P450 enzymes leading to 
the formation of the proximate carcinogen 1′-hydroxyestragole (Drinkwater et al., 
1976; Zangouras et al., 1981; Miller et al., 1983; Anthony et al., 1987; Sangster et 
al., 1987). Further bioactivation of 1’-hydroxyestragole requires the involvement of 
sulfotransferases (SULTs) converting 1’-hydroxyestragole to 1’-sulfooxyestragole. 
The 1’-sulfooxy metabolite is unstable and, via a proposed reactive carbocation 
intermediate, binds covalently to different endogenous nucleophiles including 
DNA leading to DNA adduct formation (Phillips et al., 1981; Phillips et al., 1984; 
Randerath et al., 1984). Conjugation of 1’-hydroxy metabolites with glucuronic acid 
leads to the formation of a stable metabolite that is excreted in urine and therefore 
represents an important detoxification route (Solheim and Scheline, 1973; Anthony 
et al., 1987). In vitro experiments using liver S9 fractions from male rat and human 
showed that oxidation of 1′-hydroxyestragole is the major detoxification pathway of 
1′-hydroxyestragole in human whereas in rat glucurondation of 1′-hydroxyestragole 
seems to be the major pathway (Punt et al., 2009).
Genotoxicity 
Estragole was negative in genotoxicity tests with common strains of Salmonella typhimurium 
with and without metabolic activation (Dorange et al., 1977; Sekizawa and Shibamoto, 
1982; To et al., 1982; Zeiger et al., 1987; Zani et al., 1991). Methyleugenol was negative in 
multiple tests in various strains of S. typhimurium and Saccharomyces cerevisae (Dorange 
et al., 1977; Sekizawa and Shibamoto, 1982; Mortelmans et al., 1986; Schiestl et al., 1989; 
Brennan et al., 1996). The reason for these negative effects is that the sulfonation pathway, 
which is essential for the genotoxicity, is absent in these in vitro tests. However, based 
on a recent study where the mutagenicity of different isomeric hydroxylated metabolites 
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of methyleugenol was studied in an Ames test using the Salmonella typhimirum TA100 
strain expressing different SULTs it was shown that the different hydroxylated metabolites 
of methyleugenol were mutagenic in the Ames test and among the human enzymes; 
SULT1A1 showed the highest activity (Herrmann et al., 2012).
Estragole concentrations of 10-3-10-5 M did not induce the formation of chromosomal 
aberrations in V79 cells with and without metabolic activation and in primary rat 
hepatocytes (Muller et al., 1994). Methyleugenol produced sister chromatid exchange 
(SCE) in Chinese hamster ovary cells only in the presence of metabolic activation and 
at near cytotoxic levels. Therefore, the positive findings likely occurred secondary 
to cytotoxicity in which release of lysosomal nucleases may have resulted in a false 
positive response (NTP, 2000). Both substances and their 1′-hydroxy metabolites induce 
unscheduled DNA synthesis (UDS) in hepatocytes. The UDS observed in hepatocytes 
following treatment of rodents with parent compounds is most likely the result of CYP450-
mediated metabolism of the compounds to 1′-hydroxy metabolites. However, in these 
studies dose levels at which UDS occurs coincide with hepatocellular cytotoxicity (Chan 
and Caldwell, 1992; Muller et al., 1994). The majority of in vivo micronucleus induction 
studies for both compounds produced negative results (NTP, 2000, 2008).
The 1′-hydroxy metabolites of estragole and methyleugenol, and the corresponding 
sulfonate conjugates of the 1′-hydroxy metabolites form DNA adducts in vivo and in vitro 
(Smith et al., 2002). In an experiment where adult female CD-1 mice were given 58 mg/
kg bw of [3H]-labeled 1′-hydroxyestragole by ip injection and in 9-day-old male or female 
B6C3F1 mice given 14 mg/kg of labeled estragole by ip injections and sacrificed after 23 
h, three adducts were formed resulting from the reaction of the 1′ or 3′ positions (cis or 
trans isomers) of estragole at the exocyclic amino group (N2) of deoxyguanosine (Figure 
3). An additional adduct was formed by a reaction at the 3′ position of estragole and the 
(N6) position of deoxyadenosine. The three adducts of estragole deoxyribonucleoside 
were removed rapidly from mouse liver DNA (Phillips et al., 1981) (Figure 3). A rapid 
drop in total adduct formation also occurred in a 32P-post-labelling experiment with adult 
female CD-1 mice within 7 days after dosing with a 2 or 10 mg ip dose of estragole or 
methyleugenol and this drop was followed by a relatively constant level over the next 
140 days (Randerath et al., 1984). The authors noted that the significant decrease in DNA 
adduct levels was probably related to DNA repair processes (Randerath et al., 1984). 
Carcinogenicity
Short term studies in male rats given the alkenylbenzenes estragole or methyleugenol 
by gavage showed that the incidence of hepatocellular neoplasms for male rats 
administered 600 mg/kg bw/day of estragole by gavage, 5 days per week, for 93 
days is 4/10 for cholangiocarcinomas and 1/10 for adenomas. At 1000 mg/kg bw/
day of methyleugenol given by gavage, 5 days per week, for 13 weeks the incidence 
was 1/10 for adenomas (NTP, 2000; NTP, 2008). In a 2-year NTP study in mice and 
rats given methyleugenol by gavage daily at dose levels of 37, 75, or 150 mg/kg bw/
day, the incidence of hepatocellular adenomas and hepatocellular carcinomas in male 
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and female mice and rats increased in a dose dependent way (NTP, 2000). However, 
because of the evidence of toxicity of methyleugenol in all groups of rats and mice, 
the study cannot be recognized as conclusive for carcinogenicity at lower, non-toxic 
doses (Smith et al., 2002). In particular, the hepatic damage undoubtedly altered the 
metabolism of the compound, and the gastric damage possibly altered its absorption 
(Smith et al., 2002). Estragole has not been tested in a 2-year carcinogenicity bioassay. 
However, when administered to male CD-1 mice in the diet during a preweaning 
period for 12 months, estragole was positive for carcinogenicity and produced hepatic 
DNA adducts (Miller et al., 1983; Randerath et al., 1984).
Based on the carcinogenic activity of estragole and methyleugenol shown in the 
study of Miller at al. (1983) and the DNA adduct formation by these substances shown 
in the study of Phillips et al. (1984) using the same species and strain, it was concluded 
that adduct levels of at least 15 pmol/mg of DNA were required for statistically 
significant tumour formation (Phillips et al., 1984). The authors also noted that, 
compared with adults, new born mice showed greater sensitivity to alkenylbenzene 
carcinogenicity (Phillips et al., 1984).
The role of the 1′-sulfooxy metabolite in hepatotoxicity and hepatocarcinogenicity 
of alkenylbenzenes has also been proven in rodents. This was revealed in mice 
experiments by co-administration of the specific SULT inhibitor pentachlorophenol 
(PCP) which resulted in a potent inhibition of hepatic tumour induction upon long-term 
dietary administration of the closely related alkenylbenzene safrole or its metabolite, 
1’-hydroxysafrole (Boberg et al., 1983; Wiseman et al., 1987). 
Figure 3. Structure of estragole DNA adducts with 2′-deoxyguanosine as identified by Phillips et 
al. (1981) and Wiseman et al. (1985) and DNA adducts of methyleugenol with 2′-deoxyguanosine 
identified by Al-Subeihi et al. (2013) based on the analogy between the two compounds: Estragole 
and methyleugenol; E-3’-N2-dGuo, N2-(trans-isoestragol-3’-yl)-2’-deoxyguanosine; E-3’-C8-dGuo, C8-
(trans-isoestragol-3’yl)-2’-deoxyguanosine; E-1’-N2-dGuo, N2-(estragol-1’-yl)-2’-deoxyguanosine and 
E-3'-N7-dGuo, 7-(trans-estragol-3’-yl)-2’-guanine. The methoxy group in the boxes are only present 
in methyleugenol derived adduct. 
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Regulatory status
The safety of human exposure to estragole and methyleugenol at low dietary intake 
levels has been assessed several times. In 1965, the Expert Panel of the Flavour and 
Extract Manufacturers Association (FEMA) concluded that estragole and methyleugenol 
are generally recognized as safe (GRAS) under conditions of intended use as 
flavouring substances in food (Smith et al., 2002). In 1979, the Panel again evaluated 
the available data and affirmed the GRAS status of estragole and methyleugenol for 
use as flavouring substances (Smith et al., 2002). In 2000, the National Toxicology 
Program (NTP) investigated the carcinogenicity of methyleugenol and concluded 
that methyleugenol is carcinogenic in both rats and mice (NTP, 2000). In 2001, the 
FEMA Expert Panel reassessed the available data for methyleugenol and estragole 
and confirmed that there is no considerable cancer risk resulting from consumption of 
estragole and methyleugenol as flavouring substances and affirmed the GRAS status 
at the use levels as flavouring substances (Smith et al., 2002). In the FEMA evaluation 
it was taken into account that there are experimental data suggesting a non-linear 
relationship between dose and profiles of metabolism and metabolic activation and 
that exposure due to use as flavouring substances is relatively low (Smith et al., 2002).
In 2001, the Scientific Committee on Food (SCF) of the European Union published 
scientific opinions on estragole and methyleugenol in which it was concluded that 
both compounds are genotoxic and carcinogenic and that reductions in exposure and 
restrictions in use levels are indicated (SCF, 2001a, b). Based on these findings, the use 
of estragole and methyleugenol as pure substances in foodstuffs has been prohibited 
since September 2008 within the European Union (European Commission, 2008). An 
evaluation performed by the Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) in 2008, has indicated that although evidence of carcinogenicity to rodents 
given high doses of alkenylbenzenes exists, further research is needed to assess the 
potential risk to human health at relevant dietary exposure levels (JECFA, 2008). 
The occurrence of these different expert opinions in risk assessment of 
alkenylbenzenes originates in part from the absence of scientific agreement to support 
the unequivocal translation of carcinogenicity data of rodent animal experiments 
obtained at high levels of exposure to the relevant human situation. Predicting the 
cancer risk in humans at relevant dietary intake levels requires extrapolation of the 
animal carcinogenicity data taking into consideration species-, dose- and interindividual 
variation. Furthermore, it implies extrapolation from rat or mouse studies with high 
dose levels of the pure compound to the human situation in which exposure at low 
dose levels occurs within the context of a complex food matrix.
Risk assessment approaches
Alkenylbenzenes such as estragole and methyleugenol occur naturally in botanicals and 
botanical preparations present in food and therefore they cannot readily be eliminated 
or avoided. Estimation of the cancer risk from alkenylbenzenes at low dose levels 
relevant for human intake is essential from a public health point of view. However, 
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there is no international agreement on how to evaluate the potential risk of genotoxic 
carcinogens that naturally occur in food. One of the commonly used approaches in risk 
assessment practices especially in the United States is the linear extrapolation of animal 
carcinogenicity data obtained at high dose levels to low dose levels which are relevant 
to human intake. This approach requires definition of a point of departure to be derived 
from the animal data at high dose levels from which the extrapolation can be performed 
to zero risk at zero dose level. The point of departure may be the T25 which is the dose 
that increases the tumour incidence by 25% (Barlow et al., 2006; Dybing et al., 2008). 
It may also be the so-called Benchmark Dose 10 (BMD10) (the Benchmark Dose 
that gives a 10% extra cancer incidence) or the lower confidence bound of the BMDL10 
determined using the Benchmark Dose (BMD) approach (EFSA, 2005; US EPA, 2005). 
The BMD approach provides a useful tool for deriving a point of departure within the 
observable dose range by fitting a curve to the dose-response data from an animal 
bioassay and using this curve fit to estimate the intake level that corresponds to a fixed 
tumour incidence. The simplest way to estimate the risk associated with the average 
dietary human intake is to apply linear extrapolation from the BMD10 or T25 as the point 
of departure to zero risk at zero dose. Based on this extrapolation a so-called virtual 
safe dose (VSD) can be derived, corresponding to the dose that results in an additional 
cancer risk of one in a million upon lifetime exposure, which is generally considered an 
acceptable risk by risk managers. 
There are major problems with linear extrapolation of cancer incidences based on 
data obtained in animal bioassays at high dose levels that are orders of magnitude 
higher than the realistic intake levels for the human situation. Such problems are the 
presence of uncertainties in the shape of the dose-response curve at dose levels 
relevant for dietary human intake, interspecies variations in metabolism and metabolic 
activation and the larger interindividual variability within the human population, as 
compared to the variability in the inbred strains used for the rodent bioassays.
An alternative approach that has been suggested by the European Food Safety 
Authority (EFSA) for the risk assessment of compounds that are both genotoxic and 
carcinogenic like alkenylbenzenes is the so-called margin of exposure (MOE) approach 
which can be used to set priorities in risk management (EFSA, 2005). The MOE is 
defined as the ratio between the lower confidence limit of the benchmark dose that 
gives 10% extra cancer incidence (BMDL10) and the estimated daily intake (EDI) (EFSA, 
2005). EFSA considered that, when the MOE is higher than 10,000, the compound is 
considered to be of low priority for risk management actions (EFSA, 2005). This margin 
of 10,000 takes into consideration the various uncertainties in the MOE approach, 
such as interspecies differences and human variability in biokinetics and biodynamics, 
the shape of the dose-response curve below the experimental data, and human 
interindividual variability in cell cycle control and DNA repair (EFSA, 2005; Barlow et 
al., 2006; Dybing et al., 2008). The magnitude of the MOE does not indicate a safe 
dose of a chemical but indicates whether the estimated daily intake is (or is not) close 
to dose levels actually causing increased tumour incidences in animal bioassays so 
that risk management actions might (not) be required (Dybing et al., 2008). 
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Also, it is worth mentioning that some allometric approaches can provide a useful 
tool to extrapolate across different species as recommended by the US FDA and US 
EPA. In this regard two methods can be used to calculate human equivalent doses, 
one is based on body surface area scaling (body mass raised to the 2/3 power of the 
test animal relative to humans, BW2/3), the other is based on metabolic rate scaling 
(BW3/4). Scaling based on body surface area is considered to be more conservative, 
and is recommended by the FDA to estimate the maximum safe starting doses in 
initial clinical trials for therapeutics in adult healthy volunteers (US FDA, 2005). EPA 
recommends metabolic rate scaling for interspecies extrapolation (US EPA, 2005). 
For oral exposures, the EPA suggests to scale daily applied doses experienced for a 
lifetime in proportion to body weight raised to the 3/4 power (metabolic rate scaling) 
(US EPA, 2005). Using allometric scaling when extrapolating between species is mainly 
used in the US but is not generally applied by regulatory bodies in Europe.
Generally, extrapolation of animal tumour data at high doses using mathematical 
modeling in order to obtain estimates of the risk to humans at low exposures has 
been much debated, since it is not known whether or not the model chosen actually 
reflects the underlying biological processes. In addition, numerical estimates may be 
misused or misinterpreted in further risk management and risk communication, if the 
uncertainties and inaccuracy connected to the model are not communicated (EFSA, 
2005). To address major issues of debate in risk assessment strategies new tools such 
as physiologically based biokinetic (PBBK) modeling can be used. PBBK modeling 
provides a method to obtain a better mechanistic basis for extrapolations from high to 
low dose as well as for interindividual and interspecies extrapolations (Andersen and 
Krishnan, 1994; Clewell et al., 2001; Clewell Iii et al., 2002) as explained in more detail 
in the section on PBBK modeling below. 
PBBK modeling
The main challenge in the current risk assessment strategies is the need to extrapolate 
the cancer risk from high dose levels at which most animal studies are performed to low 
dose levels relevant for human dietary intake. Another issue is to extrapolate between 
species giving that differences in metabolism and metabolic activation might differ 
substantially between the different species. In addition, the modulating effects by 
the food matrix in which the food borne-toxicants occur has to be taken into account. 
A useful tool to address these issues is the use of physiologically based biokinetic 
(PBBK) modelling. A PBBK model consists of a set of mathematical equations that 
together describe the absorption, distribution, metabolism and excretion (ADME) 
characteristics of a compound within an organism. Input data for any PBBK model 
consist of three types of parameters, namely, physiological, physiochemical and 
biochemical parameters (Krishnan et al., 2002). Target tissues are generally represented 
as individual compartments (e.g. liver, lung, or kidney) while non-target tissues are 
lumped together in one compartments (e.g. slowly perfused tissues such as muscle 
and skin or richly perfused tissues such brain and spleen). Each compartment has its 
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own physiological (e.g. blood flows), physicochemical (e.g. partition coefficients) and 
biochemical (e.g. metabolic rates) parameters. Kinetic parameters for PBBK models, 
including metabolic parameters, are, at present, often obtained by optimizing the fit 
of the model to an informative data set (Krewski et al., 1994; Clewell and Clewell Iii, 
2008). Alternatively, kinetic parameters might also be derived from in vitro experiments 
using relative tissue fractions, primary cell cultures, or tissue slices of organs involved 
in the metabolism of the compound. Some advantages of using in vitro metabolic 
parameters to define PBBK models include the ability to separately define and analyze 
individual metabolic processes, such as phase I metabolism and phase II metabolism, 
or bioactivation and detoxification, and to compare contributions from individual 
conversions to the overall metabolism across species and between individuals. This is 
especially of use when limited in vivo data are available as is often the case for humans 
(Lipscomb and Poet, 2008). PBBK models quantitatively describe actual physiological 
processes within the relevant tissues of the body (Krishnan et al., 2002). 
Output data expected from such PBBK models are, for example, prediction of 
internal concentrations at a certain dose, that have not been directly measured, (e.g. 
the predicted plasma or tissue levels of a parent compound or its reactive metabolites 
over time) in animal bioassays, as well as in human exposure scenarios (Andersen 
and Krishnan, 1994). Such an internal dose metric is considered to be more closely 
related to the toxic response than the applied external doses. Extrapolation of the 
cancer risk from high to low doses and from animals to humans can be performed 
based on the internal dose metrics rather than the applied external doses (Andersen 
and Krishnan, 1994). Furthermore, such PBBK models can be developed for different 
species, which facilitates interspecies extrapolation. In addition, by incorporating 
equations and kinetic constants for metabolic conversions by samples from different 
human individuals and/or specific isoenzymes, modeling of interindividual variations 
and genetic polymorphisms becomes feasible (Bogaards et al., 2000). 
Recently, PBBK models have been developed to study the bioactivation and 
detoxification of the alkenylbenzenes estragole and methyleugenol in rat and 
human (Punt et al., 2008, 2009; Al-Subeihi et al., 2011, 2012). These PBBK models 
provide mechanistic insight in the dose-dependent, interspecies and interindividual 
difference in the metabolism of the two compounds. For example, the estragole PBBK 
models revealed that the species difference in the ultimate overall bioactivation and 
formation of the 1′-sulfooxyestragole between rat and human is about twofold and 
thus smaller than the default factor of 4 generally assumed to reflect interspecies 
variation in kinetics (Punt et al., 2009) whereas in the methyleugenol PBBK models 
species differences in the formation of 1′-sulfooxymethyleugenol is negligible despite 
the significant difference in especially the metabolic pathways of the proximate 
carcinogenic metabolite 1′-hydroxymethyleugenol between human and male rat (Al-
Subeihi et al., 2012). PBBK models of estragole and methyleugenol also showed that 
the formation of the ultimate carcinogen, the 1′-sulfooxy metabolite, in rat as well as in 
human from doses as high as the BMDL10 at which actual increased tumour incidences 
are observed in rodent bioassays, down to as low as the virtual safe dose (VSD) is 
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linear with the dose (Punt et al., 2009; Al-Subeihi et al., 2012) and thus do not provide 
an argument against linear extrapolation from high dose animal data to the low dose 
human situation (Rietjens et al., 2010). 
Not only the bioactivation of alkenylbenzenes can be studied by these PBBK models 
but also the modulation of their bioactivation. This can be achieved by integrating the 
kinetics for this modulation in the PBBK model. Thus the original PBBK models can 
be modified and updated with newly generated data to allow representation of dose- 
and species-dependent effects of this modulation (e.g. matrix effect by herbs or their 
constituents) on the formation of the ultimate carcinogenic metabolite, the 1′-sulfooxy 
metabolite, in the target organ, the liver.
Objective and outline of the thesis
This PhD research was based on the outcomes from the study of Jeurissen et al. 
(2008) where it was shown that a methanolic extract of basil was able to inhibit the 
formation of estragole DNA adducts in human HepG2 hepatoma cells exposed to the 
proximate carcinogen 1′-hydroxyestragole (Jeurissen et al., 2008) and that inhibition 
takes place at the level of SULT-mediated bioactivation of 1′-hydroxyestragole into 
1′-sulfooxyestragole (Jeurissen et al., 2008). 
The objective of this PhD research was to identify the SULT inhibitor(s) present 
in the basil extract able to inhibit estragole DNA adduct formation and to identify 
the presence of other SULT inhibitors in a series of alkenylbenzene-containing herbs 
and spices. An additional objective was to predict the reduction in bioactivation of 
alkenylbenzenes when they are consumed with either a single SULT inhibitor or with 
a mixture of SULT inhibitors at relevant dose levels of the alkenylbenzene and the 
SULT inhibitor(s) using an integrated approach of in vitro, in vivo and physiologically 
based biokinetic (PBBK) models. The later was achieved by using the PBBK models 
recently developed to study the bioactivation and detoxification of estragole and 
methyleugenol in rat (Punt et al., 2008; Al-Subeihi et al., 2011) and human (Punt et 
al., 2009; Al-Subeihi et al., 2012). The estragole and methyleugenol PBBK models 
were updated based on data obtained in the present thesis to study the inhibition of 
estragole and methyleugenol bioactivation by the different SULT inhibitors.
Chapter 1, the present chapter of this thesis, presents an introduction to the 
bioactivation, detoxification, genotoxicity and carcinogenicity of the alkenylbenzenes 
estragole and methyleugenol as well as a short introduction to PBBK modeling and 
the state-of-the-art knowledge on risk assessment strategies and regulatory status for 
alkenylbenzenes. The aim and contents of the present thesis are also presented. 
Chapter 2 describes the identification of the natural SULT inhibitor nevadensin in the 
methanolic extract of basil responsible for the inhibition of estragole DNA adduct 
formation by the methanolic basil extract described previously (Jeurissen et al., 2008) 
and investigates the kinetics for this inhibition using in vitro assays. The effect of the newly 
identified SULT inhibitor, nevadensin, on the SULT-mediated bioactivation and DNA 
adduct formation of 1′-hydroxyestragole was investigated in primary rat hepatocytes. In 
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order to investigate possible in vivo implications of nevadensin on the overall formation 
of the ultimate carcinogenic metabolite, 1′-sulfooxyestragole, the SULT inhibition by 
nevadensin was also integrated into the male rat and human estragole PBBK models. 
Chapter 3 identifies the presence of other SULT inhibitors in a series of alkenylbenzene-
containing herbs and spices and the kinetics of inhibition by each individual SULT inhibitor 
and by a mixture of SULT inhibitors. The effect of a mixture of SULT inhibitors on the SULT-
mediated bioactivation and DNA adduct formation of 1′-hydroxyestragole is investigated 
in human HepG2 cells. To investigate possible in vivo implications of the different SULT 
inhibitors on the formation levels of 1′-sulfooxyestragole, the SULT inhibition by the 
mixtures was also integrated into the male rat and human estragole PBBK models. 
Chapter 4 investigates the activity of nevadensin on the SULT-mediated bioactivation 
and DNA adduct formation of estragole in vivo using male Sprague–Dawley rats. It 
also describes the development of a new PBBK model for nevadensin in male rat and 
human. In a next step the estragole and nevadensin PBBK models are connected to 
form a binary estragole-nevadensin PBBK model based on the type of interaction 
between estragole and nevadensin defined in the present research. To extend the PBBK 
model from predicting levels of 1’-sulfooxyestragole formed to predicting levels of DNA 
adducts formed, the equation describing DNA adduct formation as a function of PBBK 
predicted levels of 1′-sulfooxyestragole described previously (Paini et al., 2012) was 
also integrated in the PBBK models. The resulting binary estragole-nevadensin PBBK 
models allow simulation of the dose- and species-dependent effect of nevadensin on 
the formation of estragole DNA adducts in the liver of male rat and human. 
Chapter 5 investigates the potential of nevadensin to inhibit the SULT mediated 
bioactivation and subsequent DNA adduct formation of methyleugenol using human 
HepG2 cells as an in vitro model. To obtain some insight in the in vivo relevance of 
these observations the physiologically based kinetic (PBBK) model for bioactivation and 
detoxification of methyleugenol in male rat (Al-Subeihi et al., 2011) was combined with the 
recently developed PBBK model for nevadensin in male rat to investigate consequences 
of this co-exposure on the formation of DNA adducts by methyleugenol in vivo. 
Chapter 6 investigates whether the nevadensin-mediated reduction in alkenylbenzene 
DNA adduct formation is accompanied by a reduction in early markers for 
carcinogenesis using methyleugenol as the model alkenylbenzene. The early markers 
of carcinogenesis investigated in this chapter were hepatocellular proliferation, 
formation of hepatocellular altered foci in addition to DNA adduct formation. 
Finally, Chapter 7 presents a discussion of the results obtained in this thesis and their 
implications for the risk assessment of the alkenylbenzenes.
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Identification of nevadensin as 
an important herb-based constituent inhibiting 
estragole bioactivation and physiologically based 
biokinetic modeling of its possible in vivo effect2
ABSTRACT
Estragole is a natural constituent of several herbs and spices including sweet basil. 
In rodent bioassays, estragole induces hepatomas, an effect ascribed to estragole 
bioactivation to 1′-sulfooxyestragole resulting in DNA adduct formation. The present 
paper identifies nevadensin as a basil constituent able to inhibit DNA adduct formation 
in rat hepatocytes exposed to the proximate carcinogen 1′-hydroxyestragole and 
nevadensin. This inhibition occurs at the level of sulfotransferase (SULT)-mediated 
bioactivation of 1′-hydroxyestragole. The Ki for SULT inhibition by nevadensin was 4 nM 
in male rat and human liver fractions. Furthermore, nevadensin up to 20 μM did not inhibit 
1′-hydroxyestragole detoxification by glucuronidation and oxidation. The inhibition of 
SULT by nevadensin was incorporated into the recently developed physiologically based 
biokinetic (PBBK) rat and human models for estragole bioactivation and detoxification. 
The results predict that co-administration of estragole at a level inducing hepatic 
tumours in vivo (50 mg/kg bw) with nevadensin at a molar ratio of 0.06, representing 
the ratio of their occurrence in basil, results in almost 100% inhibition of the ultimate 
carcinogen 1′-sulfooxyestragole when assuming 100% uptake of nevadensin. Assuming 
1% uptake, inhibition would still amount to more than 83%. Altogether these data 
point at a nevadensin-mediated inhibition of the formation of the ultimate carcinogenic 
metabolite of estragole, without reducing the capacity to detoxify 1′-hydroxyestragole 
via glucuronidation or oxidation. These data also point at a potential reduction of 
the cancer risk when estragole exposure occurs within a food matrix containing SULT 
inhibitors compared to what is observed upon exposure to pure estragole.
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INTRODUCTION
Ocimum basilicum L., or sweet basil is an important botanical in the production of 
essential oils, medicinal products and for providing the culinary market with pot, dry 
and fresh herbs (Lawrence, 1992). It contains aromatic compounds that belong to 
the group of alkenylbenzenes which make up the larger part of its essential oil (De 
Vincenzi et al., 2000). According to the Scientific Committee on Food (SCF), several 
of these alkenylbenzenes, including estragole (Figure 1) which makes up 20–88% 
of basil essential oil, have been shown to be genotoxic and carcinogenic in rodent 
studies and therefore, restrictions in their use were indicated (SCF, 2001a, b, c).  The 
European Medicines Agency (EMEA) released a public statement on the use of herbal 
medicinal products containing estragole concluding that estragole is a naturally 
occurring genotoxic carcinogen, but that at the low levels of exposure resulting from 
consumption of herbal medicinal products, it does not pose a significant cancer 
risk (EMEA, 2005). This conclusion is consistent with that of Smith et al. (2002) who 
published a safety assessment on alkenylbenzenes derivatives, including estragole, 
used as flavouring substances. 
The European Food Safety Authority (EFSA) suggested the so-called margin 
of exposure (MOE) to be used to set priorities in risk management with respect to 
compounds that are both genotoxic and carcinogenic (EFSA, 2005). This MOE is defined 
as the ratio between the lower confidence limit of the benchmark dose that gives 10% 
extra cancer incidence (BMDL10) and the estimated daily intake (EDI). Based on the EDI 
of estragole from different food sources (EDI=0.07 mg/kg bw/day) (SCF, 2001a), and the 
BMDL10 which can be derived from available tumour data and ranges from 9 to 33 mg/kg 
bw/day, the MOE for estragole amounts to 129–471 (Rietjens et al., 2010). According to 
EFSA a MOE lower than 10,000 as in the case of estragole can be considered a priority 
for risk management (EFSA, 2005). This is also illustrated by the fact that the Joint FAO/
WHO Expert Committee on Food Additives (JECFA) has put estragole (as well as some 
other alkenylbenzenes) on the list of compounds to be re-evaluated (JECFA, 2008). 
Figure 1 presents an overview of the bioactivation and detoxification pathways 
of estragole (Punt et al., 2009 as adapted from Smith et al. (2002)). Bioactivation of 
estragole proceeds by initial metabolic hydroxylation by cytochrome P450 enzymes 
leading to the formation of the proximate carcinogen 1′-hydroxyestragole which has 
been detected in the β-glucuronidase treated urine of men dosed with 1 μg estragole/
kg bw (Sangster et al., 1987).
Further bioactivation of 1′-hydroxyestragole requires the involvement of 
sulfotransferases (SULTs) which convert 1′-hydroxyestragole to the ultimate carcinogen 
1′-sulfooxyestragole. This sulfonated metabolite is unstable and degrades in aqueous 
environment to a reactive carbocation capable of binding covalently to different 
endogenous nucleophiles including glutathione, protein, RNA and DNA (Phillips et 
al., 1981; Phillips et al., 1984; Randerath et al., 1984). The role of the 1′-sulfooxy 
metabolites of alkenylbenzenes in the formation of hepatic macromolecular adducts 
and tumour formation has been also demonstrated in vivo (Boberg et al., 1983). 
31
2
Estragole has been shown to induce hepatomas in rodent bioassays when dosed as a 
pure compound at high dose levels (Miller et al., 1983). Therefore, an issue that remains 
to be solved is whether these animal studies using high levels of pure compounds 
without the normal food matrix being present, represent a good starting point for 
the risk assessment of these botanical constituents. Phillips et al. (1981) reported 
observing two major and two minor liver DNA adducts in adult female CD-1 mice and 
preweanling B6C3F1 mice given an intraperitoneal injection of 1′-hydroxyestragole. 
These four adducts were (I) N2-(trans-isoestragol- 3′-yl)deoxyguanosine, (II) N6-(trans-
isoestragol-3′-yl)deoxyadenosine, (III) N2-(estragole-1′-yl)deoxyguanosine and (IV) N2-
Figure 1. Bioactivation and detoxification pathways of estragole.
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(cis-isoestragol-3′-yl)deoxyguanosine. Later work (Fennell et al., 1985) investigated 
in vivo adduct formation in 12-day old mice dosed with 1′-hydroxyestragole and 
confirmed formation of three of these adducts. However, two additional adducts of 
guanine at positions C-8 (V) and N-7 (VI) were observed and characterized. In our 
subsequent work on DNA adduct formation, focus was on formation of the major DNA 
adduct N2-(trans-isoestragol-3′-yl)-2′-deoxyguanosine (E-3′-N2-dGuo). 
Recently, we demonstrated that formation of E-3′-N2-dGuo in incubations with liver 
S9 fractions in the presence of the proximate carcinogen 1′-hydroxyestragole and 
the cofactor for SULT-mediated conversion 3′-phosphoadenosine-5′-phosphosulfate 
(PAPS), and 2′- deoxyguanosine could be inhibited by a methanolic basil extract 
(Jeurissen et al., 2008). The inhibition of the major estragole DNA adduct (E-3′-N2-
dGuo) formation by the basil extract was also found in intact HepG2 human hepatoma 
cells exposed to 1′-hydroxyestragole (Jeurissen et al., 2008). Because similar inhibition 
took place when using the well-known competitive-SULT inhibitor pentachlorophenol 
(PCP) and because the inhibition was not observed in incubations with the direct 
electrophile 1′-acetoxyestragole, it was concluded that the inhibition by the basil 
extract occurs at the level of the SULT-mediated bioactivation of 1′-hydroxyestragole 
to 1′-sulfooxyestragole (Jeurissen et al., 2008). Although it remains to be established 
whether the SULT-mediated inhibition by the methanolic basil extract demonstrated in 
vitro would also occur in vivo, the results suggest that the likelihood of bioactivation 
and subsequent adverse effects may be lower when estragole is consumed in a matrix 
of other basil components than what would be expected on the basis of experiments 
using estragole as a single compound (Jeurissen et al., 2008). 
The aims of the present study were i) to identify the active compound( 
s) present in the basil extract that are responsible for the inhibition of DNA 
binding of 1′-hydroxyestragole by inhibiting the SULT-mediated bioactivation of 
1′-hydroxyestragole to 1′-sulfooxyestragole and ii) to predict the possible effects 
of combined exposure by incorporating the kinetics for SULT inhibition into our 
recently developed physiologically based biokinetic (PBBK) models for formation 
of 1′-sulfooxyestragole in the liver of rat (Punt et al., 2008) and human (Punt et al., 
2009). The possible effects of the identified inhibitor(s) on the detoxification of 
1′-hydroxyestragole by glucuronidation and oxidation (Figure 1) were quantified in 
vitro as well. This is important because only when the SULT-mediated bioactivation 
of 1′-hydroxyestragole is inhibited without affecting the detoxification pathways of 
1′-hydroxyestragole, the SULT inhibition can be expected to shift metabolism in favour 
of detoxification at the cost of bioactivation.
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MATERIALS AND METHODS
Materials and chemicals
1′-Hydroxyestragole and 1′-acetoxyestragole are carcinogenic compounds and 
caution should be taken when handling them. 
Dried basil (Silvo; Papendrecht, The Netherlands) was purchased from a local 
supermarket, 7-hydroxycoumarin (7HC; 99%), 7-hydroxycoumarin sulfate (7HCS; 95%), 
pentachlorophenol (PCP; 98%), chromatography grade acetonitrile and methanol were 
obtained from Sigma-Aldrich (Steinheim, Germany). Tris-hydroxymethylaminomethane 
(tris) was from Gibco BRL Life Technologies (Paisley, Scotland), dimethylsulfoxide 
(DMSO; spectroscopic grade, 99.9%) and pro analysis grade acetic acid were 
purchased from VWR Merck (Darmstadt, Germany). 
Nevadensin was purchased from Apin Chemicals (Milton, UK). Pooled male rat liver 
S9 and microsomes (Sprague–Dawley) and pooled human liver S9 and microsomes 
were purchased from BD Gentest (Woburn, MA). PAPS was purchased from Fluka 
(Buchs, Switzerland). ENZYLINE™ LDH Optimise 10 kit lactate dehydrogenase (LDH) 
was purchased from Bio Merieux (Lyon, France). William’s E medium, L-glutamine, 
hepes pH 7.4, ITS+, 15,000 U penicillin/streptomycin, dexamethasone, 5% fetal 
bovine serum (Hi-clone), and Earle’s balanced salt solution (EBSS) were purchased from 
Sigma (Basel, Switzerland). Matrigel was obtained from Biomedical Products (Bedford, 
MA). 1′-Hydroxyestragole was synthesized as described previously (Drinkwater et 
al., 1976) based on a method described by (Borchert et al. (1973) for the synthesis 
of 1′-hydroxysafrole. Structural confirmation by means of GC–MS was carried out as 
described in our previous work (Punt et al., 2007).
Preparation of methanolic basil extract
A methanolic basil extract was prepared according to the method described previously 
(Jeurissen et al., 2008) with minor modifications. In short, basil extract was prepared 
by stirring 5 g of dried basil twice for 2 h at room temperature, each time with 100 mL 
of a mixture of methanol, ultra-pure water, and acetic acid (ratio 80:19:1). The extracts 
obtained were filtered using a folded filter (Schleicher & Schuell) and the pooled 
filtrates were evaporated to dryness under vacuum using a Rotavapor apparatus 
(Heidolph LABOROTA 4000 efficient, Metrohm USA). The extraction yield was about 
10%–20% (w/w) (Jeurissen et al., 2008). Thereafter, three concentrated extract stocks 
in methanol were prepared (2, 5 and 20 mg/mL). For fractionation, a concentrated 
stock of 150 mg/mL dissolved in a mixture of ultra-pure water and methanol (ratio 1:1) 
was prepared and all stocks were stored at −20°C until use. All stocks were filtered 
using a 0.45 μM FP filter (Schleicher & Schuell, Dassel, Germany).
Measurement of SULT activity
To detect inhibition of SULT activity by basil extract or by fractions of basil extract, 
7HC was used as a substrate instead of 1′-hydroxyestragole because the metabolite 
resulting from the sulfonation of 7HC is stable in aqueous solution and can be detected 
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and quantified by HPLC–UV (Otake et al., 2002; Wang et al., 2005) whereas the highly 
reactive sulfonated metabolite of 1′-hydroxyestragole degrades in aqueous environment 
upon formation (Drinkwater et al., 1976; Boberg et al., 1983; Wiseman et al., 1987). 
Pooled male rat liver S9 fractions at a final concentration of 0.4 mg protein/mL were 
incubated with 25 μM 7HC added from a 200 times concentrated stock solution in DMSO 
and 0.1 mM PAPS in a total volume of 100 μL with 0.1 M Tris–HCl buffer (pH 7.4) for 10 
min at 37°C in the absence or presence of increasing concentrations of methanolic basil 
extracts (10, 25, and 100 μg/mL, added from 200 times concentrated stock solutions in 
methanol). The reactions were terminated by adding 25 μL of ice-cold acetonitrile, and 
the samples were centrifuged at 16,000 g for 5 min (Eppendorf centrifuge, type 5415C, 
Hamburg, Germany). The supernatants were subjected to HPLC–UV analysis to quantify 
the amount of the sulfonated metabolite, 7HCS, formed. Control incubations without 
basil extract or in the presence of 25 μM of the known SULT inhibitor, PCP, (added from 
a 200 times concentrated stock solution in DMSO) were performed. 
HPLC–UV analysis and quantification of 7HCS 
The supernatants obtained from the SULT activity incubations were analyzed by HPLC–
UV on a M600 Waters liquid chromatography system connected to an Alltima C18 5 
μm column, 150 mm×4.6 mm (Grace Alltech, Breda, The Netherlands). The gradient 
was made with ultra-pure water containing 0.1% (v/v) acetic acid and acetonitrile and 
the flow rate was set to 1 mL/min. The acetonitrile percentage was increased from 0% 
to 20% in 2 min, increased to 21% in 10 min, increased to 100% in 2 min, and kept 
at 100% for 1 min. Initial conditions were retained in 2 min, and then the system was 
equilibrated at these conditions for 10 min. Detection was carried out using a 2996 
photodiode array detector (Waters, Milford MA) at 280 nm for the quantification of 
7HCS. For quantification based on peak areas at 280 nm, a calibration curve of 7HCS 
was made using a commercially available standard.
Fractionation of methanolic basil extract
After confirming the SULT inhibitory capacity of the methanolic basil extract, the extract 
was fractionated into 60 fractions upon injecting 50 μL of a 150 mg/mL basil extract 
dissolved in methanol/water 1:1 and filtrated through a 0.45 μMFP filter onto an Alltima 
C18 5 μM column, 150 mm×4.6 mm (Grace Alltech, Breda, The Netherlands). The 
gradient was made with ultra-pure water containing 0.1% (v/v) acetic acid and methanol 
and the flow rate was set to 1 mL/min. A linear gradient was then applied as follows: the 
methanol percentage was increased from 0% to 100% in 60 min, and kept at 100% for 
10 min. Initial conditions were retained in 10 min, and the system was equilibrated at 
these conditions for 10 min. Every 1 min a single fraction was collected in an Eppendorf 
tube. Subsequently, methanol was evaporated under a nitrogen atmosphere and 
fractions were frozen at −80°C to allow freeze drying using a freeze dryer (Christ Alpha 
RVC, Leerdam, the Netherlands) under the following conditions: 10–20 bar for 3 h. 
Methanol evaporation and freeze dying had no effect on the SULT inhibitory capacity of 
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the fractions (data not shown). To have more concentrated fractions, the fractionation 
was performed five times and the replicates were pooled together in 50 μL methanol 
following freeze drying. Thereafter, each fraction was examined for its inhibitory potential 
on SULT activity using the SULT activity assay described above.
LC–ESI–MS/MS analysis
The fraction with the highest inhibitory effect on SULT activity was analyzed on a Finnigan 
Surveyor HPLC system coupled to an LXQ ion trap mass spectrometer (Thermo Finnigan, 
San Jose, CA, USA) fitted with an ESI source. Aliquots of 20 μL (injected volume) were 
separated on a Gemini C18 5 μm column, 150 mm×4.6 mm (Phenomenex, Torrance, 
CA). The gradient was made with acetonitrile and ultra-pure water containing 0.1% (v/v) 
formic acid and the flow rate was set to 0.1 mL/min. A linear gradient was applied from 
0% to 100% acetonitrile over 30 min and was kept at 100% acetonitrile for 2 min. Mass 
spectrometric analysis was performed in positive ion mode using a spray voltage of 5 kV, 
a capillary temperature of 275°C, and nitrogen as sheath gas (8 arbitrary units). Initially, full 
scan data (m/z 125–2000) were obtained to identify the main protonated molecular ion 
[M+H]+ present in the sample. Subsequently, a collision induced dissociation spectrum was 
derived at a normalized collision energy of 30% to aid additional structural characterization.
1H–NMR analysis
1H–NMR was performed using a Bruker Avance III 600 MHz (Ettlingen, Germany) with 
cryoprobe. A Noesygppr1d pulse sequence with 3 s delay, 0.1 s mixing time and a 1.8 
s acquisition time were used (18,028 Hz sweep width, 64 K data points). Spectra were 
obtained at 25°C. Resonances were reported relative to methanol-d4 at 3.34 ppm.
Cytotoxicity assay
Cytotoxicity of 1′-hydroxyestragole and nevadensin towards isolated rat hepatocytes 
was determined by measuring the amount of lactate dehydrogenase (LDH) leakage 
into the medium after 4 h incubation with the tested concentrations. The concentration 
of 1′-hydroxyestragole of 50 μM was selected because it represents a concentration 
at which no cytotoxicity was reported in the HepG2 hepatoma cell line but at which 
the quantification of the resulting DNA adducts was feasible (Jeurissen et al., 2008). 
LDH activity was measured by analyzing the appearance of lactate at 340 nm using a 
spectrophotometer Cobas Mira Plus analyzer (Minnesota, USA). An ENZYLINETM LDH 
Optimise 10 kit (BioMerieux® SA, Lyon, France) was used which provides the substrate 
pyruvate and the cofactor nicotinamide adenine dinucleotide (reduced NADH).
Cultures of primary rat hepatocytes
Primary rat hepatocytes were obtained by perfusion of the liver of male Sprague–
Dawley rats (220–250 g) with a collagenase solution as previously described (Sidhu 
et al., 1993; Cavin et al., 2001). Cell viability, estimated by trypan blue exclusion, 
was found to range from 90% to 95%. The cells were seeded at a density of 3.5×106 
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cells/cm2 per 60 mm plastic tissue culture dishes in 2.5 mL of William’s E medium 
supplemented with 2 mM L-glutamine, 10 mM hepes pH 7.4, 1% ITS+, 15,000 U 
penicillin/streptomycin, 100 nM dexamethasone and 5% fetal bovine serum (Hi-clone). 
Hepatocytes were allowed to attach for 2 h and then washed with Earle’s balanced 
salt solution (EBSS) to remove debris and unattached cells. Fresh serum-free medium 
containing 25 nM of dexamethasone was added and an overlay of matrigel (233 μg/
mL) was then applied. 1′-Hydroxyestragole and nevadensin were added to the culture 
media 24 h after cell seeding at the required concentrations (as described below).
Treatment of primary rat hepatocytes
Primary rat hepatocytes were treated with 50 μM 1′-hydroxyestragole (added from a 1000 
times concentrated stock solution in DMSO) in William’s E exposure medium supplemented 
with 2 mM L-glutamine, 10 mM hepes pH 7.4, ITS+, 15,000 U penicillin/streptomycin, 25 
nM dexamethasone. In addition, increasing concentrations of the identified SULT inhibitor 
(0 (control), 0.02, 0.2, and 4 μM, added from 200 times concentrated stock solutions in 
DMSO) were added. The cells were exposed for 4 h at 37°C in a humidified atmosphere 
containing 5% CO2 and 95% normal air. After exposure, cells were scraped in EBSS, and 
cells from three dishes were pooled in an Eppendorf vial and centrifuged at 6,000 rpm 
for 5 min (Eppendorf centrifuge, type 5415C, Hamburg, Germany) to obtain pellets. 
Thereafter, pellets were used for DNA extraction and digestion.
Extraction and digestion of E-3′-N2-dGuo formed in primary rat 
hepatocytes
DNA was isolated from rat hepatocyte pellets using the Get pure DNA Kit-Cell, 
Tissue kit (Dojindo Molecular Technology Inc., Kumamoto, Japan), according to the 
accompanying protocol. DNA pellets were dissolved in 100 μL ultra-pure water and 
stored at 4°C until DNA digestion. To this end, 12 μL of phosphodiesterase II solution 
(0.0004 U/μL), 10 μL of nuclease P1 solution (0.5 μg/μL in water), and 20 μL buffer 
(300 mM sodium acetate, 1 mM zinc sulfate, pH 5.3) were added to the DNA solution. 
The samples were incubated for 4 h at 37°C. Thereafter, 6 μL of a 1 U/μL alkaline 
phosphatase solution (1.3 U), 13 μL of phosphodiesterase I solution (0.00026 U/μL in 
water), and 20 μL buffer (500 mM Tris, 1 mM EDTA, pH 8) were added (Delatour et 
al., 2008). The samples were incubated for another 2 h at 37°C. Then, samples were 
filtered using Eppendorf tubes with a cut off membrane of 5,000 NMWL (Millipore). The 
hydrolyzed samples were evaporated to dryness using a speed vacuum Concentrator 
5301 (Westbury, NY, USA) and reconstituted in 50 μL water.
Quantification of E-3′-N2-dGuo by isotope dilution LC–ESI–MS/MS
Quantification was done using a sensitive method by isotope dilution, the LC–ESI–MS/
MS method was adapted from our previous study (Punt et al., 2007). Detailed explanation 
of the LC–ESI–MS/MS instrument method, sample preparation, and synthesis of the 
estragole nucleoside (15N5) E-3′-N
2-dGuo and E-3′-N2-dGuo are described previously 
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(Paini et al., 2010). Briefly, LC–ESI–MS/MS analysis was performed on an Agilent 
1100 series liquid chromatography system (Waldbronn, Germany) coupled to a TSQ 
Quantum triple quadruple mass spectrometer (Thermo Scientific, Sweden). 50 μL of 
the digested sample were mixed with 10 μL of the internal standard (15N5) E-3′-N
2-
dGuo (0.012 nmol). Aliquots of 10 μL were injected onto an Agilent Zorbax Extend 
C18 column, 2.1×50 mm, 3.5 Micron 80 Å (Basel, Switzerland), with a Zorbax guard 
column. Sample analysis was carried out by the selected reaction monitoring (SRM). 
Mass spectrometric analysis was done in a positive ion mode. The ion at m/z 414 
corresponds to the protonated molecule and the major product ion at m/z=298 is 
formed by the loss of the 2′-deoxyribose moiety (MW=116 Da); corresponding to the 
adducted base guanine (MW=298 Da). The internal standard (15N5) E-3′-N
2- dGuo and 
the E-3′-N2-dGuo were synthesized from a reaction between 1′-acetoxyestragole and 
2′-deoxyguanosine following the protocol previously described (Phillips et al., 1981). 
The adduct E-3′-N2-dGuo detected in the samples was adjusted to the total DNA 
amount detected in the sample and corrected for the MW of dGuo 347.2 g/mol in 
order to quantify the number of adducts formed per 1000 dGuo.
Determination of IC50
To determine the The half maximal inhibitory concentration (IC50) of the SULT 
inhibition by the identified SULT inhibitor of basil extract, increasing concentrations 
(0–4 μM) of the commercially available identified SULT inhibitor were incubated with 
pooled rat or human liver S9 fractions in the presence of 25 μM 7HC. The incubation 
conditions were as described above for the SULT activity assay, except for the final 
volume of the mixture which was increased to 200 μL. Moreover, the inhibitor was 
dissolved in DMSO instead of methanol to avoid evaporation and maintaining the 
initial concentrations. The inhibitor was added from 200 times concentrated stocks 
and the control incubations were performed without the SULT inhibitor but in the 
presence of 0.5% DMSO. The IC50 of the DNA adduct inhibition by the identified 
SULT inhibitor was calculated from the data obtained in primary rat hepatocytes 
using 1′-hydroxyestragole as a substrate (as described above) Thereafter, the IC50 was 
derived as described in the data analysis section.
Determination of the inhibition constant (Ki)
The Ki for SULT inhibition by the identified SULT inhibitor was determined by performing 
incubations for SULT activity by pooled rat and human liver S9 fractions, performed as 
described above but in the presence of increasing concentrations of 7HC (0–25 μM) 
in the absence or presence of 2 nM of the identified SULT inhibitor (a concentration 
that is close to the identified IC50 in the two S9 fractions) (see Results section). The 
apparent maximum velocity (Vmax(app)), apparent Michaelis–Menten constant (Km(app)) 
and the inhibition constant (Ki) for the SULT activity were determined by fitting the 
obtained data from triplicate independent measurements to the standard Michaelis–
Menten equations as described below (see Data analysis section).
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Effect of the identified inhibitor on 1′-hydroxyestragole 
glucuronidation and oxidation
The effect of the identified SULT inhibitor on 1′-hydroxyestragole oxidation was 
examined with pooled human and male rat liver microsomal fractions whereas the 
effect on 1′-hydroxyestragole glucuronidation was examined with pooled human 
liver microsomal fractions and male rat S9 fractions. The incubations were performed 
as described by our group previously (Punt et al., 2008; Punt et al., 2009) in the 
absence or presence of 20 μM of the identified SULT inhibitor added from a 200 
times concentrated stock solution in DMSO. The choice of the liver fractions was 
according to our previous studies (Punt et al., 2008; Punt et al., 2009) where the kinetic 
parameters for these reactions were determined.
Data analysis
The apparent maximum velocity (Vmax(app)) and apparent Michaelis–Menten constant 
(Km(app)) for the formation of phase II metabolites of estragole were determined by 
fitting the data to the standard Michaelis–Menten equation v=Vmax/(1+(Km/[S])),with 
[S] being the substrate concentration, using the Life Science Workbench (LSW) data 
analysis toolbox (version 1.1.1,MDL information Systems, Inc.). The IC50 was obtained 
by fitting the data to the standard hyperbolic equation Y=Vmax (1−(X/(IC50+X)))+Y2, 
with Y representing the percentage of the inhibited 7HCS compared to control, and 
Y2 representing the lowest value of Y. Analysis was performed using the LSW data 
analysis toolbox. The inhibition constant (Ki) was calculated by fitting the Vmax for the 
inhibited as well as the uninhibited sulfonation to the Michaelis–Menten equation for 
non-competitive inhibition (V′max=Vmax/(1+([I]/Ki))), with V′max being the inhibited Vmax 
and [I] being the inhibitor concentration (μM). To test whether the change in the Vmax 
and Km in the presence of nevadensin was significant, a two sample t-test (one sided) 
was performed after determining variances equality by the Levene’s version of the F 
test with SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA).
Estragole PBBK model
The rat and human PBBK models in our previous work to describe the dose-dependent 
bioactivation and detoxification of estragole in male rat liver (Punt et al., 2008) and 
human liver (Punt et al., 2009) were used in the present study to model the possible 
consequences of SULT inhibition for estragole bioactivation and detoxification. The 
models include separate compartments for liver, lung and kidney, which were found 
to be involved in the metabolism of estragole. Furthermore, a separate compartment 
for fat tissue was included in order to take into account the relatively higher partition 
coefficient of estragole in fat tissue. All other tissues were lumped into a rapidly 
perfused tissue group or a slowly perfused tissue group. The kinetic constants for 
phase I metabolism as well as for sulfonation of 1′- hydroxyestragole were according to 
our previous studies (Punt et al., 2007; Punt et al., 2008; Punt et al., 2009). The kinetic 
constants for glucuronidation and oxidation of 1′-hydroxyestragole were obtained in 
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the present study using similar incubation conditions as previously described by us 
(Punt et al., 2008, 2009) (see Results section). The values of the apparent maximum 
velocity (Vmax(app)) for the different phase I and II pathways were scaled to the liver 
assuming an S9 and microsomal protein yield of 143 and 32 mg per g liver respectively 
based on our previous work (Punt et al., 2008, 2009). The rate of estragole metabolism 
was calculated using Michaelis–Menten equations representing the various phase I 
and II reactions. Based on our previous work, estragole uptake from the gastro 
intestinal tract was assumed to be efficient and following first order kinetics in rat (Punt 
et al., 2008) and human (Punt et al., 2009). This is in line with studies reported in the 
literature (Sangster et al., 1987) where it was demonstrated that estragole was readily 
absorbed from the gastrointestinal tract when administered to human volunteers at a 
dose level close to the ones encountered in the diet (100 μg 14C-estragole). 
In the present study the inhibition of SULT-mediated conversion by the identified 
inhibitor from basil extract was integrated in the model. Since the inhibitor nevadensin 
was shown to inhibit the SULT catalyzed conversion of 7HC to 7HCS in a non-
competitive way, reducing Vmax and not affecting Km, a modulation factor (1+([I]/Ki)) for 
the apparent Vmax value was included in the Michaelis–Menten equation representing 
the sulfonation pathway as follows: 
dAMHES/dt= Vmax,L-HES/(1+([I]/Ki))×CLHE/PLHE/(Km,L-HES+(CLHE/PLHE)) 
where AMHES is the amount of 1′-sulfooxyestragole (μmol), Vmax,L HES is the maximum 
rate of formation of 1′-sulfooxyestragole, [I] is the concentration of the identified 
SULT inhibitor nevadensin in the liver (μmol/L), Ki is the inhibition constant for 
inhibition of the sulfonation by nevadensin (μmol/L), CLHE is the concentration of 
1′-hydroxyestragole in the liver (μmol/L), PLHE is the liver/blood partition coefficient, 
and Km is the Michaelis–Menten constant for the formation of 1′-sulfooxyestragole 
(μmol/L). The inhibition constant (Ki) for inhibition of the conversion of 7HC to 7HCS 
by the identified inhibitor was used in the model of estragole assuming equal Ki values 
for the two substrates (1′-hydroxyestragole and 7HC) and this was based on the fact 
that the type of inhibition was found to be non-competitive and, thus, not occurring at 
the substrate binding site of SULT. 
Using our PBBK models for estragole bioactivation and detoxification (Punt et al., 2008, 
2009), the time dependent concentration of estragole (CLE) in the liver of rat and human 
following an exposure to different doses of estragole can be predicted over a period of 
24 h. As a first approximation, the molar ratio (f) between estragole and nevadensin was 
kept at a constant value during the modeling time. To this end, nevadensin was assumed 
to follow a similar time dependent concentration curve in the liver as estragole and this 
was represented in the model by using the following equation [I]=CLE×f where CLE is the 
concentration of estragole in the liver (μmol/L) and f represents the molar ratio between 
the nevadensin and estragole concentrations. To obtain some insight into the effects 
resulting from possible differences in kinetics and bioavailability of the two compounds, 
the modeling was performed at different molar ratios (f). Thus the molar ratio (f) was varied 
40
2
from 0 (no nevadensin) to 2 (representing a nevadensin concentration that is twice as high 
as estragole). Accordingly, the effect of varying doses of nevadensin on the formation 
of 1′-sulfooxyestragole, 1′-hydroxyestragole glucuronide, and 1′-oxoestragole after 24 h 
could be predicted at different estragole doses. 
The doses of estragole chosen for the modeling were 0.07 mg/kg bw, the dose level 
considered relevant for human dietary exposure from all food sources (SCF, 2001a) and 50 
mg/kg bw representing a dose level at which different alkenylbenzenes were demonstrated 
to induce liver DNA adducts and/or hepatomas in rodents (Hagan et al., 1965; Boberg et 
al., 1983; Miller et al., 1983; NTP, 2000; Ellis, 2007; Rietjens et al., 2010).
RESULTS
Inhibition of SULT activity by a methanolic basil extract
Increasing concentrations of the methanolic basil extract inhibited SULT enzyme activity 
in a dose-dependent manner (Figure 2A). SULT activity was completely blocked at 100 
μg basil extract/mL similar to the effect induced by 25 μM of the SULT inhibitor PCP. 
Blanc incubations, which lacked the cofactor PAPS or which lacked the rat or human 
S9 fractions, did not show any formation of 7HCS (data not shown) indicating that the 
7HCS formation that was inhibited by the basil extract was totally dependent on the 
presence of PAPS and the SULT content of S9 fractions.
SULT inhibition by different fractions of basil extract
The methanolic basil extract was fractionated into 60 fractions using HPLC. The potency 
of each fraction in inhibiting SULT activity was examined. As shown in Figure 2B, different 
basil fractions were able to inhibit SULT activity to a different extent. The fraction with 
the highest inhibition potency was fraction 50 (Figure 2B) and when re-analyzed on 
HPLC-UV this fraction appeared to contain only one major constituent (data not shown).
Identification of a potent SULT inhibitor in basil extract
LC–ESI–MS/MS analysis of fraction 50 revealed the presence of a single peak 
eluting at 29.6 min, corresponding to a compound with a quasi-molecular ion at 
m/z 345. Fragmentation of this ion at m/z 345 gave rise to three major fragment 
ions at m/z 330 (100%), 315 (30%), and 312 (20%). Both the observed molecular 
ion and its fragmentation pattern appear to correspond to those reported for the 
compound nevadensin (5,7-dihydroxy-6,8,4′-trimethoxy flavone) (Grayer et al., 1996) 
(Figure 3). The UV spectrum with λmax
MeOH values observed at 283 and 330 nm was 
also in accordance to what has been described for nevadensin (Grayer et al., 1996) 
and similar to the UV spectrum of a commercially available standard of nevadensin. 
1H–NMR analysis of the compound and comparison of the 1H–NMR characteristics to 
those of a commercially available standard, also confirmed the compound in fraction 
50 to be nevadensin. 1H–NMR analysis of the compound and comparison of the 1H–
NMR characteristics to those of a commercially available standard, also confirmed the 
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compound in fraction 50 to be nevadensin (Grayer et al., 1996; Liu et al., 1996). 1H–
NMR analysis revealed the following characteristics: Nevadensin (C18O7H16); 
1H–NMR 
(CD3OD, δ ppm): 8.02 (2H, d, J=8.9 Hz, H-2′,6′), 7.15 (2H, d, J=8.9 Hz, H-3′,5′), 6.67 
(1H, s, H-3), 3.97, 3.93, 3.91 (3*3H, s, OMe-6,8,4′).
Figure 2. Inhibition of SULT catalyzed conversion of 7HC to 7HCS by (A) pooled rat liver S9 
homogenates in the presence of increasing concentrations of crude basil extracts or 25 µM 
PCP, and (B) HPLC collected basil fractions. 100% 7HCS formation is equal to 1.8 ± 0.68 nmol/
min/mg S9 protein. Data points represent mean (+SD) of triplicate measurements obtained 
in independent experiments. An asterisk (*) indicates a significant inhibition compared to the 
incubation without inhibitor (P < 0.05).
Figure 3. Structural formula of nevadensin; the SULT inhibitor from basil identified in the present study.
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Inhibition of E-3′-N2-dGuo formation by nevadensin in primary rat 
hepatocytes exposed to 1′-hydroxyestragole
To investigate whether the inhibition of SULT activity by nevadensin in a subcellular 
system such as S9 is maintained in an intact cell system, the effect of nevadensin on E-3′-
N2-dGuo adduct formation in primary rat hepatocytes exposed to 1′-hydroxyestragole 
was quantified. To this end, primary rat hepatocytes were exposed to 50 μM 
1′-hydroxyestragole in the absence or presence of increasing nevadensin concentrations 
(0–4 μM) and the major adduct E-3′-N2-dGuo was quantified by LC–ESI–MS/MS. The 
compounds were not cytotoxic to primary rat hepatocytes under the conditions used 
in these experiments as indicated by LDH activity measurements (data not shown). The 
results obtained revealed that the inhibition of E-3′-N2-dGuo was dose-dependent with 
an IC50 of 0.16±0.09 μM nevadensin (Figure 4), suggesting that the flavonoid nevadensin 
is able to pass through the cell membrane and exert an intracellular effect. 
Effect of nevadensin on the kinetics of SULT activity
The addition of increasing concentrations (0–4 μM) of nevadensin to SULT incubations 
with rat and human pooled liver S9 fractions, PAPS and 25 μM 7HC as the substrate 
revealed a dose-dependent inhibition of SULT activity with IC50 values of 4 nM and 
3 nM in incubations with male rat and human liver S9 fractions respectively (Figure 5). 
Plots of 7HCS formation by pooled liver S9 fractions of the two species versus 
the substrate concentration in the presence or absence of 2 nM of nevadensin are 
shown in Figure 6. The apparent Km and Vmax values derived from these curves for 
7HCS formation by male rat and human liver S9 fractions in the absence and presence 
of 2 nM nevadensin are presented in Table 1. The catalytic efficiency for the SULT-
Figure 4. E-3′-N2-dGuo formation in primary rat hepatocytes exposed for 4 h to 50 µM 
1′-hydroxyestragole in the absence or presence of increasing concentrations (0-4 µM) of 
nevadensin. Data points represent mean (+SD) of triplicate measurements obtained in 
independent experiments. An asterisk (*) indicates a significant inhibition compared to the 
incubation without inhibitor (P < 0.05).
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Figure 5. Inhibition of SULT activity in incubations with male rat S9 (dotted line) and pooled 
human liver S9 (solid line) by increasing concentrations of nevadensin (0-4 µM).
Table 1. Kinetic parameters of SULT-dependent formation of 7HCS by rat and pooled human 
liver S9 in the absence or presence of 2 nM nevadensin.
Without nevadensin with 2 nM nevadensin
Species
apparent Vmax
(pmol/min/ mg S9 
protein)
apparent Km 
(μM)
apparent Vmax
(pmol/min/ mg S9 
protein)
apparent Km 
(μM)
Ki
(μM)
Rat 1901±252 3.7±0.6 1251±173 3.1±0.2 0.004
Human 884±102 2.6±0.3 606±73 2.4±0.3 0.004
dependent formation of 7HCS, calculated as the apparent Vmax/Km, was about 1.5 
fold higher for male rat liver S9 than for human liver S9 fractions. The apparent Vmax 
for sulfonation was lowered 1.5 times for human as well as rat S9 fractions in the 
presence of 2 nM of nevadensin while the apparent Km values remained unaffected. 
These results point at a non-competitive type of inhibition for both rat and human 
SULT activity in the liver by nevadensin. The inhibition constant (Ki) obtained from the 
data amounted to 4 nM for both rat and human S9 fractions.
Effect of nevadensin on 1′-hydroxyestragole glucuronidation 
and oxidation
The kinetics of 1′-hydroxyestragole glucuronidation and oxidation in the absence and 
presence of 20 μM nevadensin were investigated for male rat as well as for pooled 
human liver S9/microsomal fractions (Table 2). The apparent Vmax and Km values 
for 1′-hydroxyestragole oxidation in the two fractions and for 1′-hydroxyestragole 
glucuronidation in pooled human microsomes (Table 2) in the absence of nevadensin 
were in agreement to what we have reported previously (Punt et al., 2008, 2009). 
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Figure 6. SULT dependent formation of 7HCS in incubations with male rat liver S9 (A) and pooled 
human liver microsomal fractions (B) in the absence (▲) or presence (●) of 2 nM nevadensin 
and increasing concentrations (0-25 µM) 7HC. Data points represent mean (+SD) of triplicate 
measurements obtained in independent experiments.
Table 2. Kinetic parameters for conversion of 1′-hydroxyestragole to 1′-oxoestragole in incubations 
with male rat and pooled human liver microsomal fractions and for 1′-hydroxyestragole 
glucuronide formation in male rat liver S9 and pooled human liver microsomal fractions in the 
absence or presence of  20 µM nevadensin.
Species
Without nevadensin with 20 µM nevadensin
apparent Vmax
(pmol/min/ mg S9 
protein)
apparent Km
(μM)
apparent Vmax
(pmol/min/ mg S9 
protein)
apparent Km
(μM)
Oxidation
Rat 15±0.6 2890±286 11±0.8 1937±169
Human 13±1.7 830±114 10.7±5 1089±664
Glucuronidation
Rat 151±20 241±40 138±23 209±16
Human 1.3±0.2 1708±405 1.3±0.2 1721±393
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For 1′-hydroxyestragole glucuronide formation in male rat liver S9 fractions, 
the apparent Vmax was 151± 20 nmol/min/mg S9 protein which is 21 fold higher 
than reported in our previous work (Punt et al., 2009) probably reflecting intra-
species variation. However the obtained Km of 241±41 μM was in the same order of 
magnitude. The addition of 20 μM of nevadensin to the incubations had no effect on 
the glucuronidation of 1′-hydroxyestragole in both rat S9 as well as pooled human 
microsomal fractions since the decrease in the apparent Vmax and Km values was not 
significant compared with the values of the uninhibited reaction (without nevadensin) 
(Table 2). Similarly, the addition of 20 μM nevadensin did not have an effect on the 
kinetics for oxidation of 1′-hydroxyestragole to 1′-oxoestragole by the human liver 
microsomal fractions (Table 2). In contrast, when using the male rat liver microsomal 
fractions of rat, the addition of 20 μM nevadensin resulted in a small but significant 
(P <0.01, obtained with a Student t-test in SPSS) decrease in the apparent Vmax and 
Km values for 1′-hydroxyestragole oxidation suggesting an un-competitive type 
of inhibition (Figure 7; Table 2). In this type of inhibition, the relative decrease in 
the apparent Vmax and Km values is similar (about 1.36) and thus the Ki value can be 
calculated either by fitting the kinetic parameters to the equation (V′max=Vmax/ (1+([I]/
Ki))) or (K′m =Km/(1+([I]/Ki))). Characteristic for this type of inhibition is that the inhibition 
becomes only significant at a relatively high substrate concentration which in this case 
was found to be higher than 1000 μM 1′-hydroxyestragole (Figure 7). Based on our 
previous PBBK data (Punt et al., 2008; Punt et al., 2009), this is not in the range of 
1′- hydroxyestragole concentrations expected in the in vivo situations.
Figure 7. Rate of 1′-oxoestragole formation in incubations with male rat microsomes containing 
increasing concentrations of 1′-hydroxyestragole in the absence (▲) or presence (●) of 20 
µM nevadensin. Data points represent mean (+SD) of triplicate measurements obtained in 
independent experiments.
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PBBK based predictions for estragole phase II metabolism  
in the presence of nevadensin
Figure 8 illustrates the PBBK predicted effect of an increasing dose of nevadensin 
(expressed as molar ratio to estragole) on the formation of 1′-sulfooxyestragole in 
rat and human liver. The data calculated for varying molar ratios of nevadensin to 
estragole also reflect what would happen if the uptake of nevadensin would be lower 
than 100% (Han et al., 1981). As predicted by the PBBK model, the co-administration 
of a dose of estragole of 0.07 mg/kg bw (SCF, 2001a) together with an increasing 
dose of nevadensin will lead to a dose dependent decrease in the formation of the 
ultimate carcinogen 1′-sulfooxyestragole, whereas the levels of 1′-hydroxyestragole 
glucuronide and 1′-oxoestragole formation remain unaffected (data not shown). 
Assuming 100% uptake of nevadensin and metabolic conversion similar to that of 
estragole, the PBBK model predicts that at a molar ratio between estragole and 
nevadensin of 1, a 91% and 96% inhibition of the formation of 1′-sulfooxyestragole in 
the liver of male rat and human can be expected (Figure 8A).
Assuming a 1% instead of a 100% uptake of nevadensin (theoretically similar to a 
nevadensin: estragole molar ratio of 0.01), the model still predicts about 17% and 43% 
inhibition of 1′-sulfooxyestragole formation as compared to control in rat and human 
respectively (Figure 8A). Figure 8B presents the results obtained when the same PBBK 
modeling was performed at a dose of estragole of 50 mg/kg bw representing a dose 
level at which different alkenylbenzenes were shown to induce hepatic tumours and/or 
DNA adducts in vivo (Hagan et al., 1965; Boberg et al., 1983; Miller et al., 1983; NTP, 
2000; Ellis, 2007; Rietjens et al., 2010). At a molar ratio of nevadensin to estragole of 
0.06, at which the two compounds are expected to be present in basil (as characterized 
in the present study by HPLC by means of a calibration curve), the model predicts 
an almost complete inhibition of 1′-sulfooxyestragole formation in the liver of male 
rat and human when assuming 100% uptake of nevadensin (Figure 8B). Assuming 
1% uptake of nevadensin (theoretically similar to a nevadensin: estragole ratio of 
6×10−4), the PBBK model still predicts 84% and 88% inhibition of 1′-sulfooxyestragole 
formation in the two species respectively (Figure 8B). 
DISCUSSION 
The present study identifies nevadensin (5,7-dihydroxy-6,8,4′-trimethoxyflavone) as a 
major SULT inhibiting ingredient in basil. Nevadensin is a partially methylated flavone 
aglycone. The presence of three methoxy groups explains its elution at a high methanol 
concentration (∼83%) due to an increased lipophilicity compared to non-methylated 
flavones (Grayer et al., 1996; Vieira et al., 2003) nevadensin has been reported as a major 
flavone constituent in the Lamiaceae family from the genus Ocimum basilicum and has 
been reported to amount to 5.6–58.4% of the total flavones present (Grayer et al., 1996). 
In addition to nevadensin, basil may contain other flavone aglycones, including, for 
example, apigenin, cirsilineol, eupatorin, and salvigenin (Grayer et al., 1996). However, 
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most of these flavones are present in relatively lower quantities than nevadensin or may be 
absent in some varieties of basil, which, together with the data of the present study, leads 
to the conclusion that nevadensin is the major flavone type SULT inhibitor present in basil. 
Several other studies already reported that some flavones exert an inhibitory effect 
on SULT activity (Surh, 1983; Gilissen et al., 1994; Kato and Yamazoe, 1994; Miller, 
1994; Morimitsu et al., 2004). The study of Morimitsu et al. (2004) even revealed a 
structure activity relationship for the inhibitory action of flavonoids on sulfonation. 
In agreement with the present study, nevadensin was found to possess the structural 
requirements for effective inhibitory activity linked to the presence of C5 and C7 
hydroxyl substituents on the A ring and also a C2–3 double bond in conjunction with 
Figure 8. PBBK-based predictions for the dose dependent effect of nevadensin on 1′-sulfooxyestragole 
formation in the liver of rat (gray bar) and human (black bar) at (A) 0.07 mg/kg bw and (B) 50
 
mg/ kg 
bw of estragole. 
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the C4 carbonyl group on the C-ring. Salvigenin, a major flavone constituent in basil 
(Grayer et al., 1996) is not expected to exert an effect on sulfonation because it lacks 
these structural requirements. Apigenin on the other hand which is a minor flavone 
constituent in basil (Grayer et al., 1996) is reported to inhibit sulfonation formation 
in cultured hepatocytes (Morimitsu et al., 2004) and also possesses the structural 
features for SULT inhibition mentioned above. 
Since the composition and levels of flavonoids and other active ingredients like 
alkenylbenzenes in a herb or spice can vary significantly based on different factors such 
as plant maturity at harvest, harvesting techniques, storage conditions, processing (e.g. 
drying), and method of measurement (e.g. extraction), present state-of-the-art intake 
estimates for ingredients from botanicals and botanical preparations are not refined 
to such an extent that the actual human exposure levels of these two chemicals can 
be determined in an accurate way. However to get an impression about the effect of 
nevadensin on estragole bioactivation at different levels of intake and bioavailability/
uptake, PBBK modeling was performed at various molar ratios of the two compounds. 
The Michaelis–Menten constants obtained in the present study for 7HCS formation 
in incubations with S9 fractions from male rat and human liver were in agreement with 
our previous work and literature (Wang et al., 2006; Punt et al., 2007). The kinetics for 
the inhibition of SULT activity by nevadensin obtained in the present study indicate a 
non-competitive inhibition since the addition of 2 nM of nevadensin resulted in lowering 
the apparent Vmax values without an effect on the apparent Km value. It is not unexpected 
to observe a non-competitive inhibition type as there were a few reports showing that 
several dietary flavonoids such as quercetin, kaempferol, genistein, and diadzein were 
found to inhibit the sulfonation of estradiol by SULT1A1 non-competitively with Ki values 
ranging from 100 to 700 nM (Walle et al., 1995; Eaton et al., 1996; Ghazali and Waring, 
1999; Mesía -Vela and Kauffman, 2003). In comparison, the Ki value for nevadensin 
dependent SULT inhibition (4 nM) for both male rat and human liver S9 fractions was two 
orders of magnitude lower, indicating that nevadensin is a potent SULT inhibitor. 
In addition to the effect of nevadensin on SULT activity, also its possible effect 
on other phase II pathways contributing to 1′-hydroxyestragole conversion in rat and 
human liver, namely, the glucuronidation and oxidation of 1′-hydroxyestragole, was 
characterized  in the present study. The relative inhibition of SULT activity as compared 
to 1′-hydroxyestragole detoxification through glucuronidation and oxidation can be 
expected to ultimately determine whether metabolism of 1′-hydroxyestragole will be 
shifted toward detoxification at the expense of sulfonation. In sharp contrast to the 
effect of nevadensin on sulfonation, nevadensin up to a concentration of 20 μM did 
not inhibit detoxification via glucuronidation and oxidation of 1′-hydroxyestragole 
to any significant extent at physiologically relevant doses of the ultimate carcinogen 
1′-hydroxyestragole in S9 and microsomal liver fractions. 
Due to the practical constraints when using 1′-hydroxyestragole as substrate for 
the SULT assay, because of the instability of its sulfonated metabolite, conversion of 
7HC to 7HCS was used in the present study to characterize the kinetics for nevadensin 
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SULT-mediated inhibition. This raises the question regarding the relevance of the Ki 
obtained for sulfonation when using 7HC instead of 1′-hydroxyestragole as a substrate. 
This is mainly because the catalytic efficiency of the SULT-mediated conversion is 
dramatically different for the two substrates, amounting to 559 and 0.3 pmol/min/mg 
S9 protein in male rat and 353.6 and 0.01 pmol/min/mg S9 protein in human liver S9 
fractions for 1′-hydroxyestragole and 7HC respectively. However, the type of inhibition 
by nevadensin was found to be non-competitive, meaning that only the apparent Vmax 
and not the apparent Km of the enzyme was found to be affected, and this corroborates 
the assumption that nevadensin does not interfere with the substrate binding site and 
exerts its inhibiting effect by interaction with another site on the enzyme that is not 
involved in substrate binding (Simmons, 1996). Therefore, the Ki is not expected to 
be significantly different when using 1′-hydroxyestragole or 7HC as the substrate. This 
would be in line with the results reported by Eaton et al. (1996) showing that the Ki values 
for the quercetin-mediated inhibition of sulfonation for the substrates acetaminophen, 
minoxidil, and p-nitrophenol, each showing a vastly different Km value, were similar and 
all SULT conversions were inhibited in a non-competitive way by this other flavonoid. 
It is also of importance to note that flavonoid glucuronides and sulfonates are 
reported to be the predominant circulating chemical species and this may hold 
for nevadensin as well. However, studies in which cells in vitro were exposed 
to glucuronidated and sulfonated conjugates of a related flavonoid, quercetin, 
demonstrated that within the cells the flavonoid was no longer conjugated, due to 
efficient extra- and/or intracellular deconjugation (Lee-Hilz et al., 2008). 
The actual SULT isoenzyme responsible for 1′-hydroxyestragole sulfonation has 
not yet been elucidated, and also identification of the SULT enzyme inhibited by 
nevadensin remains a subject for future research. 
In a next step of the present study the inhibition of SULT by nevadensin was 
incorporated into our physiologically based biokinetic (PBBK) models for estragole 
bioactivation and detoxification in rat and human (Punt et al., 2008, 2009). These 
modified PBBK models allow evaluation of the bioactivation and detoxification of 
estragole in the liver of male rat and human when exposure to estragole is combined 
with exposure to nevadensin. This approach illustrates the conclusions reported before 
that PBBK modeling facilitates the extrapolation of the occurrence and magnitude of 
interactions of binary mixtures from the in vitro to the in vivo situation (Krishnan et 
al., 2002). The models thus obtained in the present study allowed prediction of the 
dose-dependent inhibition of the formation of the ultimate carcinogenic metabolite 
1′-sulfooxyestragole in the liver of male rat and human by co-administered dose levels 
of nevadensin and estragole. The models also predict the nevadensin-mediated 
changes in the overall formation of the metabolites that reflect detoxification by 
glucuronidation and oxidation of 1′-hydroxyestragole. Since the actual kinetic 
parameters for nevadensin were not available and because the quantification of these 
parameters was beyond the scope of the present paper, in a first approximation, 
both estragole and nevadensin were assumed to follow a similar time dependent 
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concentration curve. Different molar ratios of the two compounds were modelled to 
provide some insight in the effects of possible differences in kinetics and uptake of 
the two compounds. The PBBK models developed predict that at an estragole dose 
level of 50 mg/kg bw and a nevadensin: estragole ratio of 0.06, the estimated ratio 
between the two compounds in basil, nevadensin would inhibit 1′-sulfooxyestragole 
formation in male rat and human liver by respectively 99.7% and 99.5% or 84% and 
88% assuming 100 or 1% nevadensin uptake. Thus formation of 1′-sulfooxyestragole 
is expected to be significantly, though not completely blocked. 
Other flavonoids that are part of the human diet possess a potent SULT inhibitory 
effect as well (Gibb et al., 1987; Marchetti et al., 2001; De Santi et al., 2002; Morimitsu et 
al., 2004) implying that the formation of 1′-sulfooxyestragole could be even lower due to 
the combination of estragole exposure with other food borne SULT inhibitors together 
with nevadensin from basil. Moreover, not only can the bioactivation of alkenylbenzenes 
be affected by the food matrix but also their bioavailability might be reduced (Schilter 
et al., 2003) due to reduced absorption from the gastrointestinal tract which can be 
attributed to slow or inadequate release of alkenylbenzenes from the complex food 
matrix. Another point of interest is that the modeling also reveals that the effect of a 
given ratio of nevadensin to estragole on 1′-sulfooxyestragole formation varies with 
the dose of estragole. Thus at a molar ratio of nevadensin to estragole of 0.06, the 
percentage of inhibition decreases going from 99.7 and 99.5% at an estragole dose 
of 50 mg/kg bw to 51% and 75% at an estragole dose of 0.07 mg/kgbw in the liver of 
rat and human respectively. This can be explained by the fact that the concentration of 
the inhibitor nevadensin is higher in the former situation (at 50 mg/kg bw) than in the 
latter situation (at 0.07 mg/kg bw) resulting in more efficient inhibition given the Ki of 4 
nm in the two species. This is a well-known characteristic of non-competitive inhibition 
(Simmons, 1996). Altogether, the PBBK modeling reveals that the inhibition of SULT-
mediated bioactivation to 1′-sulfooxyestragole upon combined exposure to estragole 
and nevadensin may be significant even at realistic low dose human exposure levels and 
even when the uptake of ND would be significantly lower than 100%. 
Furthermore it may be of interest to note that many flavonoids have been shown to 
interact with efflux transporters such as ABCB1, MRP1, MRP2, and BCRP in vitro as well 
as in vivo (Brand et al., 2006; Morris and Zhang, 2006) but no such studies were found for 
nevadensin in particular. Thus to predict how these effects would influence the results and 
conclusions is difficult to quantify. In a qualitative way inhibition of apical ABC transporters 
in intestinal cells will increase bioavailability whereas inhibition of basolateral transporters 
may oppose bioavailability. Thus, one can assume for example that bioavailability of both 
compounds will be affected in a similar way and this is actually what has been done in the 
present modeling approach assuming toxico kinetics for nevadensin to mimic those of 
estragole keeping the ratio between the two compounds constant in time.
Nevadensin was also shown to inhibit the DNA adduct formation in 
1′-hydroxyestragole exposed primary rat hepatocytes with an IC50 value of 0.16±0.09 
μM and thus one order of magnitude higher than the IC50 required for in vitro inhibition 
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of SULT-mediated conversion of 7HC in S9 fractions. Taking into account that the DNA 
adduct inhibition occurs at the SULT enzyme level, the IC50 for the inhibition of DNA 
adduct formation can be compared to that obtained for the SULT inhibition in liver 
S9 fractions. The difference in IC50 values might be attributable to high serum protein 
binding, poor plasma membrane permeability, as well as degradation to inactive 
metabolites (Griffiths and Smith, 1972; Kühnau, 1976). These findings are in line with 
those of Morimitsu et al. (2004) where the IC50 for the inhibited sulfonation by a series 
of flavonoids in primary rat hepatocytes was one order of magnitude higher than 
in liver cytosolic fractions. The efficiency of nevadensin in inhibiting the sulfonation 
of 1′-hydroxyestragole and thus its potential protective effect against bioactivation 
of estragole to the proximate carcinogen still needs to be established in in vivo 
experiments where other factors such as its bioavailability and metabolic stability 
should play a crucial role. Of interest in this respect is that methylated flavones such as 
nevadensin have been demonstrated to be much more metabolically stable than their 
unmethylated analogues which are reflected by their resistance to hepatic metabolism 
and stability in the intestinal epithelial cell layer. Furthermore, they also have higher 
intestinal absorption through Caco-2 cell monolayers. Both factors should greatly 
increase their oral bioavailability (Wen and Walle, 2006; Walle, 2007). 
According to our previous studies, it is also important to stress that species 
dependent differences in the in vivo metabolism of estragole may exist (Sangster et 
al., 1987; Punt et al., 2009; Rietjens et al., 2010). For example, detoxification of 1′ 
-hydroxyestragole in rat mainly proceeds through glucuronidation whereas in human it 
mainly proceeds by oxidation to 1′-oxoestragole (Punt et al., 2009). Clearly, the PBBK 
models will be of use to investigate also the possible species differences in the effects 
of the inhibitor nevadensin on the in vivo metabolic pathways of estragole. The initial 
modeling results presented in Figure 8 for example already suggest that the inhibiting 
effect of nevadensin on 1′-sulfooxyestragole formation levels may be somewhat more 
pronounced in human than in rat.
In conclusion, the present study identifies the potent SULT inhibitor present in basil to 
be nevadensin, an important and major flavonoid constituent of basil. This also points 
at a strong matrix effect of combined exposure to estragole and nevadensin. The 
SULT inhibition was shown to lead to the inhibition of the formation of the ultimate 
carcinogenic metabolite, without reducing the rate of detoxification of the proximate 
carcinogen 1′-hydroxyestragole via glucuronidation or oxidation. If the PBBK predicted 
data can be validated in vivo, which is an important issue for future research, this 
would imply that the consumption of estragole within a matrix of sweet basil or other 
food items containing SULT inhibitors would not pose a significant risk if any. Dietary 
SULT inhibitors include a wide variety of compounds such as for example flavonoids 
like nevadensin, which was identified in the present paper to be a highly efficient SULT 
inhibitor, but also epicatechin gallate, epigallocatechin gallate, gallocatechin gallate 
(Coughtrie and Johnston, 2001), quercetin (Walle et al., 1995), and also including 
some food additives such as carmoisine, octyl gallate, tartrazine and vanillin (Bamforth 
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et al., 1993). The safety of alkenylbenzene-containing botanicals could consequently 
be judged and regulated on the basis of the estimated daily intakes of the different 
alkenylbenzenes compared to the estimated daily intakes of the different respective 
SULT inhibitors that are present in the diet. Further research investigations are directed 
at screening estragole-containing botanicals for the presence of SULT inhibitors, 
quantifying their inhibiting efficiencies as potential chemopreventive compounds, 
reducing DNA adduct formation and ultimately carcinogenic risk in vivo.
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Matrix modulation of the bioactivation 
of estragole by constituents of different 
alkenylbenzene-containing herbs and spices 
and physiologically based biokinetic (PBBK) 
modeling of possible in vivo effects
Based on: Alhusainy W, van den Berg SJPL, Paini A, 
Campana A, Asselman M, Spenkelink A, Punt A, Scholz G, 
Schilter B, Adams TB, van Bladeren PJ, and Rietjens IMCM 
Toxicological Sciences 129 (2012), 174–187
ABSTRACT
The alkenylbenzene estragole is a constituent of several herbs and spices. It induces 
hepatomas in rodents at high doses following bioactivation by cytochrome P450s 
and sulfotransferases (SULTs) giving rise to the ultimate carcinogenic metabolite 
1’-sulfooxyestragole which forms DNA adducts. Methanolic extracts from different 
alkenylbenzene-containing herbs and spices were able to inhibit SULT activity. 
Flavonoids including quercetin, kaempferol, myricetin, apigenin, and nevadensin 
were the major constituents responsible for this inhibition with Ki values in the nano 
to micromolar range. In human HepG2 cells exposed to the proximate carcinogen 
1′-hydroxyestragole, the various flavonoids were able to inhibit estragole DNA adduct 
formation and shift metabolism in favour of glucuronidation which is a detoxification 
pathway for 1′-hydroxyestragole. In a next step, the kinetics for SULT inhibition were 
incorporated in physiologically based biokinetic (PBBK) models for estragole in rat and 
human to predict the effect of co-exposure to estragole and (mixtures of) the different 
flavonoids on the bioactivation in vivo. The PBBK model based predictions indicate 
that the reduction of estragole bioactivation in rat and human by co-administration of 
the flavonoids is dependent on whether the intracellular liver concentrations of the 
flavonoids can reach their Ki values. It is expected that this is most easily achieved for 
nevadensin which has a Ki value in the nanomolar range and is, due to its methylation, 
more metabolically stable than the other flavonoids.
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INTRODUCTION
Herbs and spices have a long history of use as food, flavouring and coloring agents 
throughout the world (Smith et al., 2002; Dearlove et al., 2008). In culinary usage, 
herbs are most commonly seasonings derived from leaves of plants. Spices, in 
contrast, are obtained from seeds, berries, fruits, barks, or roots (Dearlove et al., 
2008). Alkenylbenzenes such as estragole (1-allyl-4-methoxybenzene), present in the 
volatile oils, contribute to the characteristic taste and fragrance of many herbs and 
spices including nutmeg, basil, anise, mace, tarragon, fennel, and pimento (Smith et 
al., 2002). Oral intake of estragole results primarily from consumption of foods, mainly 
herbs and spices, and of their essential oils. 
Based on rodent studies, estragole was found to be genotoxic and carcinogenic 
(Drinkwater et al., 1976; Miller et al., 1983). Based on these findings, the addition of 
estragole as a pure substance in foodstuffs has been prohibited since September 2008 
within the European Union (European Commission, 2008). Realistic daily intake levels 
of estragole have been estimated to range from 0.01 mg/kg bw/day (Smith et al., 
2002) to 0.07 mg/kg bw/day (SCF, 2001). Given that at present addition of estragole 
as a pure compound to individual food categories is no longer allowed, the value of 
0.01 mg/kg bw/ day resulting mainly from herbs and spices (Smith et al., 2002) is taken 
in the present study as the value for current levels of dietary human intake. 
Figure 1 presents an overview of the bioactivation and detoxification pathways of 
estragole. Based on in vivo studies, at low doses (<10 mg/kg bw), O-demethylation 
appears to be more favoured in humans and in rodents and yields phenolic derivatives 
which are to a large extent excreted as the sulfonate or glucuronic acid conjugate (Anthony 
et al., 1987; Sangster et al., 1987). Bioactivation of estragole proceeds by 1′-hydroxylation 
to 1′-hydroxyestragole and subsequent sulfonation to 1′-sulfooxyestragole. The sulfonate 
conjugate of 1′-hydroxyestragole is unstable and hydrolyzes to form a reactive electrophilic 
intermediate (carbocation ion) which has been linked to glutathione (GSH) depletion, 
oxidative stress, protein-, DNA-, and GSH-adduct formation, probably at or near the site 
of formation (Phillips et al., 1981; Smith et al., 2002). Therefore, the sulfonate conjugate of 
1′-hydroxyestragole is considered to be the ultimate hepatotoxic and hepatocarcinogenic 
agent in rodents (Boberg et al., 1983). This conclusion was corroborated by co-
administration of the specific sulfotransferase (SULT) inhibitor pentachlorophenol (PCP), 
which resulted in a potent inhibition of hepatic tumour induction by long-term dietary 
administration of the closely related alkenylbenzenes safrole or 1′-hydroxysafrole and 
a significant decrease of SULT activity and hepatic DNA and RNA adduct formation by 
1′-hydroxysafrole in mice (Boberg et al., 1983). 
A significant difficulty in evaluating the metabolic, biochemical, and toxicological 
data for estragole as well as other alkenylbenzenes is that human exposure to these 
substances results from exposure to a complex mixture of food, spice, and spice oil 
constituents which may significantly impact the biochemical fate and toxicological risk of 
the alkenylbenzenes. In this respect, we have previously demonstrated that a methanolic 
extract from basil, which contained estragole, also contained the flavone nevadensin 
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(5,7-dihydroxy-6,8,4′-trimethoxyflavone) which was able to inhibit DNA-adduct 
formation in rat hepatocytes exposed to the proximate carcinogen 1′ hydroxyestragole 
(Jeurissen et al., 2008; Alhusainy et al., 2010). This inhibition by nevadensin was shown 
to occur at the level of SULT-mediated bioactivation of 1′-hydroxyestragole (Jeurissen 
et al., 2008; Alhusainy et al., 2010). Altogether, the results of our previous research 
point at a reduction of DNA-adduct formation and consequently a potential reduction 
of cancer risk when estragole exposure occurs within a food matrix containing SULT 
inhibitors compared with what is observed upon exposure to pure estragole. Given 
these previous results, the objectives of the present study were i) to identify the presence 
Figure 1. Bioactivation and detoxification pathways of estragole.
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and nature of possible SULT inhibitors able to interfere with estragole bioactivation in 
other alkenylbenzene-containing botanical preparations and ii) to predict the possible 
effects of combined exposure to a mixture of SULT inhibitors on formation levels of the 
ultimate carcinogen 1′-sulfooxyestragole at physiologically relevant concentrations by 
incorporating the kinetics for SULT inhibition by the compounds in the mixture into our 
recently developed physiologically based biokinetic (PBBK) models for estragole in the 
liver of rat (Punt et al., 2008) and human (Punt et al., 2009).
MATERIALS AND METHODS
Materials and chemicals
1′-Hydroxyestragole and 1′-acetoxyestragole are genotoxic and carcinogenic 
compounds and caution should be taken when handling them. 
Twelve dried herbs and spices were purchased from local supermarkets: nutmeg 
and mace (Myristica fragrans Houtt.), star anise (Illicium verum Hook. f.), parsley 
(Petroselinum crispum (Mill.) Nyman ex A.W. Hill), pimento/allspice (Pimenta dioica 
(L.) Merr.), cinnamon (Cinnamomum zeylanicum J. Presl.), dill (Anethum graveolens 
L.), laurel (Laurus nobilis L.), tarragon (Artemisia dracunculus L.), fennel (Foeniculum 
vulgare Mill.), anise (Pimpinella anisum L.), and basil (Ocimum basilicum L.). 
7-Hydroxycoumarin (7HC; 99%), 7-hydroxycoumarin sulfate (7HCS; 99%), quercetin, 
kaempferol, myricetin, apigenin, luteolin, 3′-phosphoadenosine-5′-phosphosulfate 
(PAPS), GSH, uridine 5′-diphosphoglucuronic acid (UDPGA), and fetal bovine serum 
were obtained from Sigma Aldrich (Steinheim, Germany). Nicotinamide adenine 
dinucleotide (NAD+) was obtained from Roche Diagnostics (Mannheim, Germany). 
Nevadensin was purchased from Apin Chemicals (Milton, U.K.). Trifluoroacetic 
acid was obtained from Mallinckrodt Baker B.V. (The Netherlands). Methanol (Ultra 
Liquid Chromatography/Mass Spectrometry, ULC/MS) and acetonitrile (ULC/MS) 
were obtained from Biosolve (Valkenswaard, The Netherlands), and pro-analysis 
grade acetic acid was purchased from VWR (Darmstadt, Germany). Hanks Balanced 
Salt Solution (HBSS), PBS, and gentamicin were purchased from Gibco (Paisley, U.K.). 
DMEM-F12 L-glutamine medium, tris-hydroxymethylaminomethane (tris), and trypsin 
were obtained from Invitrogen (Breda, The Netherlands). Dimethyl sulfoxide (DMSO), 
spectroscopic grade (99.9%) was supplied by Acros Organics (Geel, Belgium). 
Pooled male rat (Sprague–Dawley), pooled human liver S9, and microsomal 
homogenates were obtained from BD Gentest (Woburn, MA), and PCP (98%) was 
obtained from Sigma-Riedel de Haen (Seelze, Germany). Nano pure water was 
obtained from a Barnstead Nano pure Type I ultrapure water system. 
1′-Hydroxyestragole was synthesized as described previously by Drinkwater et al. 
(1976) based on a method described for the synthesis of 1′-hydroxysafrole (Borchert et 
al., 1973). Structural confirmation by Gas Chromatography-Mass Spectrometry (GC–
MS) was carried out as described previously (Punt et al., 2007).
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Preparation of methanolic herb and spice extracts
Methanolic herb and spice extracts were prepared according to the method described 
previously (Jeurissen et al., 2008; Alhusainy et al., 2010). In short, herb and spice 
extracts were prepared by stirring 5 g of dried herb or spice twice for 2 h at room 
temperature, each time with 100 mL of a mixture of methanol, ultra-pure water, and 
acetic acid (ratio 80:19:1). The extracts obtained were filtered using a folded filter 
(Schleicher & Schuell), and the pooled filtrates were evaporated to dryness under 
vacuum using a Rotavapor apparatus (Heidolph Laborota 4000 efficient). Star anise 
was first minced using a pair of scissors, and then using a pestle and mortar to obtain 
an efficient extraction yield. The extraction yields for the different herbs and spices 
ranged between 18 and 49% (w/w). Afterwards, the dried extracts were dissolved 
in methanol to achieve three concentrated extract stocks (2, 5, and 20 mg/mL) as 
described previously (Alhusainy et al., 2010). 
Measurement of SULT activity
SULT activity and its inhibition by different herb and spice extracts (nutmeg, mace, star anise, 
parsley, pimento/allspice, cinnamon, dill, laurel, tarragon, fennel, anise, and basil) were 
quantified using the standard substrate 7-hydroxycoumarine (7HC) in line with our previous 
work (Alhusainy et al., 2010). Unlike the sulfonated metabolite of 1′-hydroxyestragole, the 
metabolite resulting from the sulfonation of 7HC is stable in aqueous solution and can 
be detected and quantified by High Performance Liquid Chromatography-Ultraviolet 
detection (HPLC–UV) as described previously (Wang et al., 2006; Alhusainy et al., 2010). 
Identification of SULT inhibitors in alkenylbenzene-containing herbs 
and spices
The methanolic herb and spice extracts which resulted in the most potent inhibition of 
SULT activity were fractionated using HPLC–UV, and the fractions obtained were tested 
for their effect on SULT activity as described in our previous work (Alhusainy et al., 2010). 
The compounds in the most active fractions were identified based on comparison of their 
UV spectra and retention time to the UV spectra and the retention times of commercially 
available reference compounds. In addition, a literature review was made to screen for 
major SULT inhibitors present in these alkenylbenzene-containing herbs and spices.
Kinetics for inhibition of SULT-catalyzed conversion of 7HC into 7HCS 
and of oxidation and glucuronidation of 1′-hydroxyestragole 
into 1′-oxoestragole and 1′-hydroxyestragole glucuronide 
by selected flavonoids
The Ki for SULT inhibition was determined by performing incubations for SULT activity 
with pooled male rat liver S9 fractions in the presence of increasing concentrations of 
7HC (0–100 μM) in the absence or presence of 0.75 μM quercetin, 0.3 μM kaempferol, 
5 μM myricetin, or 0.35 μM apigenin. These flavonoid concentrations were selected 
because they were close to the identified inhibitory concentration 50% (IC50) values 
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determined with pooled male rat liver S9 fractions (data not shown). Incubations were 
performed as described previously (Alhusainy et al., 2010). 
The possible effects of the identified SULT inhibitors on the detoxification of 
1′-hydroxyestragole by glucuronidation and oxidation (Figure 1) were quantified in 
vitro as well. The Ki for the inhibition of 1′-hydroxyestragole oxidation was determined 
by performing incubations with pooled human liver microsomes in the presence of 
increasing concentrations of 1′-hydroxyestragole (0–1000 μM) in the absence or 
presence of 5 μM quercetin, 5 μM kaempferol, 10 μM myricetin, and 10 μM apigenin. 
These flavonoid concentrations were selected because they were close to the 
identified IC50 values determined with pooled human liver microsomal fractions (data 
not shown). Incubations were performed as previously described (Alhusainy et al., 
2010). Subsequently, the maximum velocity (Vmax), the Michaelis–Menten constant (Km), 
and the inhibition constant (Ki) for the formation of 7HCS and 1′-oxoestragole were 
determined as described below (Data Analysis). 
Incubations for testing the effect of the identified SULT inhibitors on 
1′-hydroxyestragole glucuronidation were also performed. In short, the effect of 
the identified botanical constituents quercetin, kaempferol, myricetin, and apigenin 
on 1′-hydroxyestragole glucuronidation was examined with pooled human liver 
microsomes. The incubations were performed as described previously (Punt et 
al., 2009; Alhusainy et al., 2010) in the absence or presence of each respective 
flavonoid up to a concentration of 80 μM and at 1000 μM of 1′ hydroxyestragole (a 
concentration close to the Km value determined by Punt et al. (2009) for the formation 
of 1′-hydroxyestragole glucuronide by pooled human liver microsomes, both added 
from 200 times concentrated stock solutions in DMSO.
Effect of flavonoid mixtures on SULT activity and on oxidation  
of 1′-hydroxyestragole
Incubations for testing the SULT inhibition by a mixture of quercetin, kaempferol, 
apigenin, and nevadensin (each flavonoid added from a 400 times concentrated 
stock solution in DMSO) were performed using pooled male rat liver S9 fractions at 
concentrations equal to 0Ki (DMSO control), 0.2Ki, 0.5Ki, 1Ki, 2Ki, 5Ki, or 10Ki of each 
flavonoid together with 25 μM of the substrate 7HC with incubation conditions similar 
to what was described previously (Alhusainy et al., 2010). 
Incubations for testing inhibition of conversion of 1′ hydroxyestragole to 
1′-oxoestragole by a mixture of quercetin, kaempferol, myricetin, and apigenin were 
performed using pooled human liver microsomes. These flavonoids were added to 
the incubation mixtures from 400 times concentrated stock solutions in DMSO at 
final concentrations equal to 0Ki (DMSO control), 0.1Ki, 0.2Ki, 0.5Ki, 1Ki, or 2Ki of 
each flavonoid together with 400 μM of the substrate (a concentration close to the 
Km value determined by Punt et al. (2009) for the conversion of 1′-hydroxyestragole 
to 1′-oxoestragole by pooled human liver microsomes) using incubation conditions 
similar to what was described previously (Alhusainy et al., 2010). 
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Cultivation and treatments of HepG2 cells
A total of approximately 1×106 HepG2 cells/well were seeded in a six-well plate with each 
well containing DMEM/F12 medium containing GlutaMax, 10% fetal bovine serum, and 50 
μg/mL gentamycin and incubated in a humidified incubator, 5% CO2 and 95% air at 37°C 
until confluent monolayers were obtained. Then, cells were washed with HBSS. Cytotoxicity 
of the test compounds was evaluated using the MTT test (Hussain et al., 1993). 
For testing detoxification and bioactivation of 1′-hydroxyestragole in response to 
different flavonoid treatments, cells were exposed to 50 μM 1′-hydroxyestragole, added 
from a 1000 times concentrated stock solution in DMSO, in the absence or presence 
of the flavonoid mixtures. All flavonoids when tested individually or in a mixture (Table 
4 in the Results section) were added individually from 800 times concentrated stock 
solutions in DMSO to DMEM/F12 containing GlutaMax and 50 μg/mL gentamicin and 
incubations were performed for 22 h at 37°C in a humidified atmosphere. 
 To measure the effect of the different flavonoids or their mixtures on the formation of 
the major DNA adduct N2-(trans-isoestragol-3′-y1)-2′-deoxyguanosine (E-3′-N2-dGuo), 
cells were scraped in PBS and the cells of six wells were pooled in an Eppendorf vial 
and centrifuged at 6,000 rpm for 5 min (Eppendorf centrifuge, type 5415C, Hamburg, 
Germany) to obtain pellets. The pellets were stored at −20°C until DNA isolation using 
a Dojindo Get pure DNA Kit Cell, Tissue kit (Dojindo, Amsterdam, The Netherlands), 
according to the accompanying protocol. Extraction, digestion, and quantification of 
E-3′-N2-dGuo were performed as previously described (Paini et al., 2010).
Identification, analysis, and quantification of metabolites
Identification and analysis of 7HCS, 1′-hydroxyestragole glucuronide, and 
1′-oxoestragole by HPLC–UV and their quantification by calibration curves using 
available standards was performed as described in our previous work (Punt et al., 
2008, 2009; Alhusainy et al., 2010). Detection and quantification of the major DNA 
adduct N2-(trans-isoestragol-3′-y1)-2′-deoxyguanosine (E-3′-N2-dGuo) by Liquid 
Chromatography Electrospray Ionization Mass Spectrometry (LC–ESI–MS/MS) was 
performed as previously described (Paini et al., 2010).
Data analysis
The maximum velocity (Vmax) and Michaelis–Menten constant (Km) for the formation 
of 7HCS and 1′-oxoestragole were determined by fitting the data to the standard 
Michaelis–Menten equation V = Vmax[S]/(Km+[S]), with [S] being the substrate 
concentration (μM), using the Life Science Workbench data analysis toolbox (version 
1.1.1, MDL information Systems, Inc.). The inhibition constant (Ki) for each of the 
selected flavonoids was calculated using the Michaelis–Menten equation for non-
competitive inhibition (Vappmax=Vmax/(1+([I]/Ki)), with V
app
max being the apparent Vmax for 
the reaction in the presence of inhibitor(s) (nmol/min/mg S9 or microsomal protein), 
Vmax being Vmax for the reaction in the absence of inhibitor(s) (nmol/min/mg S9 or 
microsomal protein), and [I] being the inhibitor concentration (μM). 
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The Michaelis–Menten equation representing an additive effect for a group of non-
competitive inhibitors was derived as follows:
V=Vmax/(1+([I1]/Ki1) +([I2]/Ki2)… +([In]/Kin))*[S]/(Km+[S])
The derivation is based on the assumption that each enzyme molecule can combine 
with no more than one of the inhibitors at a time. To test whether the change in the 
Vmax and Km in the presence of the different inhibitors or whether the SULT inhibition 
by the methanolic herb and spice extracts as compared with control was significant, a 
two-sample t-test (one sided) was performed after determining variances equality by 
the Levene’s version of the F test with SPSS 15.0 for Windows (SPSS Inc., Chicago, IL).
Estragole PBBK model
To obtain insight in the quantitative dose- and species-dependent effects of the flavonoid 
inhibitors on the formation of the ultimate carcinogenic metabolite 1′-sulfooxyestragole, 
in the target organ, the liver, we modified our previously developed PBBK models to 
take the inhibition into account. These models were originally developed to simulate the 
bioactivation, and detoxification of estragole in both rat (Punt et al., 2008) and human (Punt 
et al., 2009). The original models were described in detail previously (Punt et al., 2008, 
2009) and include separate compartments for liver, lung, and kidney, representing organs 
which were found to be involved in the metabolism of estragole. A separate compartment 
for fat tissue was included in order to take into account the relatively higher partition 
coefficient of estragole in fat tissue. All other tissues were lumped into either a rapidly 
perfused or slowly perfused tissue group (Ramsey and Andersen, 1984). The physiological 
parameters were obtained from literature (Brown et al., 1997). The partition coefficients 
were estimated from the log Kow based on a published method (DeJongh et al., 1997). 
Log Kow values were estimated using the software package ClogP version 4.0 (Biobyte, 
Claremont, CA) and amounted to 3.1 for estragole and 1.6 for 1′-hydroxyestragole. The 
apparent Vmax values for the different phase I and II reactions, expressed as nmol/min/mg 
microsomal or S9 protein were determined in vitro and were scaled to the liver using a 
microsomal protein yield of 32 mg/g liver (Barter et al., 2007) or using an S9 protein yield 
of 143 mg/g liver (Medinsky et al., 1994). The apparent Km values were also determined in 
vitro and were assumed to correspond to the apparent in vivo Km values. The absorption 
rate constant (Ka) was set to 1.0/h, resulting in a rapid absorption of estragole from the 
gastrointestinal tract with an absorption half-life of 0.7 h (Anthony et al., 1987).
Mass balance equations were applied to describe the Absorption, Distribution, 
Metabolism and Excretion (ADME) of estragole in the different tissue compartments, 
and the kinetic parameters for the different bioactivation and detoxification reactions 
of estragole were based on in vitro kinetic data obtained using relevant rat and human 
tissue fractions. A full description of the mass balance equations can be found in our 
previous papers (Punt et al., 2008, 2009). Model equations were coded and numerically 
integrated in Berkeley Madonna 8.0.1 (Macey and Oster, UC Berkeley, CA, USA) using 
the rosenbrock’s algorithm for stiff systems. The predictions of the PBBK model for 
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male rat (Punt et al., 2008) for the formation of 4-allylphenol and 1′-hydroxyestragole 
glucuronide were in good agreement with observations in the literature in female Wistar 
rats in vivo (Anthony et al., 1987), and the PBBK model for human (Punt et al., 2009) could 
predict levels of the same metabolites within the same order of magnitude compared 
with the reported levels in vivo in two human volunteers (Sangster et al., 1987). 
The uptake of estragole from the gastrointestinal tract in the PBBK models is 
described by a first-order process, assuming direct entry from the intestine to the liver 
compartment; thus, uptake of estragole into the liver is set at 100% in line with what 
is described in literature for estragole (Sangster et al., 1987; Punt et al., 2008, 2009).
In the present study, the PBBK models developed by Punt et al. (2008, 2009) for 
rat and human were modified as described below to take the flavonoid inhibition into 
account. The modified models were subsequently used to predict the effect of three 
different flavonoid scenarios (Table 5 in the Results section), representing relevant 
dietary flavonoid intakes, on the formation of the ultimate carcinogenic metabolite, 
1′-sulfooxyestragole, using an estragole dose of 0.01 mg/kg bw/day, representing the 
estragole dose considered relevant for human dietary exposure from herbs and spices 
mainly (Smith et al., 2002). Only flavonoids which had an effect on SULT activity, as 
well as on oxidation of 1′-hydroxyestragole, were included in the first two scenarios 
(Table 5 in the Results section). The modified models did not include sub-models for 
ADME characteristics of each flavonoid inhibitor. Rather, as a first approximation, each 
flavonoid included was assumed to follow a similar time-dependent concentration 
curve in the liver of rat and human as that of estragole. To make the link between 
the external dose of compounds and the internal dose in the liver, the molar ratio 
(L) between estragole at a dose of 0.01 mg/kg bw/day and each SULT inhibitor was 
calculated based on the relevant intake scenarios in Table 5 and assumed to be 
maintained in the liver by keeping the molar ratio (L) between estragole and each 
flavonoid constant during the modeling time (24 h). This was represented in the model 
using the following equation: [I] =CLE×L×f, where [I] is flavonoid concentration in the 
liver (μmol/l), CLE is the concentration of estragole in the liver (μmol/l), L is the molar 
ratio between estragole and each SULT inhibitor which is calculated based on an 
estragole dose of 0.01 mg/kg bw/day and the relevant intake scenario of flavonoid(s) 
(Table 5 in the Results section). To obtain some insight into the effects resulting from 
differences in kinetics and uptake of estragole on one hand and the flavonoids on 
the other hand, the product of CLE×L was multiplied with the factor (f) which varied 
from 0 to 1. Thus, when f equals 0, this represents no uptake of the flavonoid into the 
liver, whereas when f equals 1, this represents a 100% uptake of the flavonoid into 
the liver. The Michaelis–Menten equation representing the sulfonation or oxidation of 
1′-hydroxyestragole in the presence of a single inhibitor was as follows:
dAMHES/dt = Vmax,L-HES/(1+([I]/Ki))×CLHE/PLHE/(Km,L-HES +(CLHE/PLHE))
and
dAMHEO/dt = Vmax,L- HEO/(1+([I]/Ki)) ×CLHE/PLHE/(Km,L-HEO+(CLHE/PLHE))
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where dAMHES/dt is the rate of 1′-sulfooxyestragole formation (μmol/h) and 
dAMHEO/dt is the rate of 1′-oxoestragole formed (μmol/h), Vmax,L-HES is the maximum 
rate of formation of 1′-sulfooxyestragole, Vmax,L-HEO is the maximum rate of formation 
of 1′-oxoestragole, [I] is the concentration of quercetin (second scenario, Table 5 
in the Results section) or nevadensin (third scenario, Table 5 in the Results section) 
in the liver (μmol/l). Correspondingly, Ki is the inhibition constant for the inhibition 
by the respective flavonoids (μmol/L). Km,L-HES is the Michaelis–Menten constant for 
the formation of 1′-sulfooxyestragole (μmol/L), Km,L-HEO is the Michaelis–Menten 
constant for the formation of 1′-oxoestragole (μmol/L), CLHE is the concentration of 
1′-hydroxyestragole in the liver (μmol/L), PLHE is the liver/blood partition coefficient. 
The Michaelis–Menten equations representing the sulfonation or oxidation of 
1′-hydroxyestragole in the presence of a mixture of non-competitive inhibitors were 
derived assuming an additive effect and that each enzyme molecule can combine with 
no more than one of the inhibitors at a time and were as follows:
dAMHES/dt = Vmax,L-HES/(1+([I1]/Ki1)+([I2]/Ki2)+([I3]/Ki3)+([I4]/Ki4))×CLHE/PLHE/(Km,L-HES 
+(CLHE/PLHE))
and
dAMHEO/dt = Vmax,L HEO/(1+([I1]/Ki1)+([I2]/Ki2)+([I3]/Ki3)+([I4]/Ki4))×CLHE/ PLHE /(Km,L-HEO
+(CLHE/PLHE))
where [I1], [I2], [I3], and [I4] are the concentrations of the inhibitors: quercetin, kaempferol, 
myricetin, and apigenin in the liver (μmol/L), respectively. Correspondingly, Ki1, Ki2, 
Ki3, and Ki4, are the inhibition constants for the inhibition by the respective inhibitors 
(μmol/L), which were assumed to be equal in liver of human and rat.
RESULTS
Inhibition of SULT activity by methanolic herb and spice extracts
Figure 2 presents the effect of increasing concentrations of a series of methanolic 
herb and spice extracts on SULT activity. With the exception of fennel, increasing 
concentrations of all methanolic herb and spice extracts inhibited SULT enzyme 
activity in a dose-dependent manner. The extract from basil was the most potent 
followed by the extracts from pimento/ allspice, nutmeg, and mace. Extracts from 
parsley, star anise and cinnamon displayed only moderate SULT inhibition and the 
extracts from tarragon and laurel significantly inhibited SULT activity only at the 
highest concentration tested (100 μg extract/mL). Blank incubations, which lacked 
the cofactor PAPS or which lacked the pooled male rat liver S9 fraction, did not show 
any formation of 7HCS (data not shown). This indicates that the inhibition of 7HCS 
formation by the herb and spice extracts was fully dependent on the presence of PAPS 
and the S9 fraction containing SULT. Incubations with the SULT-inhibitor PCP inhibited 
SULT activity completely at 25 μM (data not shown).
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Identification of SULT inhibitors in the methanolic herb and spice 
extracts
Based on our previous work (Alhusainy et al., 2010), the flavonoid nevadensin was 
identified as the major SULT-inhibiting constituent in the methanolic extract from basil. In 
the present work, based on comparison of HPLC–UV and retention time characteristics 
to HPLC–UV and retention time characteristics of commercially available reference 
compounds, apigenin was identified as the second most potent constituent in the same 
methanolic extract. Among the other most potent methanolic herb and spice extracts, 
the extract from nutmeg was fractionated and the compounds in the most active 
fractions were identified as (+) catechin and (−) epicatechin, whereas in the methanolic 
extract from pimento/allspice, eugenol was identified as the major SULT inhibitor.
Based on the observation that in potent extracts flavonoids appeared to be 
the major SULT inhibitors identified, a literature review was made to screen for 
major flavonoids present in alkenylbenzene-containing herbs and spices focusing 
on flavonoids which have been reported to be SULT inhibitors (Eaton et al., 1996; 
Morimitsu et al., 2004). Table 1 presents an overview of the flavonoids reported to be 
present in alkenylbenzene-containing herbs and spices as derived from literature and 
also reported to be SULT inhibitors. The overview presented reveals that in a series 
of 15 selected alkenylbenzene-containing herbs and spices, quercetin, kaempferol, 
apigenin, and luteolin are among the most abundant flavonoids, and of these 
flavonoids, quercetin and kaempferol are the most widespread in alkenylbenzene-
containing herbs and spices (Justesen and Knuthsen, 2001).
Figure 2. Inhibition of SULT-catalyzed conversion of 7HC into 7HCS by pooled male rat liver S9 
fractions in the absence (control) or presence of increasing concentrations (10, 25, and 100 μg/
mL) of different methanolic herb and spice extracts. 100% 7HCS formation is equal to 1.3 ± 0.1 
nmol/min/mg S9 protein. Data points represent mean (±SD) of triplicate measurements obtained 
in independent experiments. An asterisk (*) indicates a significant inhibition compared with the 
incubation without inhibitor (p < 0.05).
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Selection of SULT-inhibiting flavonoids to be tested in subsequent 
studies 
Given the identification of flavonoids as an important category of food-borne SULT 
inhibitors, and the fact that these flavonoids will not only be present in the herbs 
and spices analyzed in this study, the selection of the flavonoids to be used in the 
subsequent studies was based on their abundance in the diet as a whole. Generally, 
estimation of the daily dietary flavonoid intake is based on the intake of three 
quantitatively important dietary flavonols (quercetin, kaempferol, and myricetin) and 
two quantitatively important dietary flavones (apigenin and luteolin) (Hertog et al., 
1993a,b). These flavonoids are all present in alkenylbenzene-containing herbs and 
spices, as well as throughout the diet, they are all reported to have SULT inhibiting 
potency; the total estimated daily intake (EDI) levels of these flavonoids as recorded 
by different studies varies between 18.3 ± 3.4 and 25.9 ± 14.5 mg/day (Hertog et al., 
1993a; Hertog et al., 1993b; Lugasi et al., 2003; Mullie et al., 2008). 
Given these observations, the flavonoids quercetin, kaempferol, myricetin, apigenin, 
luteolin, and nevadensin, the latter being the major flavone constituent in basil (Grayer 
et al., 2004) were used in our subsequent experiments to examine the influence of 
flavonoids in mixtures or individually on the bioactivation of 1′-hydroxyestragole 
by SULT and on the detoxification of 1′-hydroxyestragole via glucuronidation and 
Table 1. flavonoids present in some alkenylbenzene-containing herbs and spices based on literature.
Herb
Major flavonoids identified 
in herbs and spices based on 
literature and their amounts References
Basil (Ocimum basilicum L.) Nevadensin (3.78-43.47)b
Apigenin (0.48-2.14)b
Luteolin (0.48-0.78)b
Catechinc
(Grayer et al., 2004)
(Grayer et al., 2004)
(Grayer et al., 2004)
(Shan et al., 2005)
Pimento (Pimenta dioica (L.) Merr.) Quercetin and myricetinc (Kikuzaki et al., 2008)
Nutmeg (Myristica fragrans Houtt.)a Catechinc
Quercetin and kaempferolc
(Shan et al., 2005)
(Suhaj, 2006)
Dill (Anethum graveolens L.) Quercetin (48-110)d
Kaempferol (16-24)d
(Justesen and Knuthsen, 2001)
(Suhaj, 2006)
Tarragon (Artemisia dranunculus L.) Quercetin (10)d
Kaempferol (11)d
Luteolin (1)d
(Justesen and Knuthsen, 2001)
(Justesen and Knuthsen, 2001)
(Justesen and Knuthsen, 2001)
Parsley (Petroselinum crispum (Mill.) 
Nyman ex A.W. Hill)
Quercetin (0-1)d
Apigenin (510-630)d
Luteolin (0-4)d
(Justesen and Knuthsen, 2001)
(Justesen and Knuthsen, 2001)
(Justesen and Knuthsen, 2001)
a Nutmeg is the actual seed of the tree while mace is the dried “lacy” reddish covering or aril 
of the seed. 
b Amounts expressed as percentages of total flavones.
c Amounts are not reported.
d Amounts expressed as (mg/100 g fresh weight).
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oxidation using relevant tissue fractions or an intact cell model. Figure 3 presents the 
structure of the flavonoid inhibitors included in the study.
Inhibition of SULT-catalyzed conversion of 7HC into 7HCS  
and of oxidation and glucuronidation of 1′-hydroxyestragole 
into 1′-oxoestragole and 1′-hydroxyestragole glucuronide 
by the selected flavonoids
After identification of major SULT inhibitors present in the selected alkenylbenzene-
containing herbs and spices (nevadensin, quercetin, kaempferol, myricetin, and 
apigenin), initial studies testing the effect of the selected flavonoids quercetin, 
kaempferol, myricetin and apigenin on SULT-mediated conversion of 7HC into 7HCS 
and on oxidation or glucuronidation of 1′-hydroxyestragole revealed that only SULT 
and oxidation activity appeared to be inhibited. Nevadensin was not included in 
these inhibition studies because its effect on sulfonation, glucuronidation, and 
oxidation was already determined in our previous work (Alhusainy et al., 2010). 
Oxidation and glucuronidation of 1′-hydroxyestragole were not inhibited by 
nevadensin to any significant extent even at nevadensin concentrations up to 20 
μM (Alhusainy et al., 2010).
The effect of the other selected flavonoids quercetin, kaempferol, myricetin, and 
apigenin on glucuronidation of 1′-hydroxyestragole was examined by adding each 
flavonoid up to 80 μM together with 1000 μM of the substrate 1′-hydroxyestragole in 
incubations with pooled human liver microsomes and the cofactor for glucuronidation 
(UDPGA). None of the flavonoids tested resulted in any significant effect on the 
formation of 1′-hydroxyestragole glucuronide. 
Figure 3. Structural formulas of (A) quercetin, (B) kaempferol, (C) myricetin, (D) apigenin, (E) 
luteolin, and (F) nevadensin, the major SULT inhibitors in alkenylbenzene-containing herbs and 
spices and/or throughout the diet.
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Because the catalytic efficiency for the SULT-catalyzed conversion of 7HC into 
7HCS and for 1′-hydroxyestragole into 1′-sulfooxyestragole is higher in the liver of rat 
compared with the liver of human (Wang et al., 2006; Alhusainy et al., 2010), in vitro 
incubations for inhibition of SULT activity by the selected flavonoids was performed 
using pooled male rat liver S9. Oxidation of 1′-hydroxyestragole to 1′-oxoestragole 
represents a minor metabolic route in the liver of male rat as compared with the liver 
of human suggesting that the inhibition of this pathway would hardly influence the 
overall bioactivation of estragole in the liver of male rat but may influence the overall 
metabolism in human. Therefore, in vitro incubations for inhibition of oxidation of 
1′-hydroxyestragole by the selected flavonoids were performed in pooled human 
liver microsomes. In this way, the kinetics for inhibition of SULT activity and of 
oxidation of 1′-hydroxyestragole were determined, and the mode of inhibition and 
the respective Ki values were defined. 
Tables 2 and 3 display the Michaelis–Menten parameters (Vmax and Km) and 
inhibition constants (Ki) for 7HCS and 1′-oxoestragole formation by pooled male rat 
liver S9 and pooled human liver microsomal fractions, respectively, in the presence 
or absence of the flavonoids quercetin, kaempferol, myricetin, and apigenin. The 
apparent Vmax values for sulfonation were lowered significantly (minus 30–33%; p < 
0.001 ) in the presence of each flavonoid, whereas the apparent Km values were not 
statistically significantly different from the Km value determined in the absence of each 
flavonoid. The apparent Vmax values for oxidation of 1′-hydroxyestragole were lowered 
significantly (minus 52–77%; p < 0.001 ) in the presence of each flavonoid, whereas 
the apparent Km values were not statistically significantly different from the Km value 
determined in the absence of each flavonoid. These results point at a non-competitive 
type of inhibition of sulfonation, as well as oxidation by each individual flavonoid. 
Applying the Michaelis–Menten equation for non-competitive inhibition, the inhibition 
constant (Ki) for SULT inhibition as calculated from the data amounted to, respectively, 
1.5, 0.6, 11.9, and 0.7 μM for quercetin, kaempferol, myricetin, and apigenin. 
The inhibition constants (Ki) for inhibition of the conversion of 7HC to 7HCS by 
the different flavonoids are not expected to be significantly different when using 7HC 
instead of 1′-hydroxyestragole as a substrate. This is based on the type of inhibition 
that was shown to be non-competitive meaning that only the apparent Vmax and not 
the apparent Km of the enzyme was found to be affected, which corroborates the 
assumption that flavonoids do not interfere with the substrate binding site and exert 
their inhibiting effect by interaction with another site on the enzyme than the site 
involved in substrate binding (Simmons, 1996). In our previous work (Alhusainy et 
al., 2010), the type of SULT inhibition (non-competitive) and the Ki (4 nM) for this 
inhibition by the flavonoid nevadensin was similar in pooled male rat and pooled 
human liver S9 fractions. Based on this result, it was assumed that the Ki and the type 
of SULT inhibition by the flavonoids quercetin, kaempferol, myricetin, and apigenin 
determined in pooled male rat liver S9 will also be similar in human liver S9, given that 
the type of inhibition by each of them was also non-competitive. 
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The inhibition constant (Ki) for inhibition of oxidation of 1′-hydroxyestragole to 
1′-oxoestragole by quercetin, kaempferol, myricetin, and apigenin amounted to 4.5, 
1.5, 5.4, and 6.7 μM, respectively (Table 3).
Effect of selected flavonoid mixtures on SULT-catalyzed conversion 
of 7HC into 7HCS and on oxidation of 1′-hydroxyestragole into 
1′-oxoestragole
Given that the diet may contain a variety of SULT inhibitors, experiments were 
performed to assess the effect of combined flavonoid exposure on SULT activity, as 
well as on oxidation of 1′-hydroxyestragole to 1′-oxoestragole. To this end, a test 
mixture was defined that mimics a realistic dietary flavonoid mixture and included four 
flavonoids which were found to be abundant in alkenylbenzene-containing herbs and 
spices and able to inhibit SULT activity, namely, quercetin, kaempferol, apigenin, and 
Table 3. Kinetic parameters of 1′-oxoestragole formation by pooled human liver microsomes in 
the absence or presence of different flavonoids.
Inhibitor
Apparent Vmax 
(nmol/min/mg protein) 
Apparent Km
(µM)
Ki a
(µM)
Quercetin (5 µM) 4.8±1.0* 1046±258 4.5
Kaempferol (5 µM) 2.3±0.3* 605±69 1.5
Myricetin (10 µM) 3.5±0.9* 727±292 5.4
Apigenin (10 µM) 4.0±0.4* 613±66 6.7
aCalculated using the Michaelis–Menten equation for non-competitive inhibition (Vappmax=Vmax/
(1+([I]/Ki)), where [I] is the flavonoid concentration (µM). 
An asterisk (*) indicates a significant inhibition compared to the incubation without inhibitor 
(P<0.001).
Note 1:The control (no inhibitor) Vmax=10±1.4 nmol/min/mg protein, and Km=688±119 µM.
Table 2. Kinetic parameters of SULT-dependent formation of 7HCS by pooled male rat Liver S9 
in the absence or presence of different flavonoids.
Inhibitor
Apparent Vmax
(nmol/min/mg protein)
Apparent Km
(µM)
Ki a
(µM)
Quercetin (0.75 µM) 1.8±0.1* 4.3±0.6 1.5
Kaempferol (0.3 µM) 1.8±0.2* 4.0±1.1 0.6
Myricetin (5 µM) 1.9±0.01* 3.8±0.3 11.9
Apigenin (0.35 µM) 1.8±0.1* 3.5±0.6 0.7
aCalculated using the Michaelis–Menten equation for non-competitive inhibition (Vappmax=Vmax/
(1+([I]/Ki)), where [I] is the flavonoid concentration (µM). 
An asterisk (*) indicates a significant inhibition compared to the incubation without inhibitor 
(P<0.001).
Note1: The control (no inhibitor) Vmax=2.7±0.2 nmol/min/mg protein, and Km=4.0±1.0 µM.
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nevadensin, the latter being previously identified as a potent SULT inhibitor present in 
basil (Alhusainy et al., 2010). 
The simultaneous addition of quercetin, kaempferol, apigenin, and nevadensin at 
concentrations equal to 0.2Ki, 0.5Ki, 1Ki, 2Ki, 5Ki, or 10Ki of each flavonoid together 
with 25 μM of the substrate 7HC lowered the SULT activity in incubations with pooled 
male rat liver S9 (Figure 4). The reduction in the formation of 7HCS was similar to 
the reduction predicted by the Michaelis–Menten equation defined for a series of 
independent non-competitive inhibitors (Figure 4), which verifies our assumption for a 
non-competitive type of inhibition by each individual flavonoid on SULT enzyme activity, 
as well as an additive interaction between the flavonoids in the mixture (Figure 4). 
With the exception of nevadensin that had no effect on 1′-hydroxyestragole oxidation in 
pooled human liver microsomal fractions (Alhusainy et al., 2010), the other SULT inhibitors 
identified in alkenylbenzene-containing herbs and spices, namely, quercetin, kaempferol, 
myricetin, and apigenin, had an inhibiting effect on the oxidation of 1′-hydroxyestragole. 
Therefore, incubations for testing the inhibition of conversion of 1′-hydroxyestragole to 
1′-oxoestragole by a mixture of quercetin, kaempferol, myricetin, and apigenin were 
performed. Figure 5 shows that the simultaneous addition of quercetin, kaempferol, 
myricetin, and apigenin at concentrations equal to 0.1Ki, 0.2Ki, 0.5Ki, 1Ki, or 2Ki, for 
each flavonoid together with 400 μM of the substrate 1′-hydroxyestragole reduced the 
formation of 1′-oxoestragole. The observed inhibition in the formation of 1′-oxoestragole 
in the presence of the flavonoid mixture at concentrations higher than their Ki values 
matched the predicted values of the derived Michaelis–Menten formula defined for a 
series of independent non-competitive inhibitors, whereas at concentrations lower than 
their Ki values, the predicted values were somewhat higher than the values actually 
observed, which may be due to different types of enzymes playing a role in the oxidation 
Figure 4. SULT-dependent formation of 7HCS as measured in incubations with pooled male rat 
liver S9 in the presence of increasing concentrations of flavonoid mixtures containing quercetin, 
kaempferol, apigenin, and nevadensin at 0Ki, 0.2Ki, 0.5Ki, 1Ki, 2Ki, 5Ki, or 10Ki of each flavonoid 
(●),or as predicted by our derived Michaelis–Menten equation assuming an additive effect for a 
series of independent non-competitive inhibitors (solid line).
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of 1′-hydroxyestragole. Thus, other modes of interactions than an additive interaction at 
concentrations lower than Ki values cannot be excluded. Nonetheless, at all concentrations 
of the flavonoid mixture, the difference between predicted values and observed ones was 
less than twofold. Moreover, a fit to the experimental data assuming the inhibition to be 
competitive instead of non-competitive matched the experimental data worse, showing 
deviations even at the high concentrations and larger variation (up to 2.2-fold) at the lower 
concentration range (data not shown). Therefore, it was concluded that the predictions 
made by the derived formula gives a reasonable first approximation.
Effect of flavonoid mixtures on conversion and DNA binding  
of 1′-hydroxyestragole in HepG2 cells
To investigate whether the inhibition of bioactivation and detoxification pathways of 
1′-hydroxyestragole would also be observed in an intact cellular system, cells from the 
human HepG2 hepatoma cell line were exposed to 1′-hydroxyestragole in the absence 
or presence of different flavonoids and their combinations, followed by detection of 
the level of 1′-hydroxestragole oxidation, glucuronidation, and sulfonation, the latter 
reflected by the formation of the major estragole DNA adduct (E-3′-N2-dGuo). Table 
4 summarizes the different flavonoid mixtures and/or individual flavonoids which were 
investigated in the HepG2 model system. The outcomes of these studies will reveal 
whether selected flavonoids and/or their mixtures are able to inhibit SULT-mediated 
bioactivation of 1′-hydroxyestragole in this cellular system, resulting in an ultimate 
shift of metabolism in favour of detoxification at the cost of bioactivation. 
The compounds were not cytotoxic to HepG2 cells under the conditions used in 
these experiments as observed by MTT activity measurements (data not shown). Figure 
6A reveals that a significant reduction in the formation of E-3′-N2-dGuo compared with 
Figure 5. Formation of 1′-oxoestragole as measured in incubations with pooled human liver 
microsomes in the presence of increasing concentrations of flavonoid mixtures containing 
quercetin, kaempferol, myricetin, and apigenin at 0Ki, 0.1Ki, 0.2Ki, 0.5Ki, 1Ki, or 2Ki of each 
flavonoid (●),or as predicted by our derived Michaelis Menten equation assuming an additive 
effect for a series of independent non-competitive inhibitors (solid line).
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control (no flavonoid) is observed in the human HepG2 cells following co-administration 
of 50 μM of the substrate 1′-hydroxyestragole and 13, 5.4, 2.3, 1.5, and 0.34 μM of a 
flavonoid mixture containing quercetin, kaempferol, myricetin, apigenin, and luteolin 
respectively (each at a concentration corresponding to its relative contribution in the 
diet, Table 4). E-3′-N2 dGuo formation in the HepG2 cells is also inhibited significantly 
by 100 μM of the same flavonoids in a mixture (each at 20 μM), by 50 μM kaempferol, 
or by 100 μM quercetin (Figure 6A). 
The data indicate that the flavonoids are able to pass the cell membrane and 
exert an intracellular effect on SULT-mediated bioactivation of 1′-hydroxyestragole. 
HPLC-UV analysis of the media revealed a significant reduction in the formation of 
1′-oxoestragole (measured as GS-1′-oxoestragole, Figure 6B) and a significant increase 
in the formation of 1′-hydroxyestragole glucuronide (Figure 6C). Altogether, the data 
indicate a shift metabolism from sulfonation and oxidation to glucuronidation, which 
is a detoxification pathway for 1′-hydroxyestragole. 
PBBK model based predictions for estragole metabolism  
in the presence of selected SULT-inhibiting flavonoids
Figure 7A illustrates the PBBK model based predictions for the formation of 
1′-sulfooxyestragole in the liver of rat and human after co-administration of 0.01 
mg/kg bw/day of estragole, representing the estragole dose considered relevant 
for human dietary exposure from herbs and spices mainly (Smith et al., 2002), and a 
mixture of the flavonoids quercetin, kaempferol, myricetin, and apigenin at a total EDI 
Table 4. Flavonoid treatments tested in human HepG2 cells exposed to 50 μM of 
1-hydroxyestragole for 22 h at 37°C.
Sample
Flavonoids 
treatments
Concentrations in 
2.5 mL medium Rationale
1 Quercetin,
Kaempferol,
Myricetin,
Apigenin,
Luteolin
13 µM
5.4 µM
2.3 µM
1.5 µM
0.34 µM
Based on dietary levels of 12, 4.6, 2.2, 1.2, and 
0.3 mg/day (Lugasi et al., 2003; Mullie et al., 2008) 
assuming 3 liter plasma and 100% bioavailability
2 Quercetin,
Kaempferol,
Myricetin,
Apigenin,
Luteolin
20 µM
20 µM
20 µM
20 µM
20 µM
High dose mixture, up to a total level of 100 µM, 
shown to be without cytotoxicity.
3 Quercetin 100 µM Based on highest dose without cytotoxicity given that 
the level in dietary quercetin supplements of 500 mg/
day, assuming 3 liter plasma and 100% bioavailability 
would amount to 552 µM.
4 Kaempferol 50 µM Kaempferol was the most potent flavonoid in inhibiting 
SULT activity and oxidation of 1′-hydroxyestragole. The 
concentration selected is equal to the concentration of 
the substrate, 1′-hydroxyestragole.
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Figure 6. Formation of (A) E-3′-N2-dGuo, (B) 1′-oxoestragole (measured as GSH adducts), and (C) 
1′-hydroxyestragole glucuronide in HepG2 cells exposed for 22 h to 50 μM 1′-hydroxyestragole 
in the absence or presence of a mixture of the following flavonoids: quercetin, kaempferol, 
myricetin, apigenin, and luteolin (13, 5.4, 2.3, 1.5, and 0.34 μM respectively), 100 μM of the same 
flavonoids in a mixture (each at 20 μM), 50 μM kaempferol, or 100 μM quercetin.
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level of 20.0 ± 6.3 mg/day (Lugasi et al., 2003; Mullie et al., 2008), which corresponds 
to 0.33 mg flavonoids/kg bw/day for a person of 60 kg. The results presented in Figure 
6A reveal that the formation of 1′-sulfooxyestragole in the liver of rat after 24 h is 
predicted to decrease by 0.18%, 1.7%, 8%, and 14.4% compared with control when 
assuming, respectively, 1%, 10%, 50%, and 100% uptake of the flavonoid mixture, 
whereas in the liver of human, the formation of 1′-sulfooxyestragole was predicted to 
decrease by, respectively, 0.5%, 5%, 18%, and 27%. 
In addition, the possible consequences of consumption of estragole together 
with a flavonoid food supplement containing 500 mg of quercetin, representing food 
supplements actually available on the market, was also studied. The PBBK model 
predictions indicated that the intake of 500 mg quercetin, which corresponds to 8.3 mg 
querectin/kg bw/day for a person of 60 kg, together with 0.01 mg/kg bw of estragole 
may decrease the formation of 1′-sulfooxyestragole in the liver of rat by 3%, 23%, 55%, 
and 69% when assuming 1%, 10%, 50%, and 100% uptake of quercetin, and in the liver 
of human, formation of 1′-sulfooxyestragole was predicted to decrease by, respectively, 
8.6%, 36%, 56%, and 63% at these levels of quercetin uptake (Figure 7B). 
In a third PBBK modeling scenario, the protective effect of nevadensin against SULT-
mediated bioactivation of estragole in consumers of basil was evaluated. Assuming that 
basil contains 0.5% of essential oil (Smith et al., 2002) and that the essential oil of basil 
contains 22.7% of estragole (Sanda et al., 1998), an EDI of 0.01 mg/kg bw/day of estragole 
would result from an intake of 529 mg basil/day. Based on our previous work (Alhusainy 
et al., 2010), the amount of nevadensin in 529 mg of basil is expected to be 0.34 mg, and 
this would result in an EDI for nevadensin of 0.0057 mg/kg bw/day for a person of 60 kg. 
At an estragole dose of 0.01 mg/kg bw/day and a nevadensin intake of 0.0057 mg/kg 
bw/day, the formation of 1′-sulfooxyestragole in the liver of rat is predicted to decrease 
by 0.77%, 7%, 26%, and 40% compared with control, whereas in the liver of human, the 
formation of 1′-sulfooxyestragole was predicted to decrease by 3.5%, 25%, 56%, and 68% 
when assuming, respectively, 1%, 10%, 50%, and 100% uptake of nevadensin (Figure 7C).
Finally, it is worth noting that even when the concentration of estragole was 
increased 1000-fold keeping the concentrations of the SULT-inhibiting flavonoids 
at the values defined in Table 5, the percentage inhibition of 1′-sulfooxyestragole 
formation remains the same as obtained at the 1000-fold lower dose of estragole. 
This is a characteristic of non-competitive inhibition, for which the level of inhibition 
depends only on the dose of the inhibitors (Simmons, 1996).
DISCUSSION
The alkenylbenzene estragole is an important natural constituent of herbs and spices. 
However, several studies have shown both genotoxic and carcinogenic properties 
for this compound in rodents (Drinkwater et al., 1976; Miller et al., 1983). These 
experiments were performed using the pure compound dosed by gavage in high 
doses, whereas in herbs and spices, estragole is present in relatively lower amounts 
together with other constituents in a food matrix, which can influence its biochemical 
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Figure 7. PBBK model based predictions for the formation of 1′-sulfooxyestragole in the liver of rat 
(black bars) and human (grey bars) after co-administration of 0.01 mg/kg bw/day of estragole and (A) a 
mixture of flavonoids at their EDI levels including 12 mg/day of quercetin, 4.6 mg/day of kaempferol, 
2.2 mg/day of myricetin, and 1.2 mg/day of apigenin; (B) quercetin at a dose level present in food 
supplements amounting to 500 mg/day; or (C) nevadensin at 0.34 mg/day, representing the dose 
level resulting from intake of 529 mg of basil, which is the amount of basil resulting in 0.01 mg/kg bw/
day of estragole (Sanda et al., 1998; Smith et al., 2002; Alhusainy et al., 2010)
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fate. The present study reports that methanolic extracts from different alkenylbenzene-
containing herbs and spices were able to inhibit SULT activity involved in the formation 
of the proximate hepatocarcinogen 1′-sulfooxyestragole. 
Flavonoids including nevadensin, quercetin, kaempferol, myricetin, and apigenin 
were the major constituents responsible for this inhibition of SULT activity with Ki 
values in the nano- to micromolar range. Apart from SULT inhibitors present in herbs 
and spices and identified in the present study, the regular human diet is rich in 
other SULT inhibitors ranging from a number of natural dietary chemicals, such as 
polyphenols (Eaton et al., 1996), to a number of food additives such as (±)-catechin, 
(+)-catechin, 4-chlorobenzoic acid, aspartame, benzoic acid, erythrosine, gallic acid, 
octyl gallate, p-hydroxybenzoic acid, propyl gallate, protocatechuic acid, saccharin, 
tannic acid, tartrazine, and vanillin, which have all been shown to be capable to inhibit 
the sulfonation of a number of xenobiotics and endobiotics in human liver cytosol to 
varying extents (Bamforth et al., 1993). 
A great volume of literature data supports the plausibility of non-competitive 
inhibition of sulfonation of various substrates by different flavonoids such as quercetin, 
genistein, (+)-catechin, kaempferol, apigenin, and diadzein (Walle et al., 1995; Ghazali 
and Waring, 1999; Mesía -Vela and Kauffman, 2003). 
The various flavonoids tested in this study were also shown to be able to significantly 
inhibit estragole DNA-adduct formation in human HepG2 cells exposed to the 
proximate carcinogen 1′-hydroxyestragole (50% reduction compared with control) even 
Table 5. Input data for PBBK models representing three possible intake scenarios of flavonoids 
and estragole at 0.01 mg/kg bw/day
Scenario
Constant (L)a
(Flavonoid:estragole)
Input PBBK
[flavonoid] ]=CLE×L×f
EDI of flavonoidsb:
Querectin (4×10-5 mol/day)
Kaempferol (1.6×10-5 mol/day)
Myricetin (7×10-6 mol/day)
Apigenin (4.4×10-6 mol/day)
9.8
4.0
1.7
1.1
[quercetin]=CLE×9.8×f
[kaempferol]=CLE×4.0×f
[myricetin]=CLE×1.7× f
[apigenin]=CLE×1.1×f
Quercetin tablets (0.002 mol/day) 408 [quercetin]=CLE×408×f
3) Nevadensin (1.1×10-6 mol/day)c 0.25 [nevadensin]=CLE×0.25×f
Note. CLE is the concentration of estragole in the liver (μmol/L), L is a constant that is determined 
based on the corresponding intake scenario and f is the molar ratio between estragole and each 
flavonoid that varies from 0 (no SULT inhibitors uptake into liver) to 1 (representing 100% uptake 
of a flavonoid into the liver).
aConstant (L) is calculated as the ratio between the EDI of a flavonoid and the EDI of estragole 
of 0.01 mg/kg bw/day (Smith et al., 2002), which is equivalent to 4.1 × 10−6 mol/day given a 
molecular weight for estragole of 148 g/mol and assuming a body weight of 60 kg.
bBased on Lugasi et al. (2003); Mullie et al. (2008).
cAssuming that basil contains 0.5% of essential oil (Smith et al., 2002) and that the essential oil of basil 
contains 22.7% of estragole (Sanda et al., 1998), an EDI of 0.01 mg/kg bw/day of estragole would 
result from a 529 mg basil/day. The amount of nevadensin in 529 mg of basil is expected to result in 
a daily intake of 0.34 mg/day or 1.1 × 10-6 mol/day for a 60 kg person (Alhusainy et al., 2010).
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at concentrations as low as 25 μM of the flavonoid mixture. The results of the present 
work also show that at levels of flavonoids sufficient to inhibit SULT activity, they can 
also inhibit the oxidation of 1′-hydroxyestragole, which is the major phase-II pathway of 
1′-hydroxyestragole in the liver of human. Additional results of the present study revealed 
that in the human HepG2 cells exposed to 1′-hydroxyestragole in the presence of 
flavonoids, reduction in the activity of sulfonation and oxidation results in a metabolic shift 
toward glucuronidation, which serves as a detoxification pathway for 1′-hydroxyestragole. 
In a next step, the kinetics for SULT inhibition and for the inhibition of 1′-oxoestragole 
were incorporated in the PBBK models for estragole in rat and human to predict the 
effect of co-exposure to estragole and (mixtures of) the different flavonoids on the 
bioactivation in vivo. The PBBK model based predictions indicate that the reduction 
of estragole bioactivation in rat and human by co-administration of the flavonoids 
is dependent on whether the intracellular liver concentrations of the flavonoids can 
reach their Ki values determined in the present study. For example, high intake levels 
of SULT inhibitors (e.g. quercetin) at levels present in food supplements currently 
available on the market might result in significant inhibition of the formation of 
1′-sulfooxyestragole even at 10% uptake of the flavonoid. Interestingly, for human 
liver, a dose of nevadensin of only 0.34 mg/day was predicted to result in comparable 
inhibition of 1′-sulfooxyestragole formation as a dose of quercetin of 500 mg/day 
(Figure 6B and C). This clearly illustrates that although nevadensin is not a major 
flavonoid constituent in the diet, its contribution to the SULT-mediated modulation 
of estragole is already achieved at relatively lower dose levels due to its Ki value of 4 
nM (Alhusainy et al., 2010), which is 2–3 orders of magnitude lower than that for other 
flavonoids. Furthermore, the inhibitory effect of nevadensin in vivo may also be more 
easily achieved than that of the other flavonoids because nevadensin is a methylated 
flavonoid, and methylated flavones such as nevadensin have been demonstrated 
to be more metabolically stable and have a higher intestinal absorption than their 
unmethylated analogues increasing the oral bioavailability of methylated flavones 
compared with their unmethylated analogues (Wen and Walle, 2006). 
In this context, it is also of interest to take into account the reported intracellular 
and circulating concentrations of the different flavonoid-type SULT inhibitors. Mean 
plasma levels of quercetin, for example, reached 7.6 μM in human volunteers after 
consuming a supplement of 160 g stewed and homogenized onions, which provided 
331 μmol of quercetin glucosides (Graefe et al., 2001), a plasma level which is sufficient 
to inhibit SULT activity giving a Ki for quercetin-mediated SULT inhibition of 1.5 μM 
as determined in the present study. Moreover, after a single oral dose of 200 mg/kg 
bw of Chrysanthemum morifolium extract to rats apigenin reached maximum plasma 
levels of 16 μM (Chen et al., 2007). 
Clearly, plasma levels of quercetin and apigenin can reach levels higher than their 
Ki. Data on human plasma levels of other flavonoids tested in the present study are 
lacking. However, plasma levels for other flavonoids, namely, the isoflavones genistein 
and daidzein, may exceed 0.5 μM in women who eat a traditional Japanese diet 
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(Uehara et al., 2000) and may even reach 1 μM in individuals consuming some dietary 
supplements (Gooderham et al., 1996), both levels are sufficient to inhibit SULT1A1 
and SULT1EI significantly given the IC50 for inhibition of SULT1A1 and SULT1EI by 
genistein of 0.5 and 1 μM, respectively (Harris et al., 2004). Moreover, plasma levels 
of other flavonoids, such as hesperetin, may reach 1–3 μM after ingestion of large 
amounts of fruit and vegetables (Erlund et al., 2002), which are concentrations sufficient 
to inhibit both SULT1A1 and SULT1E1 (Harris et al., 2004). It is important to note, 
however, that in vivo flavonoids undergo extensive conjugation to their corresponding 
glucuronic acid and sulfonate conjugates, and that in most in vivo studies, flavonoids 
are measured after deconjugation. Therefore, the reported plasma concentrations 
may reflect total flavonoid concentration in the conjugated and unconjugated forms 
instead of the concentrations of the aglycon. 
This raises the question if in these conjugated forms the flavonoids are still able 
to interact with SULTs. In this regard, it is worth to note that conjugated metabolites 
of flavonoids can retain the biological activity of the parent compound (Harris et al., 
2004). This is highly dependent on the molecular site of conjugation. Moreover, studies 
in which cells in vitro were exposed to glucuronidated and sulfonated conjugates of 
quercetin demonstrated that within the cells, the flavonoid was no longer conjugated 
due to efficient extra- and/or intracellular deconjugation (Lee-Hilz et al., 2008). Another 
issue of interest is if these flavonoids reported in literature can inhibit the same SULT 
isoforms which are involved in the sulfonation of the substrate 1′-hydroxyestragole, 
which have so far not been identified. 
Several PBPK models have been developed and investigated chemical interactions 
at the level of metabolic competition (El-Masri et al., 1996a,b; Dobrev et al., 2002; 
Krishnan et al., 2002). These models have identified thresholds for exposure, below 
which competitive inhibition is not expected. In this regard, we have shown in our 
paper that plasma levels of the different flavonoids can reach levels sufficiently high to 
inhibit SULT activity and in a non-competitive way.
Finally, it is important to note that the PBBK model analysis of the effect of the 
inhibitors on estragole bioactivation in vivo as presented is a fist approximation. More 
refined models could take into account i) sub-models for the ADME characteristics of 
the individual flavonoids and/or ii) non additive modes of interactions for the flavonoids 
in mixture on the conversion of 1′-hydroxyestragole to 1′-oxoestragole which better 
fit the experimental in vitro data for this inhibition. However, development of such 
refined models was beyond the scope of the present study. 
In conclusion, dietary flavonoids may modulate the bioactivation and thus the ultimate 
cancer risk posed by estragole provided that the physiological liver concentrations of 
the inhibitors reach their Ki values. Whether in vivo levels of flavonoids can reach their 
Ki values and whether conjugated forms of the flavonoids can still inhibit SULT activity 
are important issues that need further investigation. 
Overall, an in vivo modulation for estragole bioactivation is highly plausible given 
the facts that i) SULT inhibitors are abundant in the diet, ii) their inhibition constants 
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(Ki) for SULT activity are in the nano- to micromolar range, and iii) their combined 
effect on SULT enzyme activity was shown to be additive. If the PBBK based predicted 
data can be validated in vivo, which is an important issue for future research, this 
would imply that the likelihood of bioactivation and subsequent adverse effects might 
be lower when alkenylbenzenes are consumed in a matrix of food items containing 
SULT inhibitors than what would be expected on the basis of experiments using 
alkenylbenzenes as pure compounds. The safety of alkenylbenzene-containing 
botanicals could consequently be judged and regulated on the basis of the EDIs of 
the different alkenylbenzenes compared with the EDIs of the different respective SULT 
inhibitors which are present in the diet. Further research investigations are directed at 
investigating efficiency of SULT inhibitors in reducing-DNA adduct formation and the 
subsequent carcinogenic risk in vivo.
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In vivo validation and physiologically based 
biokinetic modeling of the inhibition 
of SULT-mediated estragole DNA adduct 
formation in the liver of male Sprague–Dawley 
rats by the basil flavonoid nevadensin
4
ABSTRACT
The present work investigates whether the previous observation that the basil 
flavonoid nevadensin is able to inhibit sulfotransferase (SULT)-mediated estragole 
DNA adduct formation in primary rat hepatocytes could be validated in vivo. 
Estragole and nevadensin were co-administered orally to Sprague–Dawley rats, at a 
ratio reflecting their presence in basil. Moreover, previously developed physiologically 
based biokinetic (PBBK) models to study this inhibition in rat and in human liver were 
refined by including a sub-model describing nevadensin kinetics. Nevadensin resulted 
in a significant 36% reduction in the levels of estragole DNA adducts formed in the 
liver of rats. The refined PBBK model predicts the formation of estragole DNA adducts 
in the liver of rat with less than twofold difference compared to in vivo data and 
suggests more potent inhibition in the liver of human compared to rat due to less 
efficient metabolism of nevadensin in human liver and intestine. Given the role of 
the SULT-mediated DNA adduct formation in the hepatocarcinogenicity of estragole, 
the results of the present study suggest that the likelihood of bioactivation and 
subsequent adverse effects in rodent bioassays may be lower when estragole is dosed 
with nevadensin compared to dosing of pure estragole.
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INTRODUCTION
The alkenylbenzene estragole (1-allyl-4-methoxybenzene) (Figure 1) is a constituent 
of many herbs and spices and their essential oils (Smith et al., 2002). Estragole has 
been demonstrated to be hepatocarcinogenic in rodents at high doses due to its 
bioactivation by cytochromes P450 leading to the formation of the proximate 
carcinogen 1′-hydroxyestragole (Figure 1). Further bioactivation of 1′-hydroxyestragole 
requires the involvement of sulfotransferases (SULTs) that convert 1′-hydroxyestragole 
to the ultimate carcinogen 1′-sulfooxyestragole (Figure 1). The 1′-sulfooxy metabolite 
is unstable and, via a putative reactive carbocation intermediate, binds covalently to 
different endogenous nucleophiles including DNA leading to DNA adduct formation 
(Phillips et al., 1984; Randerath et al., 1984). 
Therefore, 1′-sulfooxyestragole is considered to be the ultimate hepatotoxic and 
hepatocarcinogenic agent in rodents (Boberg et al., 1983). This conclusion is supported 
by observations from experiments with mice revealing that co-administration with the 
SULT inhibitor pentachlorophenol (PCP) results in a reduction in hepatic DNA and RNA 
adduct formation and tumour formation upon long-term dietary administration of the 
closely related alkenylbenzene safrole or its 1′-hydroxy metabolite (Boberg et al., 1983). 
Given its genotoxicity and carcinogenicity, the addition of estragole as a pure 
substance in food stuffs has been prohibited since September 2008 within the 
European Union (European Commission, 2008). Intake of estragole at present occurs 
primarily from consumption of foods containing sweet basil, fennel, and anise or their 
essential oils (Smith et al., 2002). A significant difficulty in evaluating the metabolic, 
biochemical, and toxicological data for the alkenylbenzene estragole and other 
alkenylbenzenes is that human exposure results from a complex mixture of food, 
spice, and spice oil constituents that may significantly impact the biochemical fate 
and toxicological risk of estragole.
In this respect, we have previously demonstrated that the natural basil flavone 
nevadensin (5,7-dihydroxy-6,8,4′- trimethoxyflavone) (Figure 2) was able to inhibit estragole 
DNA adduct (N2-(trans-isoestragol-3′-y1)-2′-deoxyguanosine (E-3’-N2-dGuo) formation 
in primary rat hepatocytes exposed to the proximate carcinogen, 1′-hydroxyestragole 
(Jeurissen et al., 2008; Alhusainy et al., 2010). This inhibition by nevadensin was 
shown to occur at the level of SULT-mediated bioactivation of 1′-hydroxyestragole into 
1′-sulfooxyestragole (Jeurissen et al., 2008; Alhusainy et al., 2010).
However, whether a potent SULT inhibiting effect by nevadensin and subsequent 
reduction of estragole E-3’-N2-dGuo DNA adduct formation occurs in vivo remained 
to be established. The aim of the present study therefore was to investigate whether 
the inhibition of SULT-mediated E-3’-N2-dGuo formation by nevadensin observed in 
vitro could be validated in vivo. Furthermore, the physiologically based biokinetic 
(PBBK) models previously developed to study this inhibition in rat and human liver 
(Punt et al., 2008, 2009; Alhusainy et al., 2010, 2012) were refined by including a 
sub-model describing nevadensin kinetics and evaluated using the newly available 
experimental in vivo data in rat.
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MATERIALS AND METHODS
Materials
Estragole, alamethicin, uridine 5’-diphosphoglucuronic acid (UDPGA), pentachlorophenol 
(PCP), 3′-phosphoadenosine-5′-phosphosulfate (PAPS), and (S-(5′-adenosyl)-L-
methionine iodide) were purchased from Sigma-Aldrich (Steinheim, Germany). Tris and 
PBS were obtained from Gibco BRL Life Technologies (Paisley, UK). TFA was obtained 
from Mallinckrodt Baker B.V. (The Netherlands). Methanol (Ultra Liquid Chromatography/
Mass Spectrometry, ULC/MS) and ACN (ULC/MS) were obtained from Biosolve 
(Valkenswaard, The Netherlands). Rats and their Teklad 2014C feed were purchased 
Figure 1. Bioactivation and detoxification pathways of estragole.
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from Harlan Laboratories (The Netherlands). Pooled mixed gender human and pooled 
male Sprague–Dawley rat intestinal S9 were purchased from Tebu-bio (Heerhugowaard, 
The Netherlands). Pooled male Sprague–Dawley rat and pooled human liver S9 were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Nevadensin was purchased from 
Sinova, Inc. (Bethesda, MD, USA) under the name lysionotin (C18H16O7). Get pure DNA 
Kit-Cell was obtained from Dojindo Molecular Technology, Inc. (Kumamoto, Japan).
Animal experiment
The animal studies were in compliance with the Dutch Act on animal experimentation 
(Stb, 1977, 67; Stb 1996, 565), revised February 5, 1997. The study was approved 
by the ethical committee on animal experimentation of Wageningen University. All 
procedures were considered to avoid and minimize animal discomfort. Six-week-old 
white male outbred Sprague–Dawley rats were housed three rats per cage. Enrichment 
was provided for each cage. A 12-h light/dark cycle for the rats was applied during 
the animal acclimatization and treatment periods. Temperature (±20°C) and humidity 
(±55%) were monitored daily. Feed and tap water were provided ad libitum. The total 
number of animals was 21 rats (136.6±5.1 g). 
After a 5-day acclimatization period, animals were put into metabolic cages 24 
h prior to gavage and were kept in the metabolic cages up to time of sacrifice (48 
h after gavage). Rats were assigned to three groups, each containing seven rats. All 
compounds were dissolved in corn oil, placed in a water bath at 30°C and vortexed 
before each gavage and the volume of gavages was 2 mg/kg bw. 
The first group, representing the control group, was dosed once with 150 mg/kg 
bw estragole only. In a study by Paini et al. (Paini et al., 2012a), the dose of 150 mg/
kg bw was the lowest dose of estragole able to induce significant levels of estragole 
DNA adducts (E-3’-N2-dGuo) in the liver, lungs, and kidneys of male outbred Sprague–
Dawley rats 48 h after gavage compared to the solvent control (vehicle) group. 
The second group was dosed once with 150 mg/kg bw estragole and 87.2 mg/
kg bw of nevadensin. The dose of nevadensin of 87.2 mg/kg bw was selected to 
mimic the ratio of estragole to nevadensin (1:0.25) present in basil (Alhusainy et al., 
2012) and the two compounds were dosed simultaneously to also mimic the real-life 
situation where the two compounds are ingested together. 
Figure 2. Molecular structure of the natural SULT inhibitor nevadensin.
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The third group, representing a positive control group for SULT inhibition, was 
dosed once with 150 mg/kg bw estragole and the SULT inhibitor PCP at 11 mg/kg 
bw, dosed simultaneously. The dose of PCP was based on literature data where a 
dose of PCP of 11 mg/kg bw/day was reported to reduce the incidence of hepatomas 
resulting from a single intraperitoneal dose of 111 mg/kg bw estragole after 10 months 
(Wiseman et al., 1987). 
After anesthesia of the animals with a mixture of isoflurane and oxygen, blood 
was removed before removing livers. Livers were then weighted, cut into pieces, snap 
frozen in liquid nitrogen, and stored at -80°C until further processing. 
Tissue DNA extraction and digestion
Prior to DNA extraction, liver samples were homogenized as follows: Two samples from the 
left lateral lobe of the liver were taken randomly and each sample was around 1 g. Then, 
4 mL cold PBS was added to each 1 g liver sample and the sample was homogenized on 
ice at 1000 rpm using a mechanical cell homogenizer (B. Braun,Melsungen, Germany). 
Thereafter, homogenates were placed in 15-mL tubes and centrifuged at 3000×g for 
5 min (Sigma centrifuge, type 4K10, Germany) to obtain pellets. DNA extraction from 
the pellets obtained was performed using a Get pure DNA Kit-Cell protocol for tissue 
following the manufacturer’s instructions. The final DNA pellet was dissolved in 200 μL 
MilliQ water. Characterization of the yield and purity of the extracted DNA, digestion 
of DNA, and quantification of E-3’-N2-dGuo DNA adducts by LC–ESI–MS/MS were all 
performed as described previously (Paini et al., 2010).
Glucuronidation, sulfonation, and methylation of nevadensin by liver 
and intestinal S9 fractions
To construct a nevadensin PBBK model describing nevadensin kinetics, the following 
studies were performed to obtain the kinetic parameters (Vmax and Km) for the main 
pathways involved in the conversion of nevadensin. 
To examine glucuronidation of nevadensin, 0.01 mg/mL pooled male rat liver or 
intestinal S9 and 0.05 mg/mL pooled human liver or intestinal S9 were incubated with 
(final concentrations) 5 mM UDGPA in 0.2 M Tris-HCl (pH 7.4) containing 10 mM MgCl2 
in a total volume of 200 μL. Incubations were pre-treated with 0.025 mg/mL of the pore-
forming peptide alamethicin added from a 200 times concentrated stock in methanol 
on ice for 15 min to overcome enzyme latency and obtain maximal glucuronidation 
activity (Fisher et al., 2000). Incubation mixtures were preincubated at 37°C for 1 min, 
after which the reactions were started by the addition of the substrate nevadensin 
from 200 times concentrated stock solutions in DMSO to obtain final concentrations 
ranging between 0.5 and 50 μM. The reactions were carried out for 10 min at 37°C. 
To examine sulfonation of nevadensin, 1 mg/mL pooled male rat or pooled human liver 
or intestinal S9 were incubated with (final concentrations) 0.5 mM PAPS in 0.1 M Tris-HCl 
(pH 7.4) in a total volume of 100 μL. Incubation mixtures were pre-incubated at 37°C for 
1 min, after which the reactions were started by the addition of the substrate nevadensin 
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from 100 times concentrated stock solutions in DMSO to obtain final concentrations 
ranging between 1 and 500 μM. The reactions were carried out at 37°C for 30 min. 
To examine methylation of nevadensin, 1 mg/mL pooled male rat or pooled 
human liver or intestinal S9 were incubated with (final concentrations) 2 mM 
S-adenosylmethionine in 0.1 M potassium phosphate (pH 7.4) in a total volume of 100 
μL. Incubation mixtures were pre-incubated at 37°C for 1 min, after which the reactions 
were started by the addition of the substrate nevadensin from 100 times concentrated 
stock solutions in DMSO to obtain final concentration of 5 or 50 μM. The reactions 
were carried out at 37°C for either 10 min or 1 h. Cold ACN was added to terminate 
all reactions (50 μL for glucuronidation and 25 μL for sulfonation and methylation) and 
incubations were centrifuged for 5 min at 5°C and 16000×g to precipitate the proteins 
and the supernatants were stored at −20°C until UPLC analysis. 
UPLC–UV detection and quantification of nevadensin metabolites
Samples were analyzed by UPLC–UV on a waters AcquityTM ultra performance LC system 
coupled to an Acquity UPLC® BEH C18 1.7 µm 2.1x 50 mm column (Waters, Ireland). 
To detect the conjugates of nevadensin, the gradient was made with ultra-pure water 
containing 0.1% v/v TFA and ACN and the flow rate was set to 0.6 mL/min. The gradient 
was started with 20% ACN. ACN was kept at 20% for 2 min, increased to 25% in 4 min, to 
80% in 0.3 min, and to 100% in 0.7 min, and kept at 100% for 0.3 min. Initial conditions 
were reset in 0.2 min and then the system was equilibrated at these conditions for 0.5 
min. Detection was carried out using an AcquityTM ultra performance LC photodiode 
array detector (Waters, Milford, MA, USA). Given that the nevadensin conjugates have a 
similar UV spectrum as that of nevadensin, they were quantified by comparison of their 
peak area at a wavelength of 280 nm to the calibration curve of nevadensin. 
Data analysis 
To test whether the change in formation of E-3’-N2-dGuo levels in the control group 
(treated with estragole only) compared to the groups treated with estragole plus 
nevadensin or PCP was significant, a two-sample t-test (one sided) was performed 
after determining equality of variances by the Levene’s version of the F tested with 
SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL, USA). The kinetic constants (Vmax and 
Km) for sulfonation and glucuronidation of nevadensin were derived from plots by 
fitting the data to the standard Michaelis–Menten equation using the Life Science 
Workbench (LSW) data analysis toolbox (version 1.1.1, MDL Information Systems, Inc.).
PBBK model based predictions for formation of E-3’-N2-dGuo 
in the liver of rat and human in the presence or absence of nevadensin
In our previous work (Alhusainy et al., 2010, 2012), the estragole PBBK models in rat 
(Punt et al., 2008) and human (Punt et al., 2009) were used to obtain insight into the 
quantitative dose- and species-dependent effects of SULT inhibition by nevadensin on 
the formation of the ultimate carcinogenic metabolite, 1′-sulfooxyestragole, in the liver. 
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Nevadensin was assumed to follow a similar time-dependent concentration curve in the 
liver of rat and human as estragole and different scenarios of uptake and bioavailability 
ranging between 1 and 100% were also simulated (Alhusainy et al., 2010, 2012). 
In the present study, we aimed at further refinement of these former PBBK models 
and evaluation of the models obtained against the newly generated in vivo data. This 
was performed by combining the previously defined estragole PBBK models with the 
PBBK models describing the dose-dependent kinetics of nevadensin in male rat and 
human. A schematic diagram for the rat and human estragole PBBK model is shown in 
Figure 3A and that for the rat and human nevadensin PBBK model in Figure 3B. The 
original PBBK models for estragole were described in detail previously (Punt et al., 2008, 
2009) and therefore in this section only the newly developed nevadensin PBBK models 
in rat and human are described. Similar to the PBBK models for estragole, the model for 
nevadensin included separate compartments for liver, fat, and rapidly and slowly perfused 
tissues. Unlike the PBBK models of estragole, the nevadensin PBBK models contained a 
compartment for intestine that was found to be involved in the metabolism of nevadensin. 
Absorption rate constant of nevadensin (KaN) was set to 0.75/h, representing a 
median value for absorption constants between the unmethylated flavonoid quercetin 
(0.5/h) (Li et al., 2009) and the fully methylated flavonoid nobiletin (1/h) (Singh et 
al., 2011). All other PBBK model parameters and kinetic constants are provided 
in the Supplementary Material (Tables S1–S6). The apparent Vmax values for the 
glucuronidation and sulfonation of nevadensin in the liver and intestine, expressed as 
(nmol/min/mg S9 protein), were determined in vitro in the present study, and scaled 
to the liver or intestine using an S9 protein yield of 143 mg/g liver (Medinsky et al., 
1994) or 11 mg/g intestine (van de Kerkhof et al., 2007). All apparent Km values were 
determined in vitro and were assumed to correspond to the apparent in vivo Km values.
Figure 3. Schematic diagram of the PBBK model for (A) estragole and (B) nevadensin, in rat and 
human with the grey colour indicating organ compartments included in the PBBK model for rat 
but not in that for human.
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Mass balance equations for nevadensin in metabolizing tissues are as follows:
Liver : dALN/dt 
= QLN× CAN+QIN × CVIN − (QLN+QIN) × CVLN −VmaxLNG × (CLN/PLN)/(KmLNG+(CLN/PLN))
−VmaxLNS × (CLN/PLN)/(KmLNS+(CLN/PLN))
CLN = ALN/VLN
CVLN = CLN/PLN
Intestine : dAIN/dt 
= dUptakeN/dt+QIN×(CAN −CVIN) −VmaxING × (CIN/PIN)/(KmING+(CIN/PIN))
dUptakeN/dt = dAGIN/dt = KaN × AGIN; 
AGIN(0)= oral dose
CIN = AIN/VIN
CVIN = CIN/PIN
where dUptakeN/dt is the amount of nevadensin taken up from the gastrointestinal 
lumen (μmol), AGIN (μmol) is the amount of nevadensin remaining in the gastrointestinal 
lumen, ALN and AIN are the amount of nevadensin in liver and intestine, respectively. 
Correspondingly, CLN and CIN are the nevadensin concentration in liver and intestine, 
respectively (μmol/L), CAN is the nevadensin concentration in the arterial blood 
(μmol/L). QLN and QIN are the blood flow rates to liver (L) and intestine (I) (L/h), QC 
is the cardiac output (L/h), VL and VI are the volumes of liver and intestine, PLN is the 
liver/blood partition coefficient of nevadensin and PIN is the intestine/blood partition 
coefficient of nevadensin and VmaxLNG, VmaxLNS, and VmaxING are the maximum rates 
(µmol/h) for the formation of nevadensin glucuronide (NG) and nevadensin sulfonate 
(NS) in the liver (L) or intestine (I), and KmLNG, KmLNS, and KmING are the Michaelis–Menten 
constants (µM) for the formation for the same metabolites of nevadensin. 
The estragole and nevadensin PBBK models were connected to form a binary PBBK 
model taking into account the type of interaction between estragole and nevadensin 
defined in our previous work to be a non-competitive type of inhibition (Alhusainy 
et al., 2010). Thus, the Michaelis–Menten equation representing the sulfonation 
pathway was modified accordingly (Alhusainy et al., 2010). Moreover, nevadensin in 
the unconjugated form (CVLN) is the presumed active form of nevadensin able to 
inhibit SULT activity. 
To predict E-3’-N2-dGuo DNA adduct levels in the liver in the absence or presence 
of nevadensin, the following equation describing the relationship between the PBBK 
predicted levels of 1′-sulfooxyestragole and the E-3’-N2-dGuo DNA adduct formation 
levels in the liver of Sprague–Dawley rats, as described previously (Paini et al., 2012b), 
was integrated into the model:
DNAdGuo = 0.006×CLHES
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where DNAdGuo is the amount of E-3’-N2-dGuo DNA adducts (#adducts/1000 nt) 
formed in the liver and CLHES is the amount of 1′-sulfooxyestragole (nmol/g liver) 
predicted by the PBBK model to be formed in the liver (Paini et al., 2012b). The full 
code for the binary estragole-nevadensin PBBK model in rat and human are provided in 
the Supplementary Material (Model Code S1 and Model Code S2, respectively). Model 
equations were coded and numerically integrated in Berkeley Madonna 8.0.1 (Macey 
and Oster, UC Berkeley, CA,USA) using the Rosenbrock’s algorithm for stiff systems.
Sensitivity analysis
A sensitivity analysis was performed to identify key parameters that influence estragole 
E-3’-N2-dGuo formation in the binary estragole-nevadensin model. A 1% increase in 
each parameter value without changing the other model parameters was chosen for 
this analysis. Normalized sensitivity coefficients for each parameter of the model were 
determined according to the following equation: SC = (C′−C)/(P′−P) × (P/C)
where C is the initial value of model output, C′ is the modified value of the model 
output resulting from an increase in parameter value, P is the initial parameter value, 
and P′ is the modified parameter value (Evans and Andersen, 2000).
RESULTS
Inhibition of E-3’-N2-dGuo formation by nevadensin
As depicted in Figure 4, co-administration of 150 mg/kg bw estragole with 87.2 mg/
kg bw nevadensin, representing their molar ratio in basil, or with 11 mg/kg bw PCP 
resulted in a significant 36 and 71% reduction in E-3’-N2-dGuo formation in the liver 
of the rats, respectively.
Figure 4. Formation E-3’-N2-dGuo estragole DNA adducts in the liver of male Sprague–Dawley rats 
exposed to 150 mg/kg bw of estragole in the absence or presence of 87.2 mg/kg bw nevadensin or 
11 mg/kg bw pentachlorophenol (PCP), the latter included as a positive control for SULT inhibition
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Identification and kinetics of nevadensin metabolite formation by rat 
and human liver and intestinal S9
Figure 5 presents the HPLC–UV chromatograms from incubations of a pooled male 
rat liver S9 with 50 µM nevadensin in the presence of (A) UDGPA or (B) PAPS. The 
peak eluting at 4.1 min (Figure 5A) represents a nevadensin glucuronide since blank 
incubations without the cofactor UDGPA or the S9 fraction lacked this peak. The peak 
at 5.0 min (Figure 5B) represents a nevadensin sulfonate since blank incubations, 
without the cofactor PAPS or the S9 fraction, lacked this peak. The peak eluting at 6.5 
min in the two chromatograms was identified as nevadensin since it shows the same 
retention time and UV spectrum as a commercially available nevadensin standard. 
Moreover, LC–MS analysis using the same conditions used for the detection of E-3’-
N2-dGuo DNA adduct using negative ion mode instead of a positive ion mode and a 
collision energy of −18 eV revealed the presence of the following ions; m/z 519→343 
(RT 3.16 min) corresponding to a nevadensin glucuronide and m/z 423→343 344 (RT 
4.44 min) corresponding to a nevadensin sulfonate. Formation of methyl conjugates 
was not observed under the experimental conditions applied. 
Glucuronidation seems to be the most efficient conjugation pathway for nevadensin 
in the liver and intestine of rat and human (Table 1). Overall, the catalytic efficiency for 
glucuronidation is 3.0- and 3.3-fold higher in the liver and intestine of rats compared to 
that in human, respectively, whereas the catalytic efficiency for sulfonation is 3.3-fold 
higher in the liver of rat compared to the liver of human (Table 1).
Figure 5. UPLC–UV chromatograms of incubations of nevadensin with rat S9 and (A) UDPGA 
for 30 min or (B) PAPS for 10 min. Peaks marked with an asterisk were also present in blank 
incubations without the respective cofactors.
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PBBK model based predictions for formation of E-3’-N2-dGuo in the 
liver of rat and human in the absence or presence of nevadensin
Two different PBBK model results are presented in Figure 6, one being the prediction 
obtained using the previously described PBBK model assuming the nevadensin uptake 
to be 1% of that of estragole in the liver during the modeling time (48 h) (Alhusainy 
et al., 2010, 2012) and the other prediction being obtained using the newly defined 
PBBK model including a sub-model describing the kinetics of nevadensin. As shown 
in Figure 6A, in the absence of nevadensin, the two models give the same result and 
predict the E-3’-N2-dGuo level in the liver of rat after 48-h exposure to 150 mg/kg 
estragole to amount to 0.058 adducts/1000 nt. At the same dose level of estragole, 
the experimentally observed level of E-3’-N2-dGuo in rat liver was 0.037±0.0086 
adducts/1000 nt, which is only 1.6-fold lower than the predicted value. 
For co-administration of 150 mg estragole/kg bw and 87.2 mg nevadensin/kg bw, 
the PBBK model predicts the E-3’-N2-dGuo level to decrease to 0.002 adducts/1000 nt 
or to 0.012 adducts/1000 nt using either the previous or the new modeling approach, 
respectively. At the dose levels of estragole and nevadensin mentioned above, the 
experimentally observed level of E-3’-N2-dGuo in rats was 0.024±0.006 adducts/1000 
nt, which is, respectively, 12-fold or twofold higher than the predicted values. 
Clearly, the new modeling approach that takes the kinetics for nevadensin into 
account better matches the experimental data compared to our previous modeling 
approach. According to Figure 6B, upon dosing 150 mg/kg bw of estragole in the 
presence of nevadensin, the formation of E-3’-N2-dGuo in the liver of human after 48 
h is predicted to decrease from 0.21 adducts/1000 nt to 0.009 adducts/1000 nt or to 
0.02 adducts/1000 nt using either the previous or the new PBBK modeling approach, 
respectively. Thus, reduction in E-3’-N2-dGuo formation is predicted to be larger in the 
liver of human compared to rat.
Table 1. Kinetic parameters for glucuronidation and sulfonation of  nevadensin in incubations 
with pooled male rat and human liver and intestinal S9 fractions
Protein Vmax (nmol/min/mg S9) Km (µM) Catalytic efficiency (Vmax/Km)
a
Glucuronidation
Rat liver S9 0.62±0.10 0.78±0.16 0.79
Rat intestinal S9 0.58±0.07 0.86±0.39 0.66
Human liver S9 0.22±0.06 0.86±0.37 0.26
Human intestinal S9 0.55±0.03 2.80±0.07 0.20
Sulfonation
Rat liver S9 0.05±0.005 26.0±3.2 0.002
Human liver S9 0.003±0.0006 5.1±1.0 0.0006
a Catalytic efficiency (Vmax/Km) is in (mL/min/mg S9 protein).
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Sensitivity analysis
The common parameters with an impact on the model predictions for formation of 
E-3’-N2-dGuo in the liver of rat and human in the presence of 150 mg/kg bw estragole 
and 87.2 mg/kg bw nevadensin are the kinetic parameters (Vmax and Km) for formation 
of nevadensin glucuronide (NG) in the liver and the inhibition constant (Ki) for the 
formation of ultimate estragole carcinogen, 1’-sulfooxyestragole (HES) by nevadensin 
(Figure S1A and S1B in the Supplementrary Material). The previous parameters have 
higher impact in the human compared to the rat model and higher impact in both 
species than the kinetic parameters (Vmax and Km) for the formation of the proximate 
carcinogen, 1’-hydroxyestragole (HE). Also of importance are the kinetic parameters 
(Vmax and Km) for the most important detoxification routes in each species, namely 
glucuronidation of 1’-hydroxyestragole resulting in the formation of 1’-hydroxyestragole 
glucuronide (HEG) in the liver of rat and oxidation of 1’-hydroxyestragole resulting in 
the formation of 1’-oxoestragole (HEO) in the liver of human.
DISCUSSION
The present work is the first report presenting data showing that a natural food-borne 
SULT inhibitor is able to inhibit SULT enzyme activity in vivo. This was demonstrated by a 
significant inhibition of SULT-mediated formation of E-3’-N2-dGuo estragole DNA adduct in 
the liver of Sprague–Dawley rats exposed to the alkenylbenzene estragole and nevadensin 
simultaneously at a molar ratio of the two compounds reflecting their natural occurrence 
in basil. This observation is of importance given that the only phenolics for which in vivo 
SULT inhibitory activity has been reported so far are PCP and 2,6-dichloro-4-nitrophenol 
Figure 6. PBBK model based predictions for formation of E-3’-N2-dGuo in the liver after a single 
oral dose of 150 mg/kg bw of estragole in the absence or presence of 87.2 mg/kg bw nevadensin 
in (A) rat and (B) human according to two PBBK modeling approaches; first, our previous PBBK 
models (Alhusainy et al., 2010, 2012) assuming a nevadensin uptake in the liver that equals 1% of 
that of estragole concentration during the modeling time (48 h) and second, the newly defined 
PBBK models including a PBBK sub-model describing nevadensin kinetics.
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(DCNP) (Koster et al., 1979). Many SULT inhibitors including a number of natural dietary 
chemicals, such as polyphenols and a number of food additives, were also shown to have 
a SULT-inhibiting activity in vitro (Bamforth et al., 1993; Morimitsu et al., 2004; Alhusainy 
et al., 2012). Different reports have also anticipated a SULT-inhibiting activity for some 
flavonoids in vivo because reported plasma concentration can reach levels higher than 
their Ki (Gooderham et al., 1996; Alhusainy et al., 2012). It is important to note, however, 
that the reported plasma concentrations often reflect total flavonoid concentrations 
including both conjugated and unconjugated forms instead of the concentrations of the 
aglycon, whereas the active form of the flavonoid exerting SULT inhibition in most in 
vitro experiments is the aglycone. Nevadensin may be an effective in vivo SULT inhibitor 
because it possesses the structural requirements for effective SULT inhibitory activity 
including the presence of C5 and C7 hydroxyl substituents on the A-ring and a C2–C3 
double bond in conjunction with the C4 carbonyl group on the C-ring (Morimitsu et al., 
2004). Furthermore, methylated flavones such as nevadensin have been demonstrated 
to be much more metabolically stable and have a higher intestinal absorption than their 
unmethylated analogs (Wen and Walle, 2006; Walle, 2007). 
The estragole DNA adduct measured in the present study is E-3’-N2-dGuo, which 
was shown to be the major DNA adduct formed in several in vitro and rodent studies 
with estragole (Phillips et al., 1981; Wiseman et al., 1985; Punt et al., 2007) and a 
similar DNA adduct was also the major adduct formed with the related alkenylbenzene 
methyleugenol in in vitro studies and even in a human study (Herrmann et al., 
2012, 2013). Some other studies reported E-3′-N6-dA to be the major adduct 
formed in rodents (Ishii et al., 2011; Suzuki et al., 2012). In the present study, as a 
first approximation, we assumed that nevadensin-mediated inhibition of formation 
of E-3’-N2-dGuo would reflect the reduction in all estragole DNA adducts. This is 
based on the fact that all estragole DNA adducts will result from a chemical reaction 
with 1′-sulfooxyestragole, which is the ultimate carcinogenic metabolite, and that it 
is the formation of 1′-sulfooxyestragole that is inhibited by nevadensin. If all adducts 
would be reduced to a similar extent, one can subsequently assume that the resulting 
mutagenicity and carcinogencity would be reduced to a similar extent as well, even 
when different adducts would display different mutagenicity. 
The newly refined PBBK modeling approach that takes the kinetics for conversion 
of nevadensin into account was shown to adequately match the experimental data with 
only twofold difference in predicted estragole E-3’-N2-dGuo level compared to 12-fold 
difference using the previous approach (Alhusainy et al., 2010, 2012). Also, PBBK 
model predictions reveal a more potent inhibition of E-3’-N2-dGuo formation in the 
liver of human compared to rat due to lower catalytic efficiencies for glucuronidation 
and sulfonation of nevadensin in the liver and intestine of human compared to rat 
resulting in higher liver concentrations of nevadensin in its unconjugated form, which 
is the form required for SULT inhibition. 
The question that might be raised now is how to integrate the current results on 
nevadensin-mediated modulation of estragole bioactivation in the risk assessment of 
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estragole. The approach suggested by the European Food Safety Authority for the risk 
assessment of compounds that are both genotoxic and carcinogenic is the so-called 
margin of exposure (MOE) approach, which can be used to set priorities in risk 
management (EFSA, 2005). The reported lower confidence bound of the benchmark 
dose that gives 10% extra cancer incidence (BMDL10) value of estragole-based tumour 
data in mice (Miller et al., 1983) varies between 3.3 and 6.5 mg/kg bw/day (van den 
Berg et al., 2011). Using these reported BMDL10 values and the estimated daily intake 
for estragole of 0.01 mg/kg bw/day (Smith et al., 2002), the MOE value varies between 
350 and 650. Matrix modulation of estragole toxicity by nevadensin cannot easily 
be reflected in the numerical MOE but one may suggest to translate the reduction 
in estragole E-3’-N2-dGuo DNA adduct levels into a proportional reduction in the 
incidence of hepatomas and then to calculate a refined BMDL10 value that can be used 
to estimate a refined MOE. The newly developed PBBK models were used to calculate 
the possible reduction in E-3’-N2-dGuo at the estragole dose levels used in the study 
of Miller et al. (Miller et al., 1983) when nevadensin would be co administered with 
estragole at a molar ratio of estragole to nevadensin of 1:0.25 reflecting their natural 
occurrence in basil as shown in the Supplementary Material (Table S7). Thereafter, 
the percentage reduction in E-3’-N2-dGuo formation was used to calculate a possible 
percentage reduction in hepatoma incidences at the dose levels of estragole used in 
the study of Miller et al. (Miller et al., 1983) as shown in Table S7 in the Supplementary 
Material. Subsequently, a benchmark dose (BMD) analysis of the newly generated dose 
response curves (Figure S2 in the Supplementary Material) was performed using BMDS 
software version 2.1.2. providing newly estimated refined BMDL10 values. Using these 
refined BMDL10 values as shown in Table S8 in the Supplementary Material and the EDI 
for estragole of 0.01 mg/kg bw/day (Smith et al., 2002), the refined MOE for estragole 
amounted to 4,300 and 7,350 pointing at a lower priority for risk management, 
than when the MOE calculation would be based on the tumour data obtained with 
pure estragole. Although this linear relation between E-3’-N2-dGuo formation and 
hepatoma formation remains to be established, the assumption was used as a first 
approximation to estimate the possible consequences of the nevadensin-mediated 
inhibition of estragole bioactivation to its DNA reactive carcinogenic metabolite. 
Overall, given the role of the SULT-mediated formation of estragole DNA adduct 
formation in the hepatocarcinogenicity of estragole in rodents, the results of the present 
study indicate that the likelihood of bioactivation and subsequent adverse effects in rodent 
bioassays may be lower when estragole is dosed in a matrix containing SULT inhibitors 
such as nevadensin compared to experiments using estragole as a single compound.
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ABSTRACT
Methyleugenol occurs naturally in a variety of spices, herbs, including basil, and their 
essential oils. Methyleugenol induces hepatomas in rodent bioassays following its 
conversion to a DNA reactive metabolite. In the present study, the basil constituent 
nevadensin was shown to be able to inhibit SULT-mediated DNA adduct formation in 
HepG2 cells exposed to the proximate carcinogen 1′-hydroxymethyleugenol in the 
presence of nevadensin. To investigate possible in vivo implications of SULT inhibition by 
nevadensin on methyleugenol bioactivation, the rat physiologically based biokinetic (PBBK) 
model developed in our previous work to describe the dose-dependent bioactivation and 
detoxification of methyleugenol in male rat was combined with the recently developed 
PBBK model describing the dose-dependent kinetics of nevadensin in male rat. The 
resulting binary methyleugenol–nevadensin PBBK model was used to predict the possible 
nevadensin- mediated reduction in methyleugenol DNA adduct formation and resulting 
carcinogenicity at the doses of methyleugenol used by the NTP carcinogenicity study. 
Using these data an updated risk assessment using the margin of exposure (MOE) 
approach was performed. The results obtained point at a potential reduction of the cancer 
risk when rodents are orally exposed to methyleugenol within a relevant food matrix 
containing SULT inhibitors compared to exposure to pure methyleugenol. 
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INTRODUCTION
Methyleugenol is a compound naturally occurring in a variety of spices and herbs, 
including clove, allspice, cinnamon leaves, walnuts, basil, nutmeg, anise, pimento, 
citronella, laurel fruits leaves and others, as well as in their essential oils (Smith et al., 
2002). The general population is primarily exposed to methyleugenol via ingestion of 
food stuffs flavoured with methyleugenol containing essential oils (Smith et al., 2010), 
including for instance, candy, cookies such as gingersnaps, ice cream, tomato ketchup 
and relish (Burdock, 1995; Leung, 1998). Realistic daily intake levels of methyleugenol 
have been estimated to range from 0.014 mg/kg bw/day (Smith et al., 2002) to 0.217 
mg/kg bw/day (SCF, 2001). Given that at present addition of methyleugenol as a pure 
compound to individual food categories is no longer allowed within the European 
Union (European Commission, 2008), the value of 0.014 mg/kg bw/day, resulting 
mainly from herbs and spices and their essential oils (Smith et al., 2002), is taken in the 
present study as the value for current levels of dietary human intake.
In 2000, the carcinogenicity of methyleugenol was investigated in mice and 
rats (NTP, 2000). The NTP reported that methyleugenol is carcinogenic in both rats 
and mice when dosed at high dose levels as a pure compound suspended in 0.5 % 
methylcellulose (NTP, 2000). Methyleugenol is unreactive by itself but undergoes 
metabolic activation to produce an electrophilic metabolite that acts as the DNA 
reactive intermediate (Miller et al., 1983; Randerath et al., 1984; Gardner et al., 1997; 
Smith et al., 2002). Figure 1 displays the bioactivation pathway of methyleugenol which 
starts with hydroxylation of the 1’-position of methyleugenol to produce the proximate 
carcinogenic metabolite 1′-hydroxymethyleugenol (Miller et al., 1983; Gardner et al., 
1997; Smith et al., 2002). In a next step, 1′-hydroxymethyleugenol can be sulfonated by 
SULT to form 1′-sulfoxymethyleugenol that can form DNA adducts (Smith et al., 2002). 
Recently, studies using Salmonella typhimurium TA100 strains expressing different 
human SULTs revealed that human SULT1A1 and SULT1C2 are specifically able to 
activate 1′-hydroxymethyleugenol to DNA reactive metabolites (Herrmann et al., 2012).
It is important to note that the carcinogenicity observed in studies in which 
animals are exposed to high dose levels of the pure compound by gavage may not 
be representative for the situation where humans are exposed to methyleugenol 
at low levels via dietary intake with a food matrix being present. For the related 
alkenylbenzene estragole it was actually demonstrated that other ingredients present 
Figure 1. Structural representation of the pathway for bioactivation of methyleugenol.
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in alkenylbenzene containing herbs or food items may inhibit the SULT-mediated 
bioactivation of estragole to its ultimate DNA reactive 1′-sulfooxy metabolite (Jeurissen 
et al., 2008; Alhusainy et al., 2010). For instance a methanolic basil extract was shown 
to cause a dose dependent inhibition of DNA adduct formation in 1′-hydroxyestragole 
exposed human HepG2 cells (Jeurissen et al., 2008). In a subsequent study, the 
flavonoid nevadensin (Figure 2) was identified as the potent SULT inhibitor present in 
these methanolic basil extracts (Alhusainy et al., 2010). So far the existence of such 
matrix dependent interactions with the bioactivation of alkenylbenzenes was only 
demonstrated for estragole (Alhusainy et al., 2010, 2012). 
Therefore the objective of the present study was to study the potential of 
nevadensin to inhibit the SULT-mediated bioactivation and subsequent DNA adduct 
formation of methyleugenol using human HepG2 cells as an in vitro model. To obtain 
some insight in the in vivo relevance of these observations our physiologically based 
biokinetic (PBBK) model for bioactivation and detoxification of methyleugenol in male 
rat (Al-Subeihi et al., 2011) was combined with the recently developed PBBK model 
for nevadensin in male rat (Alhusainy et al., 2013). This combined PBBK model was 
previously validated using in vivo data on liver adduct formation in male Sprague–
Dawley rats orally dosed with the structurally related alkenylbenzene estragole and 
nevadensin (Alhusainy et al., 2013). Using this binary PBBK model the effects of 
combined in vivo exposure to methyleugenol and nevadensin could be quantified 
as well given that the SULT inhibition by nevadensin is non-competitive in nature and 
therefore by definition independent of the nature of the SULT substrate. 
MATERIALS AND METHODS
Materials
2′-Deoxyguanosine was purchased from Sigma (Basel, Switzerland), and 1,2,3,7,9-15N5-
2′-deoxyguanosine was obtained from Cambridge Isotope Laboratories (Cambridge, 
MA). Fetal bovine serum (FBS), DMEM/F12 (L-glutamine, 15 mM HEPES) medium 
and phosphate buffered saline (PBS) (pH 7.4) were purchased from Gibco (UK). 
Dimethylsulfoxide (DMSO), methanol, zinc sulphate (heptahydrate), phosphodiesterase 
I from Crotalus adamanteus (venom phosphodiesterase), phosphodiesterase II from 
Figure 2. Structural formula of  nevadensin.
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bovine spleen (spleen phosphodiesterase), nuclease P1 and alkaline phosphatase 
were purchased from Sigma (Schnelldorf, Germany). Acetonitrile was purchased from 
Biosolve BV (Valkenswaard, The Netherlands). Formic acid and ethanol were obtained 
from VWR Merck (Darmstadt, Germany). Nevadensin was purchased from Apin 
Chemicals (Milton, UK). Pentachlorophenol (PCP; 98%) was obtained from Sigma-Riedel 
de Haen (Seelze, Germany). 1′-Hydroxymethyleugenol and 1′-acetoxymethyleugenol 
were synthesized as described previously (Al-Subeihi et al., 2011). Human HepG2 cells 
were purchased from the American type culture collection (Manassas, Virginia).
Synthesis of N2-(trans-isomethyleugenol-3′-yl)-2′-deoxyguanosine 
(ME-3’-N2-dGuo) and 15N5-labeled N
2-(trans-isomethyleugenol-3′-yl)-
2′-deoxyguanosine (15N5) ME-3’-N
2-dGuo)
ME-3’-N2-dGuo was synthesized via a reaction between 1′-acetoxymethyleugenol 
and 2′-deoxyguanosine following the protocol of Punt et al. (2007). In brief, 250 μL 
of a 0.01 g/mL solution of 1′-acetoxymethyleugenol in DMSO was added to 2250 
μL of 2.5 mM 2′-deoxyguanosine in 2.5 mM ammonium carbonate (pH 7.4). The 
same reaction was performed for the synthesis of (15N5) ME-3’-N
2-dGuo in which 
1′-acetoxymethyleugenol was allowed to react with 15N5-labeled 2′-deoxyguanosine. 
The incubations were stirred for 48 h at 37°C. Both ME-3’-N2-dGuo and (15N5) ME-
3’-N2-dGuo were purified by HPLC–UV on a M600 liquid chromatography system 
(Waters, Milford, MA) equipped with an Alltima C18 5 µm column, 150 × 4.6 mm 
(Alltech, Breda, The Netherlands). The gradient was made with ultrapure water and 
acetonitrile. The flow rate was 1 mL/min. A linear gradient was applied from 10% to 
15% acetonitrile over 30 min after which the percentage of acetonitrile was increased 
to 100% over 2 min, kept at 100% for 1 min, lowered to 10% in 2 min, and kept 
at these initial conditions for 10 min for equilibration of the system. Detection was 
carried out using a Waters 966 photodiode array detector (Waters, Milford, MA) at 260 
nm. Both ME-3’-N2-dGuo and (15N5) ME-3’-N
2-dGuo were collected at a retention time 
of 11.4 min. The purity of both ME-3’-N2-dGuo and (15N5) ME-3’-N
2-dGuo was more 
than 98%, according to LC–MS/MS and HPLC analyses.
Cytotoxicity test
The cytotoxicity of nevadensin, 1′-hydroxymethyleugenol, pentachlorophenol, and 
DMSO was evaluated using the MTT test (Mosmann, 1983; Hussain et al., 1993). 
HepG2 cells were plated in a 96-well plate at a density of 2 ×104 cells per well 24 
h prior to exposure. Just before exposure the medium was removed and cells were 
washed with 100 µL HBSS. Cells were exposed to 0.5% DMSO (control) or the test 
compounds in exposure medium (DMEM/F12 + glutamax + 50 µg/mL gentamicin) at 
concentrations of nevadensin, 1′-hydroxymethyleugenol, and/or pentachlorophenol 
as indicated and added from respectively 5000, 1000, and 400 times concentrated 
stock solutions in DMSO for 4 h in a humidified atmosphere at 37°C. Then, 5 µL of a 5 
mg/mL MTT solution in PBS was added and the cells were incubated for another hour. 
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Thereafter, the medium was removed and 100 µL of DMSO was added to all wells 
to dissolve the formazan crystals. The absorbance was measured at 562 nm and cell 
viability was defined as the ratio between the absorbance measured for nevadensin, 
1′-hydroxymethyleugenol, pentachlorophenol or DMSO treated cell samples and the 
absorption measured for untreated cell samples.
Incubation of HepG2 cells with 1′-hydroxymethyleugenol
Human HepG2 cells were cultured in a 75 cm2 flask (Corning, NY, USA) with DMEM/
F12 medium containing glutamax, 10% FBS and incubated in a humidified incubator 
under, 5% CO2 and 95% air at 37°C. Once reaching 80-90% confluence the cells were 
incubated overnight (~14 h) in the presence of 1′-hydroxymethyleugenol at a final 
concentration of 100 µM (added from a 1000 times concentrated stock solution in 
DMSO) and nevadensin at a final concentration of 0, 0.002, 0.02, 0.2, or 2 µM (added 
from 5000 times concentrated stock solutions in DMSO) or pentachlorophenol at a 
final concentration of 12.5 µM (added from a 400 times concentrated stock solution in 
DMSO). After overnight incubation cells were washed twice with phosphate buffered 
saline (PBS), scraped, collected into an Ependorf tube, and centrifuged at 1500 rpm for 
5 min (Eppendorf Centrifuge 5424). DNA was extracted from the pellet and thereafter 
digested as reported in the next section.
DNA extraction and digestion
DNA was extracted from human HepG2 cells as previously described (Jeurissen et al., 
2008; Paini et al., 2010). Briefly, DNA was extracted using the Get pure DNA Kit-Cell 
protocol (Dojindo Molecular Technology Inc., Kumamoto, Japan) with 3-10×106 
cells per sample (following the manufacturer’s instructions). The yields and purity of 
the extracted DNA were determined using the Nanodrop technique measuring the 
absorbance ratio A260 nm/A280 nm. DNA samples with an absorbance ratio of 1.8-2 
were considered sufficiently pure. The quantity of DNA per sample was calculated 
from the Nanodrop output in ng/mL using a molar extinction coefficient for double 
stranded DNA of 50 (L/mol × cm ) at a wavelength of 260 nm. Digestion of isolated 
DNA was done as reported previously (Paini et al., 2010). In short, to 50 µg DNA in 
80 µL water, 20 µL buffer P1 (300 mM sodium acetate, 1 mM ZnSO4, pH 5.3), 11 µL 
SPDE (spleen phosphodiesterase) solution (0.0004 U/µL in water), and 10 µL nuclease 
P1 (0.5 µg/µL in water) were added and the resulting solution was incubated for 4 
h at 37 °C. Following incubation, 20 µL buffer (500 mM Tris-HCl, 1 mM EDTA, pH 
8.0), 12 µL VPDE (venom phosphodiesterase) solution (0.00026 U/µL in water), and 
6 µL alkaline phosphatase (0.764 U/µL in water) were added and the mixture was 
incubated for 3 h at 37°C (Paini et al., 2010; Al-Subeihi et al., 2011). After these 
incubations samples were filtered using eppendorf tubes with a cut off membrane 
of 5.000 nominal molecular weight limit (NMWL) (Millipore). The hydrolyzed filtered 
samples were evaporated to dryness and reconstituted in 50 µL water and stored at 
-20°C until LC–ESI–MS/MS analysis.
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LC–ESI–MS/MS method for detection and quantification of ME-3’-N2-dGuo
LC–ESI–MS/MS analysis was performed on a Perkin Elmer 200 Series HPLC System (Perkin 
Elmer, Waltham, Massachusetts) coupled to an API 3000 system (Applied Biosystem, 
Foster City, California). Samples were injected on an Agilent Zorbax Extend-C18 
column, 2.1 × 50 mm, 3.5 Micron 80 Å (Basel, Switzerland), with a Zorbax guard 
column. The gradient was made with ultrapure water containing 0.1% (v/v) formic 
acid and 100% acetonitrile. The flow rate was set at 0.3 mL/min. A linear gradient 
was applied from 10% to 50% acetonitrile over 3 min, after which the percentage 
of acetonitrile was brought to 100% in 1 min, and kept at 100% acetonitrile over 2 
min. The amount of acetonitrile was lowered to 10% over 1 min, and the column was 
equilibrated at these initial conditions for 8 min. ME-3’-N2-dGuo eluted at 2.58 min. 
The mass spectrometric analysis was performed with the following settings: nebulizer 
gas (air) was set at 15 psi, curtain gas (nitrogen, which is used to keep the analyzer 
region clean) was set at 10 psi, the ion spray voltage at 4700 V, the collision gas (CAD) 
was 5 eV, the ion source temperature was set at 300 °C, the declustering potential was 
set at 37 V, the focusing potential was set at 200 V, the entrance potential at 9 V, and 
the collision cell exit was set at 15 V. Nitrogen was used as sheath gas turbo, ion spray, 
with a pressure of 7000 L/h. The dwell time per transition was 0.05 s. A divert valve 
was used in order to discard the gradient after elution of the peak. Quantification of 
the DNA adduct was carried out using selected-ion detection in the multiple reaction-
monitoring mode (MRM), the characteristic transitions for the ME-3′-N2-dGuo and for 
the (15N5) ME-3’-N
2-dGuo are displayed in Table 1.
Statistical analysis
To test whether the effect of nevadensin on formation levels of ME-3’-N2-dGuo adducts 
was significant, a two sample t-test (one-sided, equal variances) was performed, after 
an F test for equal variances was done, using Excel (Microsoft Office 2000). 
PBBK model based predictions 
To investigate possible in vivo implications of SULT inhibition by nevadensin for 
methyleugenol bioactivation, the PBBK model developed in our previous work to 
describe the dose-dependent bioactivation and detoxification of methyleugenol in 
male rat (Al-Subeihi et al., 2011) was combined with the recently developed PBBK 
Table 1. Transition reaction (m/z) and the collision energy used to obtain the daughter fragments 
by LC–ESI–MS/MS.
Transition (m/z) (used 
for quantification)
Collision 
energy (eV)
Transition (m/z) (used 
for confirmation)
Collision 
energy (eV)
ME-3′-N2-dGuo 444à328 18 444à177
444à164
37
40
(15N5)ME-3′-N
2-dGuo 449à333 18 449à169 40
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model describing the dose-dependent kinetics of nevadensin in male rat (Alhusainy 
et al., 2013). A schematic diagram for the male rat methyleugenol PBBK model is 
shown in Figure 3A and that for the male rat nevadensin PBBK model in Figure 3B. The 
original PBBK model for methyleugenol was described in detail previously (Al-Subeihi 
et al., 2011). The male rat nevadensin PBBK model was also described previously 
(Alhusainy et al., 2013). Similar to the male rat PBBK model of methyleugenol, the 
model for nevadensin included separate compartments for liver, fat, rapidly and slowly 
perfused tissues. Unlike the PBBK model of methyleugenol, the nevadensin PBBK 
model contained a compartment for intestine which was found to be involved in the 
metabolism of nevadensin (Alhusainy et al., 2013). 
The physiological, physico-chemical parameters and kinetic constants for the 
metabolism of methyleugenol and nevadensin used in the male rat PBBK models are 
described in detail in our previous work (Al-Subeihi et al., 2011; Alhusainy et al., 2013) 
and they are summarized in the Supplementary Material (Table S1-S4)
The methyleugenol and nevadensin PBBK models were connected to form a binary 
PBBK model taking into account the non-competitive type of inhibition of SULT by 
nevadensin in line with our previous work with estragole and nevadensin (Alhusainy 
et al., 2010, 2012, 2013). The non-competitive nature of the SULT inhibition by 
nevadensin implies that the inhibition and its Ki are independent of the nature of the 
substrate and therefore the Ki for the inhibition of SULT enzyme activity by nevadensin 
identified previously using the standard substrate 7-hydroxycoumarin (Alhusainy et al., 
2010) can also be used in the combined methyleugenol nevadensin PBBK modeling. 
The Michaelis–Menten equation in the model that represents the sulfonation 
pathway was modified to reflect the non-competitive type of inhibition by introducing 
a modulation factor (1+([CVLN]/Ki) for the apparent Vmax value. Nevadensin in the 
unconjugated form (CVLN) is assumed to be the active form of nevadensin able to 
inhibit SULT activity. The resulting equation for sulfonation then is as follows:
dAM1′HMES/dt=Vmax,L_1′HMES/(1+([CVLN]/Ki))×CL1′HME/PL1′HME/(Km,L_1′HMES+CL1′HME/PL1′HME)
where AM1′HMES is the amount of 1′-sulfooxymethyleugenol (μmol), Vmax,L_1′HMES is 
the maximum rate of formation of 1′-sulfooxymethyleugenol, [CVLN] is the free 
concentration of nevadensin in the liver (μmol/L), Ki is the inhibition constant for 
inhibition of the sulfonation by nevadensin (μmol/L), CL1′HME is the concentration 
of 1′-hydroxymethyleugenol in the liver (μmol/L), PL1′HME is the liver/blood partition 
coefficient of 1′-hydroxymethyleugenol, and Km,L_1′HMES is the Michaelis–Menten 
constant for the formation of 1′-sulfooxymethyleugenol (μmol/L) in the liver. Using 
our binary methyleugenol–nevadensin PBBK model for methyleugenol bioactivation 
and detoxification, the time dependent concentration of 1′-sulfooxymethyleugenol 
(CL1′HMES) in the liver of male rat following an exposure to different doses of 
methyleugenol in the presence of varying amounts of nevadensin can be predicted.
In line with our previous work (Alhusainy et al., 2013), the equation describing the 
relationship between the PBBK predicted levels of the 1′-sulfooxy metabolite and the 
levels of DNA adduct formation in the liver (Paini et al., 2012b) was as follows;
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DNAdGuo=0.006×CL1′HMES
Where DNAdGuo is the amount of ME-3’-N
2-dGuo DNA adducts (#adducts/1000nt) 
formed in the liver and CL1′HMES is the amount of the 1′-sulfooxy metabolite (nmol/g 
liver) predicted by the PBBK model to be formed in the liver. 
Model equations were coded and numerically integrated in Berkeley Madonna 
8.0.1 (Macey and Oster, UC Berkeley, CA, USA) using the Rsenbrock’s algorithm for 
stiff systems.
BMDL10 and MOE analysis
In order to estimate how reduction in methyleugenol bioactivation in the presence of 
nevadensin may in theory affect the risk assessment of methyleugenol, we investigated 
the possible consequences arising from the co-administration of methyleugenol and 
nevadensin on the so-called margin of exposure (MOE). The MOE was suggested by the 
European Food Safety Authority (EFSA) to be used to set priorities in risk management 
with respect to compounds that are both genotoxic and carcinogenic and is defined 
as the ratio between the lower confidence limit of the benchmark dose that gives 10% 
extra cancer incidence (BMDL10) and the estimated daily intake (EDI) (EFSA, 2005). An 
MOE > 10,000 is considered as a low priority for risk management actions and would 
be of low concern from a public health point of view (EFSA, 2005). The BMDL10 values 
of methyleugenol for female and male rats were obtained from the literature (van den 
Berg et al., 2011) where the values were calculated using BMDS software version 2.1.2 
based on the available incidence of hepatocellular carcinomas in female and male 
F344/N rats administered methyleugenol by gavage 5 days per week for up to 105 
weeks (NTP, 2000). The binary methyleugenol–nevadensin PBBK model in male rat was 
used to calculate the possible reduction in ME-3’-N2-dGuo at the methyleugenol dose 
levels used in the NTP study for female and male rats when methyleugenol would be 
co-administered with nevadensin at a molar ratio of methyleugenol to nevadensin of 
1:0.20 reflecting their natural occurrence in basil (Smith et al., 2002; Alhusainy et al., 
2012). Thereafter, the percentage reduction in ME-3’-N2-dGuo formation was used to 
calculate the percentage reduction in incidence of hepatocellular carcinomas at the 
respective dose levels of methyleugenol and nevadensin assuming a corresponding 
reduction in ME-3’-N2-dGuo DNA adduct and incidences of hepatocellular carcinomas. 
Subsequently a BMD analysis of the newly generated dose response curves was 
performed to estimate refined BMDL10 values. Using these refined BMDL10 values and 
the EDI for methyleugenol of 0.014 mg/kg bw/day (Smith et al., 2002), the refined MOE 
for methyleugenol was estimated as shown in the results section.
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RESULTS
Synthesis and characterization of ME-3’-N2-dGuo 
and (15N5) ME-3’-N
2-dGuo
Incubation of 1′-acetoxymethyleugenol with 2′-deoxyguanosine resulted in the 
formation of several adducts with 2′-deoxyguanosine as detected by HPLC–UV 
(Figure 4). Our chromatographic profile was comparable to that reported in the 
literature for the same reaction between the structurally related 1′-acetoxyestragole 
and 2′-deoxyguanosine (Punt et al., 2007). Based on analogy to outcomes of the 
synthesis of N2-(trans-isoestragol-3′-yl)-2′-deoxyguanosine (E-3’-N2-dGuo) from 
1′-acetoxyestragole by the same procedure it was expected that the most abundant 
peak at 11.4 min (Figure 4) corresponds to the adduct of interest ME-3’-N2-dGuo. 
Figure 5 presents the structures of the various adducts detected based on this analogy 
to previous adducts identified for E-3’-N2-dGuo. 
This nature of the major adduct is also in line with results reported previously 
(Phillips et al., 1981; Wiseman et al., 1985; Punt et al., 2007) for the nature of the 
major DNA adduct of estragole; E-3′-N2-dGuo. ME-3’-N2-dGuo thus obtained was 
collected at 11.4 min and subsequently used as a standard to confirm the formation 
of the adduct of interest and to develop the quantitative LC–ESI–MS/MS method for 
detecting and quantifying DNA nucleotide adducts of methyleugenol. 
A similar chromatographic profile was obtained when the reaction was performed 
using (15N5) ME-3’-N
2-dGuo, and the isolation of the labeled adduct was undertaken in 
the same way as described for the non-labeled analog. The characterizations of ME-3’-
N2-dGuo and (15N5) ME-3’-N
2-dGuo were carried out on the basis of the LC–ESI–MS/MS 
results depicted in Figure 6. In Figure 6A, the transitions used for the MS/MS spectrum 
of ME-3’-N2-dGuo provided a molecular ion at m/z 444 corresponding to the protonated 
molecule [M+H]+. The 5 Da up mass shift observed in the MS/MS spectrum of (15N5) 
ME-3’-N2-dGuo (m/z 449) (Figure 5B) was consistent with the penta-15N labelling of the 
guanine moiety. When fragmented by collision, the ion of ME-3’-N2-dGuo at m/z 444 
gave rise to three major fragment ions at m/z 328, 177, and 164 (insert Figure 6A). The 
Figure 4. HPLC–UV chromatogram of methyleugenol adducts with 2′dGuo formed in a reaction 
between 1′ACME and 2′dGuo. On the basis of previous identification by Phillips et al. (1981), 
Wiseman et al. (1985), and Punt et al. (2007) for the 2′dGuo adduct of estragole, peaks were 
characterized as two diastereomers of ME-1′-N2-dG and ME-3′-N2-dGuo.
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fragment ions at m/z 328, m/z 177, and m/z 164 were rationalized in terms of a loss of 
the deoxyribosyl group, loss of the 2′-deoxyguanosine group, and loss of deoxyribosyl 
and phenylethyl groups, respectively. The same MS/MS spectrum of ME-3’-N2-dGuo 
was obtained in the study of Herrmann et al. (2012). Identification of ME-3’-N2-dGuo 
was further supported by the observation of the mass loss of the deoxyribosyl group and 
the phenylethyl group in the transition m/z 449 → 333 and m/z 449 → 169, respectively 
obtained in the case of (15N5) ME-3’-N
2-dGuo (insert Figure 6B).
Inhibition of ME-3’-N2-dGuo formation in the human hepatoma 
cell line HepG2
Figure 7A shows the LC–ESI–MS/MS chromatogram for the 444 → 328 transition 
of hydrolyzed DNA isolated from human HepG2 incubated with 100 µM 
1′-hydroxymethyleugenol. The peak of ME-3’-N2-dGuo appears at 2.7 min in the 
chromatogram. Figure 7B presents the ME-3’-N2-dGuo formation detected in HepG2 
cells exposed to 100 µM 1′-HME for ~14 h in the absence and presence of increasing 
concentrations of nevadensin or 12.5 µM pentachlorophenol added as a positive 
control for SULT inhibition. At the concentrations tested the compounds were not 
toxic to the HepG2 cells according to the results of the MTT test (data not shown). 
The results of Figure 7B reveal that ME-3’-N2-dGuo formation in HepG2 cells exposed 
to 1′-hydroxymethyleugenol was almost completely blocked by co-exposure to the 
model SULT inhibitor pentachlorophenol. For nevadensin, a dose dependent inhibition 
was observed with 0.2 and 2 µM inhibiting ME-3’-N2-dGuo formation in HepG2 cells 
exposed to 1′-hydroxymethyleugenol by 80 and 88 % respectively.
major adduct 
ME-3’-N2-dGuo
minor adduct 
ME-1’-N2-dGuo
minor adduct 
ME-3’-8-dGuo
minor adduct 
ME-3’-7-dGuo
Figure 5. Expected structure of adducts of ME with 2’dGuo based on the analogy of the reaction 
of estragole with 2’dGuo as identified by Phillips et al. (1981) and Wiseman et al. (1985). dGuo 
= 2’-deoxyguanosine, ME-3’-N2-dGuo = N2-(trans-isomethyleugenol-3’-yl)-2’-deoxyguanosine, 
ME-3’-C8-dGuo = 8-(trans-isomethyleugenol-3’yl)-2’-deoxyguanosine, ME-1’-N2-dGuo = N2-
(methyleugenol-1’-yl)-2’-deoxyguanosine, and ME ME-3’-N7-dGuo= 7-(trans-methyleugenol-3V- 
yl)-2’-guanine.
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Figure 6. API 3000 Q1 spectrum of the parent ion representing: (A) the non-labeled synthesised 
ME-3’-N2-dGuo (444 m/z, Da). The insert represents the daughter ions (328, 177, 164 m/z, Da) 
formed from the parent ion (444 m/z, Da) and (B) the labeled synthesised (15N5) ME 3’-N
2-dGuo 
(449 m/z, Da). In the small figure representation of the daughter ions (338, 169 m/z, Da) formed 
from the parent ion (449 m/z, Da).
Figure 7. LC–ESI–MS/MS chromatogram of the adduct (444→328) formed in human HepG2 
cells exposed to 100 µM methyleugenol (A) and DNA adduct levels detected in human HepG2 
cells treated with 100 µM 1’HME and increasing concentration of  nevadensin or 12.5 µM PCP 
as positive control (B). Data points represent mean (±SD) of triplicate measurements obtained 
in independent experiments. An asterisk (*) indicates a significant inhibition compared to the 
incubation without inhibitor,*p < 0.05; **p ≤ 0.01.
A
B
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PBBK model based predictions for formation of ME-3’-N2-dGuo 
in the liver of rat in the absence or presence of nevadensin
To investigate possible in vivo implications for SULT inhibition by nevadensin on 
methyleugenol bioactivation, the rat PBBK model developed in our previous work 
to describe the dose-dependent bioactivation and detoxification of methyleugenol 
in male rat (Al-Subeihi et al., 2011) was combined with the recently developed PBBK 
model describing the dose-dependent kinetics of nevadensin in male rat (Alhusainy 
et al., 2013). Subsequently, the binary methyleugenol–nevadensin PBBK model was 
used to predict the percentage reduction in ME-3’-N2-dGuo formation at the doses of 
methyleugenol used in the NTP study (NTP, 2000) of 0, 37, 75 and 150 mg/kg bw/day 
when nevadensin would be co-administered with methyleugenol at respectively 0, 14, 
29 and 85 mg/kg bw/day representing a molar ratio of methyleugenol to nevadensin 
of 1:0.20 reflecting their natural occurrence in basil (Smith et al., 2002; Alhusainy et 
al., 2010). As presented in Tables S5 and Table S6 in the Supplementary Material, our 
binary methyleugenol–nevadensin PBBK model predicts a 77%, 82% and 83% inhibition 
in ME-3’-N2-dGuo formation at the respective doses of methyleugenol and nevadensin. 
Refined BMDL10 and MOE for methyleugenol in the presence 
of nevadensin
The BMDL10 values for methyleugenol derived from the data from the NTP study (NTP, 
2000) were previously reported to vary between 49 to 74 mg/kg bw/day for female 
rats and from 15 to 34 mg/kg bw/day for male rats (van den Berg et al., 2011). 
Based on an EDI of 0.014 mg/kg bw/day (Smith et al., 2002), these BMDL10 values 
result in MOE values that vary between about 3,500 to 5,300 for female rats and from 
about 1,100 and 2,400 for male rats. Table S5 and S6 in the Supplementary Material 
present an overview of the incidence of hepatocellular carcinomas in female and male 
F344/N rats respectively with increasing doses of methyleugenol as reported by the 
NTP study (NTP, 2000) and also the refined incidence of hepatocellular carcinomas 
calculated in the present study assuming nevadensin would be co-administered to 
rats together with methyleugenol at a molar ratio of methyleugenol to nevadensin 
of 1:0.20. These refined incidences of hepatocellular carcinomas at the respective 
dose levels of methyleugenol and nevadensin were calculated using the binary male 
rat methyleugenol–nevadensin PBBK model based predictions for the nevadensin-
mediated reduction in ME-3’-N2-dGuo formation assuming a corresponding reduction 
in hepatocellular carcinoma formation. Although this linear relation between ME-3’-N2-
dGuo formation and hepatocellular carcinoma formation remains to be established, the 
assumption was used as a first approximation to estimate the possible consequences of 
the nevadensin-mediated inhibition of methyleugenol bioactivation to its DNA reactive 
carcinogenic metabolite. The BMDS analysis of the newly generated refined data 
resulted in a BMDL10 value that varies from about 159 to 254 mg/kg bw/day for female 
rats (Table S7 in the Supplementary Material) and from about 129 to 142 mg/kg bw/
day for male rats (Table S8 in the Supplementary Material). Using these newly estimated 
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refined BMDL10 values and the EDI for methyleugenol of 0.014 mg/kg bw/day (Smith 
et al., 2002), the MOE for methyleugenol would amount to about 11,000 to 18,000 for 
female rats and from about 9,200 to 10,000 for male rats. Clearly, co-administration of 
nevadensin together with methyleugenol is thus predicted to increase the MOE levels 
substantially pointing at a lower priority for risk management, than when the MOE 
calculation would be based on the tumour data obtained with pure methyleugenol. 
DISCUSSION
Methyleugenol is an alkenylbenzene that occurs in many herbs and spices. The compound 
is carcinogenic in both rats and mice when administered at high dose levels (NTP, 
2000). The hepatocarcinogenicity of methyleugenol is attributed to its bioactivation by 
hydroxylation followed by sulfonation leading to DNA adduct formation and eventually 
tumour formation as demonstrated in animal models (Smith et al., 2002). 
In a previous study it was demonstrated that the flavonoid nevadensin, which 
is an important constituent of herbs like basil (Grayer et al., 1996, 2000) is able to 
inhibit the bioactivation of the related alkenylbenzene estragole to its DNA reactive 
metabolite at the level of the SULT-mediated conversion of 1′-hydroxyestragole to 
1′-sulfoxyestragole (Jeurissen et al., 2008; Alhusainy et al., 2010). 
The objective of the present study was to examine whether the herb based 
constituent nevadensin would also be able to inhibit the SULT-mediated bioactivation 
of methyleugenol and its subsequent formation of DNA adducts, and to investigate the 
possible in vivo consequences of such an inhibition using PBBK modeling. The effect of 
nevadensin on the SULT-mediated DNA adduct formation by 1′-hydroxymethyleugenol 
was investigated in the human hepatoma cell line HepG2. HepG2 cells contain different 
enzymes involved in the metabolism of 1′-hydroxymethyleugenol such as SULT and UDP-
glucuronosyltransferases (Knasmüller et al., 1998; Brandon et al., 2003, 2006). A method 
for the quantification of ME-3′-N2-dGuo was developed based on a recently described 
LC–ESI–MS/MS method to quantify the corresponding adducts from estragole (Paini et 
al., 2012a). Incubations with human HepG2 cells exposed to 1′-hydroxymethyleugenol 
in the presence of increasing concentrations of nevadensin revealed a dose-dependent 
inhibition of ME-3′-N2-dGuo formation by nevadensin at concentrations ranging from 
0.002 to 2 µM. At 2 µM ME-3′-N2-dGuo formation was inhibited by 88%. 
The DNA adduct measured in the present study (ME-3′-N2-dGuo) was shown to be 
the major adduct formed with methyleugenol in in vitro studies and even in a human 
study (Herrmann et al., 2012, 2013). It was also shown by the same studies that in 
Ames tests using the S. typhimurium TA100 strain expressing the SULT1A1 enzyme 
and exposed to varying doses of the hydroxylated metabolites of methyleugenol that 
the levels of the ME-3′-N2-dGuo adduct increased continuously with the dose and that 
adduct levels correlated with the mutagenic effect induced. In the present study, as a 
first approximation, we assumed that nevadensin-mediated inhibition of formation of 
ME-3′-N2-dGuo would reflect the reduction in all possible methyleugenol DNA adducts. 
This assumption can be made given that all methyleugenol DNA adducts will result from 
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a chemical reaction with 1′-sulfooxymethyleugenol which is the ultimate carcinogenic 
metabolite, and that it is the formation of 1′-sulfooxymethyleugenol that is inhibited by 
nevadensin. If all adducts would be reduced to a similar extent one can subsequently 
assume that the resulting mutagenicity and carcinogencity would be reduced to a similar 
extent as well, even when different adducts would display different mutagenicity.
To investigate possible in vivo implications of SULT inhibition by nevadensin on 
methyleugenol bioactivation, the rat PBBK model developed in our previous work to 
describe the dose-dependent bioactivation and detoxification of methyleugenol in male 
rat (Al-Subeihi et al., 2011) was combined with the recently developed nevadensin PBBK 
model in male Sprague–Dawley. The nevadensin PBBK model in male rat was validated in 
an in vivo study in which male Sprague–Dawley rats were co-administered the structurally 
related alkenylbenzene estragole and nevadensin orally (Alhusainy et al., 2013). Given the 
structural resemblance between estragole and methyleugenol and the similar effects of 
the two compounds in standard mutagenicity tests (Dorange et al., 1977; Sekizawa and 
Shibamoto, 1982; To et al., 1982; Mortelmans et al., 1986; Zeiger et al., 1987; Schiestl et 
al., 1989; Zani et al., 1991; Brennan et al., 1996) and in rodent carcinogenicity studies (NTP, 
2000, 2008) together with the fact that the type of inhibition exerted by nevadensin is non-
competitive and thus by definition should be evident regardless of the substrate it is likely 
to expect an effect of nevadensin on methyleugenol bioactivation in vivo will occur as well.
In a next step, we investigated the possible consequences arising from the co-
administration of methyleugenol and nevadensin on the reported MOE of methyleugenol. 
Our binary methyleugenol–nevadensin PBBK model in rat was used to predict the 
possible reduction in ME-3’-N2-dGuo at the methyleugenol dose levels used in the NTP 
study when methyleugenol would be co-administered with nevadensin at a molar ratio 
of methyleugenol to nevadensin of 1:0.20. Thereafter, the reduction in the incidence 
of hepatocellular carcinomas was calculated assuming a proportional reduction in the 
formation E-3’-N2-dGuo and the incidence of hepatocellular carcinomas. Data analysis 
showed that co-administration of nevadensin together with methyleugenol increased the 
MOE levels substantially pointing at a lower priority for risk management, than when the 
MOE calculations would be based on the tumour data obtained with pure methyleugenol. 
In conclusion, the present study points at an important matrix effect of combined 
exposure to methyleugenol and nevadensin. SULT inhibition was shown to lead to 
the inhibition of the formation of the ultimate DNA reactive metabolite. This implies 
that dosing methyleugenol to rodents within a matrix of sweet basil or other food 
items containing SULT inhibitors would pose a risk that is lower than what would be 
estimated based on results from rodent bioassays in which methyleugenol is dosed as 
a pure compound by gavage without the relevant food matrix being present. 
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The natural basil flavonoid nevadensin protects 
against methyleugenol-induced markers 
of hepatocarcinogenicity in male F344 rat6
ABSTRACT
The alkenylbenzene methyleugenol occurs naturally in a variety of spices and herbs, 
including basil, and their essential oils. At high dose levels methyleugenol induces 
hepatocellular cancer in rodents following bioactivation to 1’-sulfooxymethyleugenol 
which forms DNA adducts. The present study investigated whether the inhibitory effect 
of the basil flavonoid nevadensin on sulfotransferase (SULT)-mediated bioactivation of 
methyleugenol observed in vitro would also be reflected in a reduction of DNA adduct 
formation in the liver and a reduction in early markers for liver carcinogenesis in an 
8-week in vivo rat study. Co-exposure to methyleugenol and nevadensin by intragastric 
instillation resulted in a significant inhibition of liver methyleugenol DNA adduct 
formation and also in a significant inhibition of induction of hepatocellular altered foci, 
representing indicators for initiation of neoplasia. These results suggest that tumour 
formation could be lower in rodent bioassays when methyleugenol would be dosed in 
a matrix containing SULT inhibitors such as nevadensin compared to experiments using 
the pure methyleugenol. An estimate of the possible consequences of this reduction for 
the risk assessment of methyleugenol indicates that it would result in increased BMDL10 
(lower confidence limit of the benchmark dose that gives 10% extra cancer incidence) 
and margin of exposure (MOE) values and thus a lower priority for risk management.
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INTRODUCTION
The alkenylbenzene methyleugenol (3,4-dimethoxyallylbenzene) (Figure 1) is a natural 
constituent of many herbs, spices and their essential oils. Although methyleugenol is 
generally present in many foods at low levels, intake of methyleugenol occurs primarily 
from nutmeg, allspice, sweet basil, and fennel (Williams and Mattia, 2009). The 
National Toxicology Program reported that methyleugenol was hepatocarcinogenic 
in both rats and mice (NTP, 2000). The hepatocarcinogenicity of methyleugenol, like 
that of the chemically related safrole, is ascribed to its bioactivation by cytochrome 
P450 enzymes, leading in the case of methyleugenol to the formation of the 
proximate carcinogen 1′-hydroxymethyleugenol (Figure 1) (Miller et al., 1983; Phillips 
et al., 1984; Randerath et al., 1984; Smith et al., 2002). Further bioactivation of 
1′-hydroxymethyleugenol requires the involvement of sulfotransferases (SULTs) that 
convert 1′-hydroxymethyleugenol to the ultimate carcinogen 1′-sulfooxymethyleugenol 
(Figure 1) (Boberg et al., 1983; Wiseman et al., 1987). This sulfonated metabolite is 
unstable and, via a putative reactive carbonation intermediate, binds covalently to 
endogenous nucleophiles including DNA which results in DNA adduct formation in 
mice (Phillips et al., 1981, 1984; Randerath et al., 1984) and rats (Williams et al., 2013).
Given its genotoxicity and carcinogenicity, the addition of methyleugenol as 
a pure substance to food has been prohibited since September 2008 within the 
European Union (EU) (European Commission, 2008), whereas in the USA the use of 
methyleugenol is limited to low annual volumes (Gavin et al., 2008). A main issue that 
remains to be investigated is whether the animal studies that use high levels of the 
pure compound without the normal food matrix being present, are an appropriate 
starting point for the risk assessment of methyleugenol. In this respect, we have 
recently shown that a methanolic extract from basil, which contained methyleugenol 
and the structurally related alkenylbenzene estragole, also contained the flavone 
nevadensin (5,7-dihydroxy-6,8,4′- trimethoxyflavone) (Figure 2). Nevadensin was able 
to reduce SULT-mediated estragole DNA adduct formation significantly in primary rat 
hepatocytes exposed in vitro to 1′-hydroxyestragole and nevadensin simultaneously 
(Alhusainy et al., 2010). Nevadensin was also able to significantly (p<0.01) reduce the 
SULT-mediated methyleugenol DNA adduct formation in human HepG2 cells exposed 
Figure 1. Structural representation of the pathway for bioactivation of methyleugenol which is 
also representative for other alkenylbenzenes. 
131
6
to 1′-hydroxymethyleugenol and nevadensin simultaneously (Al-Subeihi et al., 2013). 
Even more interestingly, nevadensin was able to reduce the formation of estragole 
DNA adduct formation significantly (by 36% p<0.001) in the liver of Sprague–Dawley 
rats when exposed to estragole and nevadensin simultaneously at a molar ratio of 
the two compounds reflecting their presence in basil (Alhusainy et al., 2013). For 
methyleugenol this reduction in DNA adduct formation by nevadensin has only been 
demonstrated in an in vitro model system using HepG2 cells (Al-Subeihi et al., 2013). 
The objective of the present study was to investigate whether the inhibitory effect of 
nevadensin on SULT-mediated methyleugenol bioactivation and DNA adduct formation 
observed in the vitro model would also be observed in vivo. In addition, it would be 
appropriate to elucidate whether such a reduction would be accompanied by a reduction 
in early markers of liver carcinogenesis. To this end, an in vivo rat study was performed in 
which the animals were exposed for 8 weeks to either methyleugenol alone, methyleugenol 
in the presence of nevadensin or methyleugenol in the presence of pentachlorophenol 
(PCP), the latter included as a positive control for SULT inhibition and reduction in 
alkenylbenzene DNA adduct and tumour formation in vivo (Boberg et al., 1983). The dose 
level of methyleugenol to be tested was selected based on a recent study by Williams 
et al. (2013) which quantified the methyleugenol dose-dependent effects on endpoints 
indicative of neoplastic initiation, including formation of hepatocellular altered foci (HAF), 
changes in hepatocellular proliferation and DNA adduct formation. This paradigm was 
previously used to demonstrate anticarcinogenic effects of butylated hydroxyanisole and 
butylated hydroxytoluene (Williams and Iatropoulos, 1996), hydroquinone (Williams et al., 
2007a) and acetaminophen (Williams et al., 2007b).
MATERIALS AND METHODS
Materials
Methyleugenol (3,4-dimethoxyallylbenzene, CAS 87-86-5, lot number T1959A), 
(>98% pure) was obtained from Vigon International (East Stroudsburg, PA, USA). 
Pentachlorophenol (2,3,4,5,6-pentachlorophenol, PCP, CAS, lot number MKBG5282V) 
(>97% pure) was obtained from Sigma-Aldrich (St Louis, MO, USA). Nevadensin (5,7-
dihydroxy-6,8,4′- trimethoxyflavone, CAS 10176-66-6, product number 34463n) (>98% 
Figure 2. Molecular structure of the natural SULT inhibitor nevadensin.
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pure) was obtained from Apin Chemicals (Milton, UK). Emulsions for gavage were 
prepared by dispersion with a Dounce homogenizer in 0.5% aqueous methylcellulose. 
Methylcellulose (CAS 9004-67-5, catalog number 1489B) was obtained from ICN 
Biochemicals Inc. (Aurora, OH, USA). 2′-Deoxyguanosine was purchased from 
Sigma (Basel, CH), zinc sulphate (heptahydrate), phosphodiesterase I from Crotalus 
adamanteus (venom phosphodiesterase), phosphodiesterase II from bovine spleen 
(spleen phosphodiesterase), nuclease P1 and alkaline phosphatase were purchased 
from Sigma (Schnelldorf, Germany). Micrococcal nuclease, nuclease P1 and spleen 
phosphodiesterase used for DNA adduct digestion for 32P nucleotide postlabeling 
analysis was obtained from Sigma-Aldrich (St Louis, MO, USA). γ-32P-Adenosine 
triphosphate (~6000 Ci/mmole) was obtained from Perkin-Elmer (Waltham, MA, USA). 
Acetonitrile (ACN) was purchased from Biosolve BV (Valkenswaard, The Netherlands). 
Formic acid and ethanol were obtained from VWR Merck (Darmstadt, Germany). 
Synthesis and characterization of N2-(trans-isomethyleugenol-3′-yl)-2′-deoxyguanosine 
(ME-3’-N2-dGuo) was performed as previously reported (Al-Subeihi et al., 2013) using 
a method adapted from a protocol for the synthesis of the estragole DNA adduct, N2-
(trans-isoestragol-3′-y1)-2′-deoxyguanosine (E-3′-N2-dGuo) (Punt et al., 2007).
Animals and experiment
In the present study male F344 rats were used because that strain was used by the 
NTP (2000) carcinogenicity study, and in the dose-response study of Williams et al. 
(2013). In the latter study, male F344 rats were used to elucidate the methyleugenol 
cancer initiating effects since liver preneoplasia can be readily quantified in this 
species (Williams, 1998, 1999). In addition, male F344 were more sensitive to 
hepatocarcinogenesis by methyleugenol than females (NTP, 2000). The study was 
approved by the Institutional Animal Care & Use Committee (IACUC) of New York 
Medical College. Male F344 rats, 5-6 week old at the start of the study, obtained from 
Taconic Farms, Inc. (Germantown, NY, USA), were housed in a conventional animal 
facility, accredited by the American Association for the Accreditation of Laboratory 
Animal Care. The care provided conforms to the Guide for the Care and Use of 
laboratory Animals (NIH-78-23). Rats were housed in solid bottom polycarbonated 
cages, with irradiated corn cob bedding and a microisolator filter on top (Ancare, 
Bellmore, NY, USA). The cages for groups dosed with methyleugenol were in a 
separate room from the groups not dosed with methyleugenol to isolate the later rats 
from exposure to any volatile methyleugenol. 
Room temperature was maintained at 20 ± 2°C and relative humidity at 55 ± 20%. 
Fresh air was supplied to rooms with 18-22 exchanges/hr. Twelve hours of continuous low 
level fluorescent lighting (5 ft candles) was provided daily (7 AM to 7 PM) followed by 12 
hours of dark cycle. Water was available ad libitum throughout the study and was supplied 
by an automatic watering system. Monitoring of the drinking water for microbiological and 
chemical contaminants was routinely conducted. Upon receipt, the rats were maintained 
under observation for two weeks on 5001 diet (WF Fisher & Son, Inc., Somerville, NJ, USA). 
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The rats were allocated to groups as shown in Table 1 of the result section. The 
total number of animals at the start of the experiment was 54 male F344 rats. Rats 
were assigned to 6 groups and each group consisted of 9 rats which were housed 3 
rats per cage. The first group, representing the vehicle group, was doses with a 0.5% 
methylcellulose in aqueous solution, representing the vehicle for all compounds 
tested in the present study. All tested compounds including the vehicle solution 
were administered at 5 mL/kg bw by intragastric instillation (gavage) 3 days (Monday, 
Wednesday and Friday) per week for 8 weeks. The second group received 250 mg/
kg bw/day methyleugenol from a stock solution containing 50 mg/mL methyleugenol 
in 0.5% methylcellulose, 3 days per week. The third group received 11 mg/kg bw/day 
PCP from a stock solution containing 2.2 mg/mL PCP in 0.5% methylcellulose together 
with sufficient 1M NaOH to bring pH to neutrality and enhance solubility. The fourth 
group received 120 mg/kg bw/day nevadensin from a stock solution containing 24 mg/
mL nevadensin in 0.5% methylcellulose. The fifth group received 250 mg/kg bw/day 
methyleugenol together with 120 mg/kg bw/day nevadensin, both dosed simultaneously 
using a stock solution containing 50 mg/mL methyleugenol and 24 mg/mL nevadensin 
in 0.5% methylcellulose. The sixth group, representing a positive control group for SULT 
inhibition, was dosed with 250 mg/kg bw/day methyleugenol together with 11 mg/kg 
bw/day of the SULT inhibitor PCP, both dosed simultaneously using a stock solution 
containing 50 mg/mL methyleugenol and 2.2 mg/mL PCP in 0.5% methylcellulose. 
Morbidity, mortality and clinical observations were conducted twice daily. BW was 
recorded the day prior to study initiation, thereafter weekly to determine gavage 
volumes and before necropsy. Overnight, prior to necropsy, all rats were fasted. Rats 
were exsanguinated under isoflurane anesthesia. Thereafter, blood was removed and 
livers were harvested and weighed. Slices of all liver lobes were placed on a metal block 
on ice for cutting into smaller pieces and either frozen in liquid nitrogen and stored at 
-80°C for DNA adduct analysis or two standard liver slices were taken and immersed 
in 10% neutral (phosphate) buffered formalin for routine hematoxylin and eosin (H&E) 
and immunohistochemistry for both proliferating cell nuclear antigen (PCNA) and 
placental-type (π) glutathione S-transferase (GST-P) microscopic evaluation. 
Dose and time selection
The dose of methyleugenol of 250 mg/kg bw/day was given to rats by gavage three 
days per week for 8 weeks based on the study of Williams et al. (2013). In that study, 
the formation of methyleugenol DNA adducts, changes in PCNA and GST-P, the latter 
representing an indicator to initiation of hepatocellular cancer in rats (Williams, 1980; 
Bannasch, 1986; Williams, 1989; Enzmann et al., 1998; Williams, 1998; Williams, 1999) 
were significantly increased compared to the vehicle group (0.5% methylcellulose) 
after administration of 250 mg/kg bw/day of methyleugenol given orally to male 
F344 rats three days per week for a period of 8 weeks (Williams et al., 2013). A dose 
of 250 mg/kg bw/day of methyleugenol dosed 3 times per week yields a weekly 
cumulative dose of 750 mg/kg bw/week, which is identical to the weekly cumulative 
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dose achieved with a dose of 150 mg/kg bw/day methyleugenol, 5 days per week in 
the NTP carcinogenicity study (NTP, 2000). 
A dose of nevadensin of 120 mg/kg bw/day (3 days per week) was selected (at a molar 
ratio of methyleugenol to nevadensin of 1:0.25) from a previous study where rats were 
gavaged with nevadensin together with the closely related alkenylbenzene estragole 
at the same molar ratio representing a molar ratio at which the two compounds are 
present in basil (Alhusainy et al., 2013). In addition, the ratio was close to the molar ratio 
of methyleugenol and nevadensin in basil (1:0.20). These ratios were calculated based 
on a level of nevadensin of 0.64 mg nevadensin/g dried basil detected by us previously 
in a dried basil sample obtained from the Dutch market (Alhusainy et al., 2012), and 
methyleugenol levels reported in the literature for the Genovese Gigante cultivar of 
basil, the most commonly used cultivar in pesto preparation in north-western Italy which 
contains at least 2 mg methyleugenol/g basil (Smith et al., 2002). 
The dose of PCP was based on literature where a dose of PCP of 11 mg/kg bw/
day was reported to reduce the incidence of hepatomas resulting from a single 
intraperitoneal dose of 111 mg/kg bw estragole following 10 months of observation 
(Wiseman et al., 1987). It was also based on a no-observed-adverse-effect level 
(NOAEL) for PCP of 10 mg/kg bw/day for both reproductive and general toxicity 
studies in Sprague–Dawley rats (Bernard et al., 2002). The dose of PCP is also in 
accordance to our previous work where a dose of 11 mg/kg bw PCP resulted in a 
significant 73% reduction in estragole DNA adduct formation in the liver of Sprague–
Dawley rats when measured 48 hr after they were exposed to a single oral dose of PCP 
and estragole simultaneously (Alhusainy et al., 2013).
32P nucleotide postlabeling (NPL) analysis for overall DNA adducts
DNA was isolated using QIAGEN (Valencia, CA, USA) G100 columns following the 
manufacturer’s protocol (Qiagen, 2001). The yield and purity of the extracted DNA 
was determined using its 230/260/280 ratios measured on a Cary 1E UV-visible 
spectrophotometer and associated software (Cary WinUV Version 3.0 Bio Suite (Varian 
Inc, Walnut Creek, CA, USA) in Tris HCl buffer, pH 7.2. DNA was then processed for 
DNA adduct analysis by NPL performed as previously described (Williams, 1998; 
Jeffrey et al., 2002). Owing to the high DNA adduct levels, 1 µg of isolated DNA was 
diluted with 9 µg of calf thymus DNA before digestion in order to obtain a more linear 
response with respect to DNA adduct levels in the different samples. Isolated DNA 
(10 μg) was enzymatically digested into 2’-deoxyribonucleoside 3’-monophosphates 
using micrococcal nuclease and spleen phosphodiesterase. The digest was then 
enriched using nuclease P1 digestion (Reddy and Randerath, 1986). This enrichment 
procedure for modified DNA bases provides a better sensitivity for measurement of 
methyleugenol DNA adducts. The DNA modified bases were subsequently labeled 
using 100 µCi γ-32P adenosine triphosphate (~6000 Ci/mmole, Perkin-Elmer, Waltham, 
MA, USA). The labeled modified bases were then resolved using a two-directional 
thin-layer chromatography (TLC) system. The first elution, bottom to top direction, 
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used 2.0 M sodium phosphate pH 5.5 with a wick for 16 hours followed by washing by 
1.2 M lithium formate/2.8 M urea pH 3.5 in the same direction. Again the plates were 
washed and eluted this time left to right with 0.6 M lithium chloride, 0.25 M Tris HCl, 
4 M urea, pH 8.0. Plates were again washed and dried and then exposed to phosphor 
screen for 40 min. The radioactivity on the TLC plates was detected using a Molecular 
Dynamics Storm 860 system (GE Health Care Life Sciences, Edison, NJ, USA).
Tissue DNA extraction and digestion for LC–ESI–MS/MS analysis  
of methyleugenol DNA adduct formation
DNA extraction and digestion for the LC–ESI–MS/MS analysis was processed differently 
from the procedure used for 32P nucleotide postlabeling analysis and was in line with 
our previous work (Alhusainy et al., 2013). Prior to DNA extraction, liver samples were 
homogenised as follows: one gram of a liver slice was taken randomly and dissolved in 
4 mL cold phosphate buffered saline (PBS) and the mixture was then homogenized on 
ice at 1000 rpm using a mechanical cell homogenizer (B. Braun, Melsungen, Germany). 
Thereafter, homogenates were placed in 15 mL tubes and centrifuged at 3,000 g for 5 
min at 4ºC (Sigma centrifuge, type 4K10, Germany) to obtain pellets. DNA extraction 
from these pellets was performed using a Get pure DNA Kit-Cell protocol (Dojindo 
Molecular Technology Inc., Kumamoto, Japan) for tissue following the manufacturer’s 
instructions. The final DNA pellet was dissolved in 100 μL MilliQ water. The yield 
and purity of the extracted DNA was determined using the Nanodrop ND-100 
spectrophometer (Thermo Fisher Scientific, Inc.) by measuring the absorbance ratio 
A260 nm/A280 nm. DNA samples with an absorbance ratio of 1.8-2.0 were considered 
sufficiently pure. All DNA samples were diluted to achieve 50 µg DNA/100 µL water 
before digestion of the DNA. Digestion of DNA and quantification of the major 
methyleugenol DNA adduct (ME-3′-N2-dGuo) by LC–ESI–MS/MS were performed as 
described previously (Paini et al., 2010; Al-Subeihi et al., 2013).
Quantification of hepatocellular proliferation
PCNA immunohistochemistry was applied to monitor the rate of hepatocellular 
proliferation of individual hepatocytes, as done in other studies of hepatocarcinogenesis 
(Iatropoulos and Williams, 1996; Williams et al., 1998). Cell proliferation was assessed 
by scoring of PCNA positive cells (Iatropoulos and Williams, 1996). Neutral phosphate 
buffered formalin fixed liver sections (2 per liver and rat) were processed, cut and stained 
for PCNA at the Histology Core Facility, Department of Pathology, New York Medical 
College, (Valhalla, NY, USA) according to appropriate standard operating procedures. 
The PCNA evaluation reflected the percent replicating fraction (RF), which is derived 
from total PCNA positive nuclei counts over total hepatocellular nuclei counted from 
about 5 graticule areas (Graticules, Ltd, Tonbridge, UK). From each liver only areas 
with the highest (most intense) PCNA staining from every liver section across all groups 
were selected to be counted at a total magnification of 200x. The average range of 
hepatocellular nuclei counted across all groups was 725 – 1000 nuclei per rat liver. 
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Quantification of hepatocellular altered foci (HAF)
Preneoplastic liver lesions, designated as HAF, are useful precursor markers of neoplasia 
(Williams, 1980; Bannasch, 1986; Williams, 1989; Enzmann et al., 1998; Williams, 1998; 
Williams, 1999). These lesions precede the development of neoplasms, and, although 
they greatly exceed the number of neoplasms, they are quantitatively related to them 
(Williams, 1980; Williams, 1982). Among many useful markers of HAF, placental-type 
(π) glutathione S-transferase (GST-P) has proven to be a very effective one (Sato et al., 
1984; Williams, 1999). Quantification of HAF was therefore used to assess initiation 
of hepatocarcinogenesis (Williams, 1980). From each rat, two standard liver sections 
were taken; the first liver section was taken from a liver lobe with visible macroscopic 
lesions and the second liver section was taken from the largest left lobe. Per liver (and 
rat) the average range of the liver section surface area was 2 to 4.6 cm2. Only foci in 
clusters of 3 or more contiguous GST-P+ HAF hepatocytes over the entire microscopic 
glass slide surface area were counted. In addition, the greatest diameter in μm of each 
GST-P+ HAF was measured with a graticule (Graticules, Ltd, Tonbridge, UK). The total 
microscopic magnification was 100x. Subsequently, the average incidence of GST-P+ 
HAF per cm2 of liver tissue per exposure group was calculated.
Statistical analyses 
Statistical analysis was undertaken using SigmaStat for Windows version 3.11.0 (Systat 
Software Inc., Chicago, IL, USA). Selected statistical analysis for the data sets was an 
one-way ANOVA against vehicles for body weight, absolute and relative liver weights, 
while the DNA adducts, PCNA and GST-P evaluations were against methyleugenol 
(Systat Software Manual, 2004).
RESULTS
Evaluation of experimental conditions
No deviations occurred in ambient temperature, relative humidity or any other 
condition in the animal room that would affect animal health or the integrity of the 
study. One death occurred in the second group dosed with 250 mg/kg bw/day 
methyleugenol in the first week of gavage due to a gavage error. 
Change in body and liver weights 
The summary of mean body weights (BW) in grams at week 0 and week 8 and the 
mean absolute (ALW) and relative liver weights (RLW) at week 8 are given in Table 1. 
At the start of the experiment (week 0), all groups had similar mean BWs. At 8 weeks, 
a significant decrease in mean BW was observed in rats dosed with methyleugenol 
only (7%), methyleugenol/nevadensin (6%), or methyleugenol/PCP (7%) compared to 
the vehicle control group. Also, at 8 weeks, there was a significant increase in RLW 
in groups dosed with methyleugenol (15%), methyleugenol/nevadensin (13%) and 
methyleugenol/PCP (16%) compared to the vehicle group. 
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Effect of nevadensin on methyleugenol-induced DNA adduct formation
DNA isolation from the livers after 8 weeks exposure provided adequate yields of 
DNA and all samples had appropriate 260/280 nm absorbance ratio (1.85 + 0.03 
and 1.88 + 0.0.01 using the QIAGEN and Dojindo kits respectively) indicating that 
purity was adequate. Figure 3 presents the spot pattern for the overall DNA adducts 
analyzed by the NPL, similar to that described previously (Williams et al, 2013; Zhou 
et al., 2007) and shows the presence of one major DNA adduct and one minor 
DNA adduct in the liver of rats dosed with methyleugenol only and methyleugenol/
nevadensin compared to faint DNA adducts in the livers of rats from the vehicle 
group. This is in line with findings from two recent studies where the formation of 
ME-3′-N2-dGuo as the major methyleugenol DNA adduct (Figure 4) and ME-3′-N6-
dA as a minor methyleugenol DNA adduct were detected in vitro, in mice and in a 
human study (Herrmann et al., 2012, 2013). 
The results of NPL analysis for overall DNA adducts and the LC–ESI–MS/MS analysis 
for the major methyleugenol DNA adduct (ME-3’-N2-dGuo) are shown in Figure 5A and 
5B respectively. The NPL analysis revealed a constant ratio of major to minor spots 
averaging 4.3 to 4.6, but significant (p<0.05) reductions in the formation of the total 
DNA adducts in the liver of rats dosed with methyleugenol/nevadensin (49%) and rats 
dosed with methyleugenol/PCP (44%) compared to the rats dosed with methyleugenol 
only. In line with the NPL analysis, the LC–ESI–MS/MS analysis for ME-3’-N2-dGuo also 
showed a significant (p<0.001) reduction in the liver of rats dosed with methyleugenol/
nevadensin (88%) and rats dosed with methyleugenol/PCP (89%) compared to rats 
dosed with methyleugenol only (Figure 5B). The NPL detected the levels of total DNA 
adducts formed in the liver of rats whereas the LC–ESI–MS/MS analysis detected the 
levels of only the major DNA adduct formed (ME-3’-N2-dGuo). The levels of ME-3’-
N2-dGuo DNA adduct detected by the LC–ESI–MS/MS analysis was higher than the 
total DNA adducts detected by the NPL analysis. This is because NPL analysis tends to 
underestimate the absolute adduct levels due to incomplete recovery (Beland et al., 
1999; Morden et al., 2008), and the lack of an internal standard.
Table 1. Body weights, absolute and relative liver weights. 
Group (mg/kg bw/day) BW (week 0) BW (week 8) ALW (week 8) RLW (week 8)
1.Vehicle 254±7 317±9 14.22±0.82 4.49±0.20
2.Methyleugenol (250) a 252±7 295±12* 15.64±0.58 * 5.30±0.21*
3.PCP (11) a 253±8 311±7 14.77±0.54 4.74±0.23
4.Nevadensin (120) a 253±7 326±24 14.81±0.70 4.57±0.46
5.Methyleugenol /nevadensin (250/120) a 253±6 298±8* 15.38±0.68 * 5.17±0.28*
6.Methyleugenol /PCP (250/11) a 253±7 295±12* 15.75±0.75 * 5.34±0.27*
a Individual doses mg/kg delivered by gavage 3 days per week for 8 weeks.
* indicates values statistically significant at p<0.05 compared to vehicle group; there were 9 
rats per group except for the methyleugenol group consisting of 8 rats due to a gavage error.
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Effect of nevadensin on proliferating cell nuclear antigen (PCNA)
The replicating fraction (RF) values, expressed in percent of PCNA-positive cells 
over total hepatocytes counted, are shown in Table 2. After 8 weeks, no statistically 
significant increase in the RF was present in any of the groups compared to the 
vehicle group. Nevertheless, there was a numerically greater RF in rats dosed with 
methyleugenol only compared to rats in the vehicle group (Table 2). The vehicle group 
value was the lowest of all groups (Tables 2). Table 1 of the Supplementary Material 
provides all individual PCNA data.
Effect of nevadensin on hepatocellular altered foci (HAF)
Table 3 presents summary results on incidence, multiplicity, and size (greatest diameter of 
GST-P+ HAF) at 8 weeks, and Table 2 in the Spplementary Material provides all individual 
Figure 3. DNA spot pattern by NPL. The pattern was similar to that described by (Zhou et al., 
2007). Arrows in Figure indicate adducts used in quantitation.  
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GST-P data. Figure 6 presents microscopic images (at 200x magnification) of the GST-P+ 
HAF at 8 weeks from the liver of one methyleugenol rat of group 2 which had 2 different 
GST-P+ HAF, one with the smallest HAF being 102 μm (Figure 6A) and a second (Figure 
6B) with the greatest diameter being 204 μm. The third GST-P+ HAF is from the liver of a 
methyleugenol/nevadensin rat which has a reduced smallest diameter of 51 μm (Figure 
6C). Comparing the two smallest diameters, it is evident that nevadensin reduces by 
half the methyleugenol-induced HAF (Figure 6). As shown in Table 3, no GST-P+ HAF 
were detected in the livers of rats dosed with either the vehicle control, or nevadensin 
groups. A significant (p<0.05) increase in the incidence and mean multiplicity of the 
GST-P+ HAF was observed in rats dosed with methyleugenol only. Thus, the incidence 
(80%), multiplicity (2.4 GSTP+ HAF per rat liver, or 12-fold difference), and size (with 204 
μm as the greatest diameter per rat liver) of group 2 (methyleugenol), were significantly 
(p<0.05) different from all other groups (Table 3). 
Figure 4. Molecular structure of the major methyleugenol 
DNA adduct; ME-3'-N2-dGuo (N2-(trans-isomethyleugenol-
3'-yl)-2'-deoxyguanosine).
Table 2. Proliferating cell nuclear antigen (PCNA) marker of hepatocellular replicating fraction 
(RF) in percent.
Group Replicating fraction (mean±SD)
1.Vehicle  3.23 ± 0.41
2.Methyleugenol 4.43 ± 1.09
3.PCP 3.33 ± 0.67
4.Nevadensin 4.04 ± .062
5.Methyleugenol/nevadensin 3.58 ± 0.37
6.Methyleugenol /PCP 3.74 ± 0.27
PCP, pentachlorophenol; none of the groups was significant compared to the vehicle control group.
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Figure 5. Formation of A) total methyleugenol DNA adducts in 106 normal nucleotides 
measured by NPL (N=3), and B) of ME-3'-N2-dGuo DNA adducts in 106 normal nucleotides 
measured by LC–ESI–MS/MS, in the liver of  male F344 rats exposed orally to 250 mg/kg bw/
day methyleugenol in the absence or presence of 120 mg/kg bw/day nevadensin or 11 mg/kg 
bw/day pentachlorophenol (PCP) versus rats dosed with vehicle, nevadensin only or PCP only for 
8 weeks (3 days per week). Note: * and ** indicate values statistically significant at p<0.05 and 
p<0.001 respectively compared to methyleugenol.
DISCUSSION
The aim of the present study was to investigate whether the inhibitory effect of the 
basil flavonoid nevadensin on SULT-mediated methyleugenol bioactivation and DNA 
adduct formation observed in vitro (Al-Subeihi et al., 2013) would also be observed 
in vivo, and to elucidate whether such a reduction would be accompanied by a 
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Table 3. Incidence, multiplicity and size of microscopic preneoplastic hepatocellular GST-P+ HAF.
Group Incidence (%)a Multiplicityb Size in μmc
1.Vehicle 0/5 ( 0) * 0.0 ± 0* 0*
2.Methyleugenol 4/5 (80) 2.4 ± 2.5 204
3.PCP 1/5 (20) * 0.2 ±0.5* 102*
4.Nevadensin 0/5 ( 0) * 0.0 ± 0.0* 0*
5.Methyleugenol /nevadensin 1/5 (20) * 0.2 ± 0.5* 102*
6.Methyleugenol/PCP 1/5 (20) * 0.2 ± 0.5* 102*
PCP, pentachlorophenol.
a Percent incidence of rats with at least one GST-P+ HAF per liver sample (2 sections per slide). 
b Multiplicity per group, expressed as GST-P+ HAF per liver sample.
c The greatest diameter (size) of GST-P+ HAF in μm.
* indicates values statistically significant at p<0.05 compared to methyleugenol group.
Figure 6. Microscopic GST-P+ hepatocellular altered 
foci (HAF) at a 200x magnification from A) group 2 
(methyleugenol only) rat liver (number 2-4) which has 
the smallest diameter of about 102 μm; B) group 2 
(methyleugenol only) rat liver (number 2-4) with the 
greatest diameter of about 204 μm; and C) group 
5 (nevadensin and methyleugenol) rat liver (number 
5-6) with the smallest diameter of 51 μm.
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reduction in early markers for liver carcinogenesis, as reported in other studies of 
anticarcinogenesis (Williams and Iatropoulos, 1996; Williams et al., 2007a, b). 
In a previous study we already demonstrated that nevadensin was able to inhibit 
significantly formation of DNA adducts in the liver of rats orally exposed simultaneously 
to a single dose of nevadensin and the related alkenylbenzene estragole (Alhusainy 
et al., 2013). Since DNA adduct formation is considered a biomarker of exposure but 
generally not a biomarker of the ultimate carcinogenic effect (Paini et al., 2010), in the 
present study exposure to methyleugenol and nevadensin was extended to 8 weeks to 
enable investigation of whether the nevadensin-mediated inhibition in alkenylbenzene 
DNA adduct formation in vivo would be accompanied by an inhibition of early markers 
of liver carcinogenesis in vivo. The results of the present study revealed that co-exposure 
to methyleugenol and nevadensin at a molar ratio reflecting their natural occurrence in 
basil resulted not only in a significant (p<0.001) 79 % inhibition in methyleugenol DNA 
adduct formation (measured by LC–ESI–MS/MS), but also in a significant (p<0.05) 92 
% inhibition of the formation of HAF, which are markers for initiation of neoplasia as 
shown in numerous studies in which HAF precede the development of neoplasms and 
are quantitatively related to them (Williams, 1980; Bannasch, 1986; Williams, 1989; 
Enzmann et al., 1998; Williams, 1998; Williams, 1999). On the other hand, RF values, 
which reflect hepatocellular proliferation, were only marginally increased (1.4 times) in 
group 2 (methyleugenol only) compared to group 1 (vehicle group). This magnitude 
of increase (e.g. 1.4) is half the previous value (e.g. 2.8) reported in a previous study 
at 8 weeks exposure to methyleugenol (Williams et al., 2013). We consider this PCNA 
increase in the present study to be part of the biological variability that cannot be 
explained. Also, in the same study (Williams et al., 2013), similar methyleugenol (high 
dose) doses for 8 weeks increased hepatocellular proliferation (2.8 times) compared 
to controls, but by week 16 the RF values of methyleugenol did not increase further, 
indicating that chronic compensatory proliferation is not the critical event in the 
induction of pre- and neoplasia. The numerical RF values were somewhat lower in the 
liver of rats dosed with methyleugenol/nevadensin and methyleugenol/PCP compared 
to rats dosed with methyleugenol only. The absence of statistical significance could 
reflect the fact that we need only 5 rats per group (Eldridge and Goldsworthy, 1996). 
Unlike HAF, RFs are not indicators of initiation of neoplasia but rather a marker of 
epigenetic (trophic/promotional) events. It is of interest to note that this marginal RF 
increase was also observed for the model SULT inhibitor PCP which did significantly 
reduce methyleugenol DNA adduct formation and HAF formation, and was previously 
shown able to also inhibit hepatic tumour formation in the liver of mice upon long-term 
dietary administration of safrole or its metabolite, 1’-hydroxysafrole together with PCP 
(Boberg et al., 1983). This indicates that effects on DNA adduct and HAF formation 
may present better indicators of initiation of neoplasia. 
Given the role of the 1’-sulfooxy metabolites of alkenylbenzenes in their 
hepatotoxicity and carcinogenicity (Boberg et al., 1983), and the established 
quantitative relationship between HAF formation and neoplasm (Williams, 1980; 
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Bannasch, 1986; Williams, 1989; Enzmann et al., 1998; Williams, 1998; Williams, 
1999), the results of the present study suggest that a reduction in tumour formation 
would be expected in liver of rodents when nevadensin is dosed simultaneously with 
methyleugenol compared to studies where methyleugenol is tested alone. 
So far, the effect of nevadensin in reducing the alkenylbenzene bioactivation in 
vivo has been established for the alkenylbenzenes estragole and methyleugenol only. 
However, the results of the present work can also be extended to other alkenylbenzenes. 
This is because the SULT inhibition by nevadensin is non-competitive in nature 
(Alhusainy et al., 2010, 2013), and thus by definition should be evident regardless of 
the substrate (Simmons, 1996).
In the risk assessment of methyleugenol, an important aspect is how to integrate the 
current results on nevadensin-mediated modulation of methyleugenol bioactivation. In 
our previous work we have refined the lower confidence limit of the benchmark dose 
that gives 10% extra cancer incidence (BMDL10) and subsequently calculated margin of 
exposure (MOE) values for both estragole (Alhusainy et al., 2012) and methyleugenol 
(Al-Subeihi et al., 2013) taking into account the possible reduction in tumour formation 
when nevadensin would have been co-administered with estragole or methyleugenol in 
the rodent carcinogenicity studies for the two alkenylbenzenes. As a first approximation 
we assumed that predicted reduction in alkenylbenzene DNA adduct levels using our 
binary methyleugenol-nevadensin physiologically based biokinetic (PBBK) model 
in male rat would be proportional to reduction in the incidence of hepatocellular 
neoplasia and then we calculated a refined BMDL10 value which was subsequently used 
to estimate a refined MOE. For methyleugenol the refined MOE values increased from 
3,500 and 5,300 for female rats and from about 1,100 and 2,400 for male rats based on 
data from studies testing the pure compound to about 11,000 and 18,000 for female 
rats and about 9,200 and 10,000 for male rats when the rodent study would have 
been performed in the presence of nevadensin (Al-Subeihi et al., 2013). Although this 
linear relation between DNA adduct formation and hepatoma formation remains to be 
established, a previous study showed a correlation between the dose response curve for 
the formation of ME-3’-N2-dGuo as the major methyleugenol DNA adduct with the dose 
response curve for mutagenicity of methyleugenol (Herrmann et al., 2012). Moreover, 
the results of the present study showed that the nevadensin-mediated reduction in 
methyleugenol DNA adduct formation is accompanied by a proportional reduction 
in levels of HAF, the later are established to precede the development of neoplasms 
and are quantitatively related to development of such neoplasms ( Bannasch, 1986; 
Enzmann et al, 1998; Williams, 1980, 1982). 
An important question remaining is the relevance of these combination effects at 
daily human dietary exposure levels of estragole or methyleugenol and nevadensin, an 
objective that can be tested in rodent bioassays given that DNA adduct levels formed 
at dietary levels of methyleugenol for example can be readily quantified in mice and in 
human (Herrmann et al., 2013). However, results from our previous research (Alhusainy 
et al., 2010, 2012) using PBBK modeling indicate that these combination effects may 
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be limited at daily human dietary exposure levels of estragole or methyleugenol and 
nevadensin resulting from basil consumption, since at these levels the plasma nevadensin 
levels may not reach the Ki value of nevadensin of 4 nm (Alhusainy et al., 2012). Also, 
matrix effects may be limited for other SULT inhibiting dietary flavonoids even at high 
exposure levels of these flavonoids coming from supplements which is contributed to 
higher Ki values for SULT inhibition by these flavonoids that are 2-3 orders of magnitude 
higher than the Ki for nevadensin (Alhusainy et al., 2010, 2012). This indicates that the 
importance of a matrix effect for risk assessment of individual compounds requires case-
by-case analysis of dose dependency of the interactions detected.
Overall, the results of the present study indicate that the likelihood of bioactivation and 
subsequent adverse effects in rodent bioassays could be lower when the alkenylbenzene is 
dosed in a matrix containing SULT inhibitors such as nevadensin compared to experiments 
using pure alkenylbenzenes as single compounds. This is expected to result in increases 
BMDL10 and resulting MOE values in a subsequent risk assessment. 
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SUPPLEMENTARY MATERIAL
Table 1.Proliferating Cell Nuclear Antigen (PCNA) a Immunohistochemically Stained Liver 
Microscopic Slide Evaluation
Group Identification Rat Number
PCNA Evaluation
RF Pos/Total
1. Vehicle 1-1
1-2
1-3
1-4
1-5
3.13
3.01
2.90
3.04
3.26
32/815
25/830
29/1000
29/955
29/890
Mean ± SD 3.23 ± 0.41
2. Methyleugenol 2-3
2-4
2-5
2-7
2-8
4.13
3.56
4.65
3.59
6.21
33/800
29/815
36/775
30/835
54/870
Mean ± SD 4.43 ± 1.09 
3. PCP b 3-1
3-4
3-5
3-6
3-7
3.72
2.84
3.77
2.40
3.91
35/940
26/915
30/795
23/960
36/920
 Mean ± SD 3.33 ± 0.67
4. Nevadensin 4-1
4-4
4-5
4-6
4-7
3.66
3.97
4.32
3.31
4.94
30/820
29/730
38/880
27/815
38/770
Mean ± SD 4.04 ± 0.62
5.Methyleugenol/nevadensin 5-1
5-4
5-5
5-6
5-7
3.35
3.16
3.45
4.00
3.92
29/865
27/855
25/725
32/800
31/790
Mean ± SD 3.58 ± 0.37
6.Methyleugenol/PCP 6-1
6-4
6-5
6-6
6-7
3.78
3.46
3.54
3.78
4.16
28/740
28/810
28/790
28/740
32/770
Mean ± SD 3.74 ± 0.27
a PCNA immunohistochemistry evaluation reflecting the percent replicating fraction (RF), which 
is derived from total PCNA positive nuclei counted over total nuclei counted from ~ 5 graticule 
areas with the highest (most intense) PCNA staining at a 200x total magnification.
b PCP, pentachlorophenol.
There are no statistically significant differences among any of the groups were present.
148
6
Table 2. Incidence of GST-Pa Positive Hepatocellular Altered Foci (HAF) per cm2 of Microscopically 
and Immunohistochemically Stained and Evaluated Liver Tissue
Group Identification Rat Number
Evaluation
GSTP+ HAF /cm2 of liver tissue
1.Vehicle 1-1
1-2
1-3
1-4
1-5
0
0
0
0
0
/3.0
/3.6
/2.1
/3.1
/2.0
Mean ± SD 0 /2.8 or 0/cm2
2.Methyleugenol 2-3
2-4
2-5
2-7
2-8
1
6 b
0
4
1
/3.5
/3.7
/3.8
/3.3
/2.4
Mean ± SD 2.4 ± 2.5* /2.8 or 0.86/cm2
3.PCP c 3-1
3-4
3-5
3-6
3-7
0
0
0
0
1 d
/2.4
/3.9
/2.5
/3.6
/2.4
 Mean ± SD 0.2 ± 0.5 /3.0 or 0.07/cm2
4. Nevadensin 4-1
4-4
4-5
4-6
4-7
0
0
0
0
0
/2.6
/2.0
/2.8
/3.1
/2.8
Mean ± SD 0 /2.7 or 0/cm2
5.Methyleugenol/nevadensin 5-1
5-4
5-5
5-6
5-7
0
0
0
1 e
0
/3.5
/3.3
/3.2
/4.6
/4.4
Mean ± SD 0.2 ± 0.5 /3.8 or 0.07/cm2
6.Methyleugenol/PCP 6-1
6-4
6-5
6-6
6-7
0
0
0
0
1 e
/3.8
/2.5
/3.1
/4.6
/2.6
Mean ± SD 0.2 ± 0.5 /3.3 or 0.07/cm2
a GST-P immunohistochemically stained and evaluated liver microscopic slides reflecting 
hepatocellular altered foci (HAF), a preneoplastic lesion.
b the greatest diameter of a GST-P+ HAF was ~ 204μ.
c PCP, pentachlorophenol. 
d the greatest diameter was ~ 102μ.
e the greatest diameter was ~ 51μ; the total microscopic magnification was 100x; 
* the mean value of this group is statistically significant from all other groups at p<0.05.
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General  discussion and future perspectives7

GENERAL DISCUSSION 
Alkenylbenzenes such as estragole and methyleugenol are common components of 
spices and herbs such as tarragon, basil, fennel, mace, allspice, star anise and anise 
and their essential oils (Smith et al., 2002). There is an interest in the safety evaluation 
of alkenylbenzenes because some of these compounds can induce hepatic tumours in 
rodents when dosed orally at high dose levels (Miller et al., 1983; NTP, 2000). In 2000, 
the National Toxicology Program (NTP) has further investigated the carcinogenicity 
of methyleugenol and concluded that the compound is carcinogenic in both rats and 
mice (NTP, 2000). Based on the rodent studies with estragole, methyleugenol and the 
structurally related alkenylbenzene safrole the hepatocarcinogenicity of alkenylbenzenes 
is ascribed to their bioactivation by cytochrome P450 enzymes leading to the formation 
of the proximate carcinogen, the 1′-hydroxy metabolite, which is further bioactivated to 
the ultimate carcinogen, the 1′-sulfooxy metabolite (Miller et al., 1983; Phillips et al., 1984; 
Randerath et al., 1984; Smith et al., 2010). The 1′-sulfooxy metabolite is unstable and binds 
via a presumed reactive carbocation intermediate covalently to different endogenous 
nucleophiles including DNA (Phillips et al., 1981; Boberg et al., 1983; Miller et al., 1983; 
Phillips et al., 1984; Randerath et al., 1984; Fennell et al., 1985; Wiseman et al., 1987; 
Smith et al., 2002). Because of their genotoxicity and carcinogenicity, the addition of 
estragole and methyleugenol as pure substances to foodstuffs has been prohibited within 
the European Union since September 2008 (European Commission, 2008). In 2008, the 
Joint FAO/WHO Expert Committee on Food Additives (JECFA) re-evaluated the safety of 
six alkenylbenzenes and indicated that although evidence of carcinogenicity in rodents 
given high doses of various alkenylbenzenes exists, further research is needed to assess 
the potential risk to human health at relevant dietary exposure levels (JECFA, 2008).
A significant difficulty in evaluating the toxicological data for alkenylbenzenes is 
that human exposure to these substances results from exposure to a complex mixture 
of food, spice, and spice oil constituents. Other compounds in these mixtures may 
influence the biochemical fate and toxicological risk of the alkenylbenzenes. Such a 
combination effect can take place when the complex matrix, or one constituent in the 
matrix, alters the absorption, metabolism, distribution and/or excretion (ADME), or alters 
the dynamics (mode of action) (Dybing et al., 2002) of the alkenylbenzenes. For example 
slow or incomplete release of alkenylbenzenes from the food matrix may result in a low 
bioavailability of these compounds from the mixture compared with their bioavailability 
when dosed as pure compounds. An example of an important toxicokinetic interaction 
for alkenylbenzenes is an influence on the sulfotransferase (SULT) activity involved in 
formation of their ultimate 1′-sulfoooxy metabolite. In this regard, it was shown that a 
methanolic extract of basil inhibited the formation of estragole DNA adducts in human 
HepG2 cells exposed to the proximate carcinogen 1′-hydroxyestragole (Jeurissen 
et al., 2008). This inhibition occurred at the level of SULT-mediated bioactivation of 
1′-hydroxyestragole into 1′-sulfooxyestragole (Jeurissen et al., 2008). 
The objective of this PhD research was to study the inhibitory action of components 
in alkenylbenzene-containing herbs and spices on SULT-mediated alkenylbenzene 
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DNA adduct formation and the consequences of this combination effect for risk 
assessment using estragole and methyleugenol as the model alkenylbenzenes. To 
achieve this objective, an integrated approach of in vitro, in vivo and physiologically 
based biokinetic (PBBK) models was applied to investigate how the SULT inhibition 
influences the bioactivation and thus potentially also the toxicity and risk assessment 
of estragole and methyleugenol.  
The major lines of discussion in this chapter are depicted in figure 1 and include the 
following aspects; First the identification and presence of dietary SULT inhibitors in the 
alkenylbenzene-containing herbs and spices as well as in the diet and their estimated 
daily intake (EDI) levels will be discussed based on results from chapter 2 and 3. 
Second, based on these EDIs possible exposure scenarios to the alkenylbenzenes 
estragole and methyleugenol and the different dietary SULT inhibiting flavonoids 
will be discussed based on results from chapter 2, 3, 4, 5 and 6. Third, in vitro 
activity of dietary SULT inhibitors will be discussed based on results from chapter 
2, 3 and 5. Fourth, the in vivo effect of dietary SULT inhibitors on alkenylbenzene 
DNA adduct formation in the liver of exposed rodents will be discussed based on 
results from chapter 4 and 6 using respectively estragole and methyleugenol and 
in both studies nevadensin as the model compounds. Also, the anticipated in vivo 
activity of dietary SULT inhibitors at realistic intake levels in humans will be discussed 
based on their reported plasma levels and predictions made by our PBBK models in 
male rat and human (chapter 2 and 3). Fifth, the association between the different 
Figure 1. Schematic representation of major lines of 
discussion.
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endpoints detected in the present thesis and their relation to the carcinogenicity of 
alkenylbenzenes will be discussed based on results from chapter 6. Sixth, an updated 
risk assessment for the alkenylbenzenes estragole and methyleugenol taking the 
matrix effect into account will be discussed based on results from chapter 4 and 6. 
Finally, future research perspectives based on issues raised by this research will be 
discussed and an overall conclusion will be presented.
SULT inhibitors in the diet and their estimated daily intake (EDI) levels 
Chapter 2 and 3 report that methanolic extracts from different alkenylbenzene-
containing herbs and spices such as basil, nutmeg, mace and others are able to 
inhibit the SULT activity involved in the formation of the proximate hepatocarcinogen, 
1′-sulfooxyestragole. Based on our analytical analysis and literature data, the active 
constitutes in herbs and spices responsible for SULT inhibition were identified. 
Flavonoids including nevadensin, quercetin, kaempferol, myricetin, luteolin and 
apigenin were the major constituents responsible for this inhibition of SULT activity. 
These flavonoids are all present in alkenylbenzene-containing herbs and spices, as 
well as throughout the diet, and they are all reported to have SULT inhibiting potency. 
Table 1 presents an overview of the EDI levels of these dietary flavonoids as well as the 
EDI levels of other important flavonoids that are also reported in the literature to exert 
SULT inhibiting activity including the flavonoids hesperetin and naringenin and the 
isoflavones daidzein and genistein (Justesen et al., 1997; Ghazali and Waring, 1999; 
Mesía -Vela and Kauffman, 2003; Mullie et al., 2008). As presented in table 1, the total 
EDI values of these SULT inhibiting flavonoids (excluding isoflavonoids) as recorded by 
different studies vary between 0.18 and 0.73 mg/kg bw/day. The main dietary source 
for quercetin, representing the flavonoid with the highest intake levels are black tea 
(61% of flavonoid intake), onions (13%) and apples (10%) (Hertog et al., 1993) which is 
in agreement with results from other studies (De Vries et al., 1997; Arai et al., 2000). 
Interestingly, the mean intake levels of isoflavonesin in Asian countries ranges between 
0.42-0.67 mg/kg bw/day with a maximum isoflavone intake of 1.7 mg/kg bw/day day 
and thus may reach levels higher than the mean intake levels from all other flavonoids 
amounting to 0.18 and 0.73 mg/kg bw/day (Table 1). Although Americans and Europeans 
consume much lower levels of isoflavones, the incorporation of growing quantities of soya 
extracts into manufactured food products and the increasing use of isoflavone containing 
food supplements could result in an increase in isoflavone intake (Manach et al., 2004). 
Specific subpopulations may be exposed to high levels of these dietary SULT-inhibiting 
flavonoids such as women undergoing phytoestrogen replacement therapy for menopause 
consuming between 0.5 and 1.2 mg isoflavones/kg bw/day day in the form of soya extract 
capsules (Manach et al., 2004). Some people may be exposed to even higher levels of these 
dietary SULT-inhibiting flavonoids from some food supplements commercially present on 
the market with levels of the flavonoids up to 1000 mg per tablet and with recommended 
use levels of one to two tablets per day resulting in intake levels of up to 33 mg/kg bw/day 
(assuming a 60 kg human individual consuming 2 tablets per day). 
155
7
Ta
b
le
 1
. O
ve
rv
ie
w
 o
f i
nt
ak
e 
le
ve
ls
 (m
g
/k
g
 b
w
/d
ay
) f
o
r 
so
m
e 
im
p
o
rt
an
t 
d
ie
ta
ry
 fl
av
o
no
id
s.
St
ud
y 
p
o
p
ul
at
io
n
su
b
je
ct
s
fla
vo
no
id
s
in
ta
ke
a
(m
g
/k
g
 b
w
/d
ay
)
To
ta
l i
nt
ak
ea
(m
g
/k
g
 b
w
/d
ay
)
re
fe
re
nc
e
H
un
g
ar
ia
n
20
4 
he
al
th
y 
ad
ul
ts
 (2
5-
60
 y
r)
q
ue
rc
et
in
ka
em
p
fe
ro
l
m
yr
ic
et
in
lu
te
o
lin
ap
ig
en
in
0.
11
±
0.
11
0.
02
±
0.
03
0.
14
±
0.
44
0.
03
±
0.
04
0.
01
±
0.
01
0.
31
±
4.
70
(L
ug
as
i e
t 
al
., 
20
03
)
D
an
is
hb
q
ue
rc
et
in
ka
em
p
fe
ro
l
m
yr
ic
et
in
he
sp
er
et
in
na
rin
g
en
in
0.
21
0.
04
0.
03
0.
11
0.
04
0.
43
(J
us
te
se
n 
et
 a
l.,
 1
99
7)
Sp
an
is
hc
35
4 
co
nt
ro
l s
ub
je
ct
s
q
ue
rc
et
in
ka
em
p
fe
ro
l
M
yr
ic
et
in
0.
14
±
0.
15
0.
02
±
0.
03
0.
01
±
0.
02
0.
18
±
0.
16
(G
ar
ci
a-
C
lo
sa
s 
et
 a
l.,
 1
99
9)
Fl
em
is
hd
45
 fe
m
al
e 
d
ie
tic
ia
ns
q
ue
rc
et
in
ka
em
p
fe
ro
l
m
yr
ic
et
in
lu
te
o
lin
ap
ig
en
in
he
sp
er
et
in
na
rin
g
en
in
0.
2±
0.
13
0.
08
±
0.
07
0.
04
±
0.
04
0.
01
±
0.
01
0.
02
±
0.
08
0.
27
±
0.
29
0.
13
±
0.
20
0.
73
(M
ul
lie
 e
t 
al
., 
20
08
)
D
ut
ch
80
5 
m
en
 (6
5-
84
 y
r)
q
ue
rc
et
in
ka
em
p
fe
ro
l
m
yr
ic
et
in
lu
te
o
lin
ap
ig
en
in
0.
27
±
0.
17
0.
14
±
0.
08
N
R
N
R
N
R
0.
43
±
0.
24
(H
er
to
g
 e
t 
al
., 
19
93
)
156
7
Ja
p
an
es
e
11
5 
w
o
m
en
 (2
9-
78
 y
r)
q
ue
rc
et
in
ka
em
p
fe
ro
l
m
yr
ic
et
in
lu
te
o
lin
0.
16
±
0.
12
0.
10
±
0.
05
0.
01
±
0.
01
0.
01
±
0.
01
0.
27
(A
ra
i e
t 
al
., 
20
00
)
U
Se
37
,8
86
 m
en
 (<
50
-+
70
)
78
,8
86
 w
o
m
en
 (<
50
-+
70
)
q
ue
rc
et
in
ka
em
p
fe
ro
l
m
yr
ic
et
in
lu
te
o
lin
ap
ig
en
in
0.
25
±
0.
17
- 
0.
29
±
0.
22
0.
06
±
0.
08
- 
0.
09
±
0.
1
0.
02
±
0.
02
N
R
N
R
0.
33
±
0.
24
- 
0.
39
±
0.
29
(S
am
p
so
n 
et
 a
l.,
 2
00
2)
A
si
an
M
ea
n 
in
ta
ke
 in
 p
o
p
ul
at
io
n
M
ax
im
um
 in
ta
ke
 in
 p
op
ul
at
io
n
is
o
fla
vo
ne
s
(d
ai
dz
ei
n 
an
d 
ge
ni
st
ei
n)
0.
42
–0
.6
7
1.
7
(C
o
w
ar
d
 e
t 
al
., 
19
93
; 
A
ra
i e
t 
al
., 
20
00
) 
(C
o
w
ar
d
 e
t 
al
., 
19
93
; 
A
ra
i e
t 
al
., 
20
00
)
G
en
er
al
 p
o
p
ul
at
io
n
W
o
m
en
 u
nd
er
g
o
in
g
 
p
hy
to
es
tr
o
g
en
 r
ep
la
ce
m
en
t 
th
er
ap
y 
fo
r 
m
en
o
p
au
se
is
o
fla
vo
ne
s
(d
ai
dz
ei
n 
an
d 
ge
ni
st
ei
n)
0.
5-
1.
2
(M
an
ac
h 
et
 a
l.,
 2
00
4)
a  
in
ta
ke
 l
ev
el
s 
ar
e 
p
re
se
nt
ed
 i
n 
m
g
/k
g
 b
w
/d
ay
 a
nd
 w
er
e 
ca
lc
ul
at
ed
 u
si
ng
 d
at
a 
fr
o
m
 l
ite
ra
tu
re
 i
n 
m
g
/d
ay
/p
er
so
n 
as
su
m
in
g
 a
 h
um
an
 a
ve
ra
g
e 
b
o
d
y 
w
ei
g
ht
 o
f 6
0 
kg
.
b
 b
as
ed
 o
n 
in
ta
ke
 d
at
a 
fr
o
m
 t
he
 N
at
io
na
l s
ta
tis
tic
al
 O
ffi
ce
 o
f D
en
m
ar
k,
 H
o
us
eh
o
ld
 c
o
ns
um
p
tio
n 
su
rv
ey
 1
98
7,
 u
np
ub
lis
he
d
 d
at
a.
 
c  t
he
 in
ta
ke
 v
al
ue
 is
 b
as
ed
 o
n 
co
nt
ro
l g
ro
up
 s
ub
je
ct
s.
 
d
 m
ea
su
re
d
 b
y 
a 
4-
d
ay
 fo
o
d
 r
ec
o
rd
 (4
D
FR
). 
e  
in
ta
ke
 v
al
ue
s 
in
 t
he
 U
S 
st
ud
y 
w
er
e 
re
p
o
rt
ed
 f
o
r 
d
iff
er
en
t 
ag
e 
su
b
g
ro
up
s.
 I
nt
ak
e 
va
lu
es
 r
ep
o
rt
ed
 i
n 
th
e 
ta
b
le
 r
ep
re
se
nt
 t
he
 m
in
im
um
 i
nt
ak
e 
va
lu
e 
re
p
o
rt
ed
 a
nd
 t
he
 h
ig
he
st
 in
ta
ke
 v
al
ue
 r
ep
o
rt
ed
 a
cr
o
ss
 a
ll 
ag
e 
g
ro
up
s 
in
cl
ud
in
g
 b
o
th
 m
en
 a
nd
 w
o
m
en
157
7
Apart from SULT inhibitors present in herbs and spices and identified in the present 
study, humans may be exposed to various other dietary SULT inhibitors including a 
number of food additives such as octyl gallate and tartrazine (Bamforth et al., 1993), 
some common drugs (Bamforth et al., 1992) and amines (Matsui et al., 1995). 
Overall, it is concluded that the diet is rich in SULT inhibiting compounds including 
flavonoids, food additives, drugs and amines and literature data provide good estimates 
for their EDI levels. The presence of such a wide range of SULT inhibitors in the regular diet 
offers chances on reduction of the bioactivation of the alkenylbenzenes. However, the most 
abundant SULT inhibitors in the diet are not necessarily the most active ones in biological 
systems and therefore their in vitro as well as their in vivo activity need to be evaluated. 
Exposure scenarios for alkenylbenzenes and dietary flavonoids
Knowledge on the EDI levels of each dietary SULT inhibiting flavonoid and of the 
alkenylbenzenes is essential to define realistic exposure scenarios. One possible 
exposure scenario is by assuming that all abundant dietary flavonoids are consumed 
together at their respective EDI levels which, according to table 1, range between 
0.18 and 0.73 mg/kg bw/day -excluding isoflavones-. Likewise, EDI values of 0.01 for 
estragole and 0.014 mg/kg bw/day for methyleugenol, resulting mainly from herbs, 
spices and their essential oils (Smith et al., 2002) can be used. 
In chapter 3, both estragole and the different dietary flavonoids were assumed to 
be consumed together at their EDI levels and PBBK modeling was used to evaluate the 
influence of this co-exposure scenario on the formation of the ultimate carcinogenic 
metabolite of estragole, 1′-sulfooxyestragole, in the liver. This approach serves as a first 
approximation because dietary flavonoids as well as alkenylbenzenes were assumed 
to be consumed together at the same time and in one portion. However, in reality the 
alkenylbenzenes and the dietary flavonoids from foods may not necessarily be consumed 
together in one dose and their consumption may occur in proportions all over the day. 
Another possible exposure scenario could be at levels of the dietary flavonoids 
present in food supplements. In chapter 3, quercetin was assumed to be consumed 
from a tablet containing 500 mg of quercetin and thus resulting in a daily intake of 8.3 
mg/kg bw/day (for a 60 Kg individual) together with 0.01 mg/kg bw/day of estragole. 
In addition, a realistic exposure scenario could be based on a food item in 
which the alkenylbenzene and the SULT inhibitor(s) are present together. Therefore, 
knowledge on the levels of alkenylbenzenes and SULT inhibitor(s) in alkenylbenzene-
containing herbs and spices is essential. Such data are available in the literature, 
however, the composition and levels of flavonoids and alkenylbenzenes in a herb or a 
spice can vary significantly based on different factors such as plant maturity at harvest, 
harvesting techniques, storage conditions, processing (e.g. drying), and method of 
measurement (e.g. extraction) (Smith et al., 2002). Therefore, present state-of-the-art 
intake estimates for ingredients from botanicals and botanical preparations are not 
refined to such an extent that the actual human exposure levels to alkenylbenzenes 
and SULT inhibiting ingredients can be determined in an accurate way. 
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Nevertheless, a model alkenylbenzenes-containing herb or a spice can be selected 
and different scenarios can be investigated ranging between a worst case to a best 
case scenario for levels of the compounds of interest detected in the model herb. In 
chapter 2, 3, 4, 5 and 6 basil was selected as the model alkenylbenzene-containing 
herb. This is because basil is the herb that contributes the most to the consumption of 
estragole by a value that amounts to 50% of the EDI of estragole (Smith et al., 2002). 
Basil may also contribute to some of the highest levels of intake of methyleugenol in 
some specialised eating groups, such as for example pesto eaters since fresh pesto is 
prepared from a large quantity of fresh sweet basil (Smith et al., 2002). These special 
eating groups may have exposure levels of methyleugenol that are 10 times higher (up 
to 0.1 mg/kg bw/day methyleugenol) than normal exposure (Smith et al., 2002). Also, 
nevadensin, a potent SULT inhibiting flavonoid, has been reported as a major flavone 
constituent in basil and may reach up to 58% of the total flavones present in almost all 
varieties of basil (Grayer et al., 2004). 
In chapter 2 and 3 we investigated two possible exposure scenarios resulting from 
consumption of basil using EDI levels of estragole reported in literature and ranging 
between 0.01-0.07 mg/kg bw/day (SCF, 2001a; Smith et al., 2002) together with nevadensin 
at a molar ratio of nevadensin to estragole of 0.06 or 0.25 reflecting the molar ratio at which 
the two compounds are present in basil assuming a worst case and best case scenario 
respectively. A similar approach was also used in chapter 5 with the alkenylbenzene 
methyleugenol at an EDI of 0.014 mg/kg bw/day (Smith et al., 2002) and nevadensin at a 
molar ratio of nevadensin to methyleugenol of 0.2 reflecting their presence in basil. 
Another possible exposure scenario includes the dose levels of the alkenylbenzenes 
used in the rodent carcinogenicity studies assuming that the flavonoid would be dosed 
to rodents at a molar ratio of the alkenylbenzene to the SULT inhibitor reflecting their 
presence in an alkenylbenzene-containing herb or a spice. Since dose levels of the 
alkenylbenzene used in these carcinogenicity studies are high, also the dose of the 
SULT inhibitor will be high. This situation reflects testing the material of commerce 
itself instead of the pure compound. This exposure scenario was used in the PBBK 
modelling of chapter 4 and 5 and also in the in vivo experiments of chapter 4 and 6 to 
evaluate the effect of nevadensin on bioactivation of estragole and methyleugenol at 
a molar ratio of nevadensin to estragole or to methyleugenol reflecting their presence 
in basil and at dose levels used in rodent bioassays. This approach allowed us, as 
reported in chapter 4 and 6 to derive refined BMDL10 values for the alkenylbenzenes 
estragole and methyleugenol and thus update the risk assessment for the two 
compounds taking the matrix effect into account (see below). 
Finally exposure scenarios are not only restricted to external doses of the compounds 
based on their EDI values from foods but may also be based on internal doses of the 
compounds present in plasma or in the target tissue. Using PBBK modeling, the effect 
of SULT inhibitor(s) on the bioactivation of the alkenylbenzenes can be evaluated at 
different scenarios of internal doses in the target tissue, the liver. In chapter 2 and 3 
for example the different SULT inhibiting flavonoids were assumed to follow the same 
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kinetics as estragole in the liver and different scenarios of uptake ranging between 0% 
(no uptake of flavonoid) to 100 % (complete uptake of flavonoid) were also modelled.
Overall, given that humans in reality are exposed to complex mixtures of food 
components and have wide variation in dietary habits, different exposure scenarios need 
to be investigated. This requires a good knowledge about levels of the compounds of 
interest (e.g. alkenylbenzenes and dietary SULT inhibiting flavonoids) in the different 
food matrices and the range of variation in levels of these active components. 
In vitro inhibition by selected flavonoids
Table 2 presents kinetic data for the inhibition of SULT activity by different dietary flavonoids 
measured in vitro either in the present study (in chapters 2 and 3) or reported in the literature 
using different SULT-containing systems. Based on these kinetic data, nevadensin seems to 
be the most potent food-borne SULT inhibitor identified with a Ki value of 4 nM for SULT 
inhibition that is 2-3 orders of magnitude lower than the Ki values for the other dietary 
flavonoids tested in the present thesis or reported in literature (Table 2). 
The type of inhibition exerted by nevadensin, quercetin, kaempferol, myricetin, 
and apigenin on SULT activity was shown to be non-competitive (Alhusainy et al., 
2010, 2012) (chapters  2 and 3). A non-competitive type of inhibition has been also 
reported for genistein and daidzein on human phenol SULTs (Ghazali and Waring, 
1999). The non-competitive nature of the SULT inhibition by the different flavonoids 
Table 2. overview of IC50 or Ki values for SULT inhibition by different dietary flavonoids measured 
in vitro using different SULT-containing systems based on different reports.
Flavonoid IC50 (µM) Ki (µM) Fraction/enzyme reference
Quercetin 1.5 pooled male rat liver S9 (Alhusainy et al., 2012)
Kaempferol 0.6 pooled male rat liver S9 (Alhusainy et al., 2012)
Myricetin 11.9 pooled male rat liver S9 (Alhusainy et al., 2012)
Apigenin 0.7 pooled male rat liver S9 (Alhusainy et al., 2012)
Nevadensin 0.004 pooled male rat and 
human liver S9
(Alhusainy et al., 2012)
Genistein
0.8
0.21 human phenol SULTs
rat liver cytosol
(Ghazali and Waring, 1999)
(Mesía -Vela and Kauffman, 2003)
Daidzein
2.2
0.34 human phenol SULTs
rat liver cytosol
(Ghazali and Waring, 1999)
(Mesía -Vela and Kauffman, 2003)
Hesperetin 0.2
3.0
SULT 1A1
SULT1E1
(Harris et al., 2004)
Naringenin 4
>10
SULT 1A1
SULT1E1
(Harris et al., 2004)
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means by definition that the inhibition and its Ki are independent of the nature or 
concentration of the substrate (such as for example the 1′-hydroxy metabolites of 
the alkenylbenzenes) but rather only dependent on the inhibitor (for example the 
flavonoid) and its concentration (Simmons, 1996).
The non-competitive type of inhibition also suggests that the different flavonoids 
are poor substrates for SULTs. This was evident in our studies where we have shown the 
catalytic efficiency for nevadensin sulfonation in male rat and human liver fractions to be 
low and absent in intestinal fractions of both species. This is also supported by results from 
a previous study reporting lack of sulfonation for quercetin, kaempferol, apigenin and 
myricetin by human liver cytosols (Eaton et al., 1996) which altogether explains that most 
circulating flavonoid conjugates detected in vivo are glucuronides (Manach et al., 2004). 
Interestingly, all flavonoids tested in the present study, namely, quercetin, 
kaempferol, myricetin, apigenin, luteolin and nevadensin were found to possess the 
structural requirements for effective SULT inhibitory activity linked to the presence 
of C5 and C7 hydroxyl substituents on the A-ring and also a C2–3 double bond in 
conjunction with the C4 carbonyl group on the C-ring (Morimitsu et al., 2004).
Given that we are exposed to a mixture of dietary flavonoids and not to only individual 
components we have also investigated the combined effect for a selected series of 
flavonoids on SULT activity using pooled male rat liver S9 fractions (chapter 3). These 
studies indicated that their combined effect is additive. We have also shown in chapter 
3 that in the incubations with liver fractions at concentrations of the flavonoids shown to 
inhibit SULT activity no inhibition in glucuronidation of 1′-hydroxyestragole by any of the 
flavonoids tested occurs. This is important given that glucuronidation is a detoxification 
pathway for 1′-hydroxyestragole. On the other hand, the different flavonoids tested –with 
the exception of nevadensin- were able to inhibit the oxidation of 1′-hydroxyestragole 
with Ki values close to Ki values for the SULT inhibition by the same dietary flavonoids. 
Given these results it can be concluded that in the presence of the inhibitors the metabolic 
pathways for 1′-hydroxy alkenylbenzenes will shift in favour of glucuronidation at the cost 
of sulfonation and oxidation pointing at increased detoxification and reduced risks. 
In line with these results using liver fractions, experiments using human HepG2 cells 
exposed simultaneously to 1′-hydroxyestragole and individual flavonoids (quercetin or 
kaempferol) or to a mixture of flavonoids, showed a significant inhibition in the formation 
of SULT-mediated DNA adduct formation and a significant inhibition in the formation 
of 1′-oxoestragole. The co-exposure to 1′-hydroxyestragole and the different flavonoids 
increased the formation of 1′-hydroxyestragole glucuronide corroborating a shift in 
metabolism from bioactivation (e.g. sulfonation) to detoxification (e.g. glucuronidation). 
These data also indicate that the different flavonoids are able to pass the cell membrane 
and exert an intracellular effect on SULT-mediated bioactivation of 1′-hydroxyestragole. 
The effect of the different flavonoids on hydroxylation of estragole into its 
proximate carcinogen, 1′-hydroxyestragole, was not investigated in the present 
thesis. An inhibitory effect by these flavonoids on 1′-hydroxylation may reduce the 
ultimate levels of DNA adducts formed by estragole and methyleugenol. Kinetic 
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studies revealed that, at dietary relevant concentrations of estragole, P450 1A2 and 
2A6 are the most important enzymes for 1′-hydroxylation in the human liver (Jeurissen 
et al., 2007). Several reports have shown inhibitory activity for dietary flavonoids on 
P450 enzyme activity. For example, in an experiment on benzo(a)pyrene metabolism 
using human liver microsomes, it was shown that addition of quercetin and kaempferol 
results in inhibition of the hydroxylation of benzo(a)pyrene with IC50 values amounting 
to about 10 µM for quercetin and between 10-50 for µM kaempferol (Buening et al., 
1981). Also, the activity of CYP1A2 was inhibited by the presence of various flavonoids 
including those tested in the present study, with the most potent activity shown by 
chrysin with and IC50 value of 0.2 μM followed by apigenin (IC50 =1.35 μM) and luteolin 
(IC50 =13 μM) (Lee et al., 1998). The study even revealed a structure-activity relationship 
and it was concluded that the presence of multiple hydroxyl groups (preferably two 
in the positions 5 and 7) on the flavone skeleton plays a crucial role in the inhibitory 
capacity (Lee et al., 1998; Hodek et al., 2002), a structural criterion that is present in 
all flavonoids tested in the present thesis. However, whether such an inhibitory effect 
of the different flavonoids  on 1′-hydroxylation of estragole and methyleugenol will 
actually occur  remains to be established.
Overall, in vitro results with the different dietary flavonoids show a potent SULT 
inhibition in incubations with liver fractions accompanied by a potent inhibition of DNA 
adduct formation in intact cellular systems and a shift of metabolism from bioactivation 
of estragole to detoxification. The question that may be raised subsequently is whether 
in vivo concentrations of these SULT-inhibiting flavonoids may reach levels high enough 
to inhibit SULT activity and this will be discussed in more detail in the following section.
In vivo SULT inhibition by selected flavonoids
In vivo activity of the different flavonoid-type SULT inhibitors will depend largely 
on their levels in the diet, their absorption, distribution, metabolism and excretion 
(ADME) characteristics in the body and thus their ultimate intracellular and circulating 
concentrations or what is usually referred to as their bioavailability. 
In chapter 4 and 6, we presented data showing that nevadensin is able to inhibit 
SULT activity in vivo. This was demonstrated by a significant inhibition of SULT-mediated 
formation of DNA adducts in the liver of rats exposed to estragole (chapter 4) or to 
methyleugenol (chapter 6) in the presence of nevadensin dosed simultaneously at a 
molar ratio reflecting the natural occurrence in basil. Nevadensin may be an effective in 
vivo SULT inhibitor because it possesses the structural requirements for effective SULT 
inhibitory activity described above (Morimitsu et al., 2004). Furthermore methylated 
flavones such as nevadensin have been demonstrated to be much more metabolically 
stable and have a higher intestinal absorption than their unmethylated analogues 
(Wen and Walle, 2006; Walle, 2007). 
It is important to note that in these in vivo studies both alkenylbenzene (e.g. estragole 
or methyleugenol) and nevadensin were dosed to rats at high dose levels in order to 
allow the detection of the DNA adduct formation and its inhibition by nevadensin. This 
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raises the question of whether a SULT inhibiting effect can also take place at realistic 
dietary dose levels of the alkenylbenzenes and nevadensin or other SULT inhibiting 
flavonoids. In this regard, we have presented data in chapter 3 showing that different 
flavonoids such as quercetin, apigenin, genistein, daidzein, and hesperetin may reach 
levels in the plasma higher than their Ki value detected in our in vitro experiments or 
reported in literature and thus may inhibit SULT activity in vivo. However, reported plasma 
concentrations often reflect total flavonoid concentrations including both conjugated 
and unconjugated forms instead of the concentrations of the aglycon, whereas the active 
form of the flavonoid exerting SULT inhibition tested in most in vitro experiments is the 
aglycone. This is important given especially that flavonoid conjugation by the three main 
types of conjugation; methylation, sulfonation, and glucuronidation is highly efficient, 
and aglycones are generally either absent in blood or present in low concentrations 
after consumption of nutritional doses (Manach et al., 2004). Although so far most of 
these flavonoid conjugates have not been tested for their SULT inhibiting activity and 
their potential to inhibit SULT activity remains to be investigated, one study  reported an 
inhibitory effect for daidzein-4′-O-sulfate and daidzein-7,4′-di-O-sulfate on phenol SULT 
activity with IC50 values >100 µM (Eaton et al., 1996). Also, experiments investigating the 
activity of most dietary flavonoids on SULT activity in vivo are lacking. 
In one small pilot study to determine whether ingestion of 500 mL soy milk would 
affect SULT1A1 activity in human it was shown that daidzein resulted in a significant 
reduction in the SULT1A1 activity in women “at risk” of breast cancer as compared 
with controls (Waring et al., 2008). This has been ascribed to the fact that people “at 
risk” of breast cancer have a polymorphism in SULT1A1 which makes the enzyme more 
susceptible to inhibition by flavonoids (Waring et al., 2008). Furthermore, determination 
of the actual bioavailability of polyphenol aglycons as well as their metabolites in tissues 
may be much more important than knowledge of their plasma concentrations. For 
example, the proportion of free aglycone in some tissues may be higher than that in 
blood, as has been demonstrated  in the case of genistein in rats (Wang et al., 2002). 
This may be explained by specific uptake of the aglycone or intracellular deconjugation 
(e.g. quercetin)  (Lee-Hilz et al., 2008). Still, in vivo data about intracellular levels of 
flavonoids are very scarce and not consistent enough to give a clear view of what occurs 
inside the cells, and additional studies are certainly needed (Manach et al., 2004). 
Therefore, to evaluate the quantitative dose and species dependent effects of 
SULT inhibition by the dietary flavonoids on the formation of the ultimate carcinogenic 
metabolite, 1′-sulfooxyestragole, the estragole PBBK models in rat and human were 
used as described in chapters 2 and 3. As a first approximation the SULT inhibitor(s) 
were assumed to follow a similar time-dependent concentration curve in the liver of rat 
and human as estragole and different scenarios of uptake and bioavailability ranging 
between 1% to 100% were simulated. PBBK model predictions suggested that inhibition 
of the formation of 1′-sulfooxyestragole at a realistic dietary dose of estragole of 0.01 
mg/kg bw/day together with a mixture of the most common dietary flavonoids each 
at its EDI level does not exceed 0.2% for rat and 0.5% for human when assuming 1% 
163
7
uptake of the flavonoid mixture. Even at levels of the flavonoid quercetin present in 
one tablet containing 500 mg and thus resulting in 8.3 mg/kg bw/day of quercetin in a 
60 kg individual together with 0.01 mg/kg bw of estragole the inhibition is still limited 
amounting to 3% in rat and 9% for human assuming 1% uptake of quercetin. 
One may ask whether the 1% uptake scenario represents a realistic uptake scenario 
for flavonoids. In this regard, we have shown in chapter 4 that PBBK predictions using 
the 1% uptake scenario for nevadensin is overestimating inhibition of DNA adduct 
formation at levels of estragole and nevadensin used by our in vivo study compared 
to the observed value by 12-fold. Obviously modelling nevadensin bioavailability and 
kinetics by a nevadensin PBBK sub-model as done in chapter 4 and 6 presents a better 
description of the in vivo situation.
Overall, given the lack of in vivo data about; i) levels of free aglycone concentrations 
in plasma and or in tissues after realistic dietary dose levels of flavonoids and ii) the 
significance of deconjugation of flavonoids in important tissues such as liver and 
intestine representing target organs for alkenylbenzenes and flavonoids, it remains 
difficult to draw a definite conclusion about SULT inhibiting potency of dietary 
flavonoids in vivo and thus more in vivo experiments are required to assess the effect 
of some dietary flavonoids on SULT-mediated pathways in vivo.
Association between 1′-sulfooxy metabolite, DNA adduct formation, 
hepatic foci and carcinogenicity of alkenylbenzenes
As we presented earlier, in vitro results with the different dietary flavonoids show a 
potent SULT inhibition in incubations with liver fractions accompanied by a potent 
inhibition of alkenylbenzene DNA adduct formation in intact cellular systems and 
a shift of metabolism from bioactivation of the alkenylbenzene to its detoxification 
(chapter 2 and 3). Also, a significant in vivo inhibition of SULT-mediated formation 
of DNA adducts occurred in the liver of rats exposed to estragole (chapter 4) or to 
methyleugenol (chapter 6) in the presence of nevadensin dosed simultaneously at a 
molar ratio reflecting the natural occurrence in basil. 
The estragole DNA adduct (E-3′-N2-dGuo) measured in our in vitro (chapter 2 and 
3) and in vivo experiments (chapter 4) is the major DNA adduct formed in several in 
vitro and rodent studies with estragole (Phillips et al., 1981; Wiseman et al., 1985; Punt 
et al., 2007). Also, the methyleugenol DNA adduct (ME-3′-N2-dGuo) measured in our 
in vitro (chapter 5) and in vivo experiments (chapter 6) was the major adduct formed 
in in vitro studies, in mice and also in human (Herrmann et al., 2012; Herrmann et 
al., 2013). Some other studies reported E-3′-N6-dA to be the major adduct formed in 
rodents (Ishii et al., 2011; Suzuki et al., 2012). 
Given that in addition to the major adduct identified in our studies also other DNA 
adducts may be formed it is of interest to consider wether the adducts detected in 
our experiments are  mutagenic adducts and thus represent a good indication for 
carcinogenicity of estragole and methyleugenol. In this regard, a recent study by 
Herrmann et al. (2012) has shown that different isomeric hydroxylated metabolites 
164
7
of methyleugenol form the same DNA adducts in S. typhimurium TA100-hSULT1A1, 
namely, ME-3′-N2-dGuo and ME-3′-N6-dA. When the strain TA100-hSULT1A1 was 
treated with varying doses of the hydroxylated metabolites of methyleugenol the levels 
of these two adducts increased continuously with the dose similar to the dose response 
curve for mutagenicity. In addition, adduct levels correlated with the mutagenic effect 
induced. Moreover, ME-3′-N2-dGuo was detected as the major DNA adduct whereas 
the amount of ME-3′-N6-dA formed was only 1.5-3 % of the amount of ME-3′-N2-
dGuo detected suggesting that the dG adduct is the major adduct contributing to the 
mutagenic effects of methyleugenol (Herrmann et al., 2012). 
Overall, in the present study, as a first approximation, we assumed that nevadensin- 
mediated inhibition of formation of E-3′-N2-dGuo or ME-3′-N2-dGuo would reflect the 
reduction in all estragole and methyleugenol DNA adducts and that reduction in DNA 
adducts would be linearly proportional to the reduction in tumour incidence. This is 
based on the fact that all estragole or methyleugenol DNA adducts will result from a 
chemical reaction with their 1′-sulfooxy metabolite which is the ultimate carcinogenic 
metabolite and that it is the formation of these 1′-sulfooxy metabolites that is inhibited 
by nevadensin. If all adducts would be reduced to a similar extent one can subsequently 
assume that the resulting mutagenicity and carcinogencity would be reduced to a similar 
extent as well, even when different adducts would display different mutagenicity. 
In this regard, it has been shown in rodent experiments that co-administration of 
the specific SULT inhibitor pentachlorophenol (PCP) resulted in a potent reduction in 
cytosolic SULT activity for 1′-hydroxysafrole in both mouse and rat liver, in a potent 
decrease in the level of adducts formed from 1′-hydroxysafrole in hepatic DNA and 
RNA and, more interestingly, in a potent inhibition of hepatic tumour induction in mice 
upon long-term dietary administration of safrole or its metabolite, 1’-hydroxysafrole 
together with PCP (Boberg et al., 1983). This clearly proves the role of the 1′-sulfooxy 
metabolite and the SULT-mediated DNA adduct formation in hepatotoxicicity and 
hepatocarcinogenicity of alkenylbenzenes. 
In addition to detecting the effects of nevadensin on DNA adduct formation, in chapter 
6 we tried to move one step further towards endpoints that are even closer to initiation 
of carcinogenesis than DNA adduct formation, namely, hepatocellular proliferation and 
formation of hepatocellular altered foci (HAF). The results obtained in chapter 6 clearly 
show that co-exposure to methyleugenol and nevadensin resulted not only in a significant 
inhibition of methyleugenol DNA adduct formation in the liver but also in a significant 
proportional inhibition of induction of hepatocellular altered foci (HAF), representing an 
indicator for initiation of neoplasia. Although  HAF lesions greatly exceed the number 
of neoplasms, they were shown to precede the development of neoplasms and are 
quantitatively related to neoplasms (Williams, 1980; Williams, 1982). 
Overall, results of the present thesis clearly show that the potent in vivo inhibitory 
activity of nevadensin on SULT activity and on alkenylbenzene DNA adduct formation 
is accompanied by a potent in vivo inhibition in early markers of carcinogenesis. 
Given the role of the 1’-sulfooxy metabolite of alkenylbenzenes in the hepatotoxicity 
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and carcinogenicity of alkenylbenzenes (Boberg et al., 1983) and the established 
quantitative relationship between HAF formation and neoplasm (Williams, 1980; 
Bannasch, 1986; Williams, 1989; Enzmann et al., 1998; Williams, 1998; Williams, 1999), 
the results of the present thesis suggest that in high dose rodent bioassays a reduction 
in the incidence of liver tumour formation is expected in when alkenylbenzenes would 
be dosed simultaneously with nevadensin.
Implications for risk assessment
Risk assessment for the alkenylbenzenes estragole and methyleugenol can be 
based on applying the so-called margin of exposure (MOE) approach which is using 
data from carcinogenicity studies with rodents where the compounds (estragole or 
methyleugenol) are dosed at high levels in their pure form. The MOE approach is 
suggested by EFSA for the risk assessment of compounds that are both genotoxic and 
carcinogenic and can be used to set priorities in risk management (EFSA, 2005). An 
MOE >10,000 is considered as a low priority for risk management actions and would 
be of low concern from a public health point of view (EFSA, 2005). Using reported 
BMDL10 values for estragole and methyleugenol (van den Berg et al., 2011) and EDI 
values of 0.01 for estragole and 0.014 mg/kg bw/day for methyleugenol, representing 
intake resulting mainly from herbs, spices and their essential oils (Smith et al., 2002) 
the calculated MOE value for estragole varies between 350 and 650 and that for 
methyleugenol between 3,500 and 5,300 for female rats and between about 1,100 
and 2,400 for male rats (Al-Subeihi et al., 2013). 
The question that can be raised now is how to integrate the current results on 
nevadensin-mediated modulation of the bioactivation of  estragole (chapter 4) 
and methyleugenol (chapter 6) in the risk assessment of these two compounds. In 
chapters 4 and 5 we refined the BMDL10 and subsequently calculated MOE values 
for both estragole and methyleugenol taking into account what would happen when 
nevadensin would have been co-administered with estragole or methyleugenol in 
those rodent carcinogenicity studies. 
To this end the estragole and methyleugenol PBBK models in male rat were connected 
with a newly developed nevadensin PBBK model which was validated based on our 
in vivo study in which DNA-adducts were quantified in the liver of rats simultaneously 
exposed to estragole and nevadensin in male rat. These binary PBBK models were 
used to calculate the possible reduction in E-3’-N2-dGuo formation at the estragole 
dose levels used in the study of Miller et al. (1983) or in ME-3’-N2-dGuo formation at 
the methyleugenol dose levels used in the NTP study, when nevadensin would be co 
administered with estragole or methyleugenol at a molar ratio of 1:0.25 for estragole 
or 1:0.20 for methyleugenol reflecting their natural occurrence in basil (Smith et al., 
2002; Alhusainy et al., 2012). As a first approximation we assumed that reduction in 
alkenylbenzene DNA adduct levels would be proportional to reduction in the incidence 
of hepatomas and then we calculated a refined BMDL10 value that was subsequently used 
to estimate a refined MOE. The refined MOE for estragole increased from 350 and 650 
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for data from studies testing the pure compound to 4,300 and 7,350 when the rodent 
study would have been performed in the presence of nevadensin. For methyleugenol 
the MOE values increased from 3,500 and 5,300 for female rats and from about 1,100 
and 2,400 for male rats based on data from studies testing the pure compound to about 
11,000 and 18,000 for female rats and about 9,200 and 10,000 for male rats when the 
rodent study would have been performed in the presence of nevadensin. 
These updated MOE levels for estragole and methyleugenol clearly point at a 
lower priority for risk management when the rodent bioassays and the subsequent risk 
assessment would have been performed taking the matrix effect into account, than 
when the MOE calculation is based on the tumour data obtained with pure compounds.
FUTURE PERSPECTIVES AND CONCLUSIONS
The present thesis presents data suggesting that that the likelihood of bioactivation and 
subsequent adverse effects may be lower when the alkenylbenzene is consumed in a 
matrix containing SULT inhibitors compared to experiments using pure alkenylbenzenes 
as single compounds. However, a question remaining is whether an in vivo effect of 
SULT inhibiting flavonoids can be expected to take place at realistic dietary intake levels 
of these flavonoids despite the high conjugation efficiency for flavonoids in vivo. Up to 
date, the in vivo activity of natural SULT inhibitors has been only proven in vitro (table 2) 
with the exception of nevadensin which was shown by our studies to be able to inhibit 
SULT activity in vivo when dosed with estragole (Alhusainy et al., 2013) or methyleugenol 
(Al-Subeihi et al., 2013) at high dose levels. Therefore, it seems essential to perform 
in vivo experiments in animals to investigate the potency of the other dietary SULT 
inhibiting flavonoids at realistic dose levels of the SULT inhibitors including dose levels 
similar to levels present in food or in supplements, an objective that can be tested in 
rodent bioassays given that DNA adduct levels formed at dietary levels of methyleugenol 
for example can be readily quantified in mice and in human (Herrmann et al., 2013). 
Moreover, the present thesis focused on a single aspect of the matrix effect in 
which the toxicokinetics of the compound of concern (such as the alkenylbenzenes) 
is influenced by some components (such as dietary flavonoids) in the matrix. This 
interaction occurred at the level of the SULT-mediated pathway involved in formation of 
the ultimate carcinogenic metabolite of alkenylbenzenes, the 1′-sulfooxy metabolite, 
which was shown to be inhibited by the various flavonoids identified. However, 
constituents of the matrix might also affect the bioactivation and resulting toxicity of 
alkenylbenzenes through other pathways and this was not addressed in the present 
thesis and can be addressed in future research to further refine the risk assessment 
of alkenylbenzenes. Such factors are for example the effect of the complex matrix, or 
one of its constituent, on the absorption of both the alkenylbenzene and/or the SULT 
inhibitors in the gastrointestinal tract and/or on their release from the matrix. 
The matrix effect might also be studied to a further extent by analysing early markers 
of hepatocarcinogenesis in some specialised eating groups, such as for example 
frequent pesto eaters since they have one of the highest levels of estragole and 
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methyleugenol intake (Smith et al., 2002). Useful parameters that could be investigated 
in such a human study may include for example quantifying DNA adduct levels in 
white blood cells (WBC) in human blood samples. A previous study has reported an 
increase in WBC DNA adducts levels in rats orally dosed with methyleugenol for 16 
weeks and the authors concluded that this might be a useful biomarker since the  DNA 
of WBC can be readily obtained and monitored in humans (Williams et al., 2013). Also, 
quantification of urine and plasma levels of alkenylbenzenes, nevadensin and their 
metabolites would be of used in order to judge if these compounds reach levels that 
match the PBBK based predictions and/or relevant Ki values. 
Not only in vivo studies are required but also in vitro studies are essential to 
investigate remaining issues of interest such as the effect of the different dietary 
flavonoids on the hydroxylation of alkenylbenzenes into their proximate carcinogen, the 
1′-hydroxy metabolite. An inhibitory effect by the flavonoids on this 1′-hydroxylation 
may reduce the ultimate levels of DNA adducts. 
Also, the inhibitory activity of flavonoid conjugates on SULT enzyme activity as 
well as on 1′-hydroxylation is worth further studies, especially given the fact that most 
flavonoid inhibitors will be metabolised to their corresponding methyl, glucuronide and/
or sulfate conjugates and these forms may be the major forms in which they are present 
in the systemic circulation. However, up to date identification of circulating conjugates 
has been undertaken for only a few flavonoids (Manach et al., 2004). Furthermore, 
such studies would also require the identification of not only the nature and number 
of conjugation groups but also the positions of these groups on the flavonoid structure 
because these positions can affect the biological properties of the conjugates (Day et 
al., 2000). It also requires to identify the nature of the tissue metabolites which may 
be different from that of blood metabolites because of the specific tissue uptake or 
elimination or because of intracellular metabolism (Manach et al., 2004). 
Finally, although the addition of estragole and methyleugenol as flavouring 
substances in foodstuffs has been prohibited within the European Union since 
September 2008 (European Commission, 2008). A recent publication detected the 
presence of methyleugenol DNA adducts in surgical human liver samples from 30 
subjects at maximum and median levels of 37 and 13 per 108 nucleosides which was 
found to be close to DNA adduct levels detected in rodents ranging between 50–5500 
adducts per 108 nucleosides after repeated treatment by different rodent carcinogens 
at their TD50 (Herrmann et al., 2013)  According to the same study, similar levels of 
adducts of 7 and 22 per 108 nucleosides were detected in the liver of wild-type mice 
given single oral doses of 0.05 and 0.5 mg/kg bw of methyleugenol respectively. The 
authors conclude that it is plausible that the adducts detected in the human samples 
were indeed produced by methyleugenol present in the diet given that the mean daily 
intake of methyleugenol from food for Europe is 0.19 mg/kg bw (SCF, 2001b), a value 
that is in the range of dose levels used by the mice experiment. The DNA adduct 
levels detected in human liver were in line with the values predicted by our human 
PBBK model which amounted to 14.2 and 25.4 ME-3′-N2-dGuo DNA adducts per 108 
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nucleotides at oral doses of 0.05 and 0.5 mg/kg bw of methyleugenol respectively 
assuming nevadensin is also present at a molar ratio of  methyleugenol to nevadensin 
of 1:0.20 to reflect their occurrence in basil. In the absence of nevadensin our human 
PBBK model predicts 14.7 and 34.1 ME-3′-N2-dGuo DNA adducts per 108 nucleotides 
at 0.05 and 0.5 mg/kg bw/day respectively. These PBBK model predictions suggest 
that a limited matrix effect may be relevant at realistic dietary exposure levels.
OVERALL CONCLUSION
Overall, given the role of the SULT-mediated formation of alkenylbenzene DNA adducts 
in the hepatocarcinogenicity of alkenylbenzenes in rodents, the results of the present 
study indicate that the likelihood of bioactivation and subsequent adverse effects may 
be lower when the alkenylbenzene is consumed in a matrix containing SULT inhibitors 
such as nevadensin compared to experiments using pure alkenylbenzene as a single 
compound. The results obtained in the present thesis suggest that the consequences 
of the in vivo matrix effect are significant when estragole or methyleugenol would be 
tested in rodent bioassays at high dose levels in the presence of nevadensin at ratios 
detected in basil, thereby increasing BMDL10 and resulting  MOE values substantially 
in a subsequent risk assessment. 
However, the results also indicate that matrix effects may be lower at daily human 
dietary exposure levels of estragole or methyleugenol and nevadensin resulting from 
basil consumption. Also, matrix effects of other SULT inhibiting dietary flavonoids 
seem to be limited even at high exposure levels of these flavonoids upon supplement 
use, which can be ascribed to higher Ki values for SULT inhibition by these flavonoids 
that are 2-3 orders of magnitude higher than the Ki for nevadensin. This indicates that 
the importance of a matrix effect for risk assessment of individual compounds requires 
analysis of dose dependent effects on the interactions detected, an objective that can 
be achieved by using PBBK modeling. 
So far, the effect of nevadensin in reducing the alkenylbenzene bioactivation in 
vivo has been established for the alkenylbenzenes estragole and methyleugenol 
only. However, the results of the present work can also be extended to other 
alkenylbenzenes. This is because the SULT inhibition by nevadensin is non-competitive 
in nature (Alhusainy et al., 2010; Alhusainy et al., 2013) and thus by definition should 
be evident regardless of the substrate (Simmons, 1996).
Overall, the present study provides an example of an approach that can be used to 
characterise dose- species- and inter-individual differences as well as matrix effects in 
the risk assessment of food-borne toxicants present in botanicals (e.g. alkenylbenzenes). 
In this approach the most important toxicokinetic interactions are addressed using an 
integrated strategy of in vitro, in vivo and PBBK modeling approaches.  
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Summary8

SUMMARY
Alkenylbenzenes such as estragole and methyleugenol are common components 
of spices and herbs such as tarragon, basil, fennel, mace, allspice, star anise and 
anise and their essential oils (Smith et al., 2002). There is an interest in the safety 
evaluation of alkenylbenzenes because these compounds can induce hepatic tumours 
in rodents when dosed orally at high dose levels (Miller et al., 1983; NTP, 2000). 
Based on the rodent studies with estragole, methyleugenol and structurally related 
alkenylbenzenes like safrole the hepatocarcinogenicity of alkenylbenzenes is ascribed 
to their bioactivation by cytochrome P450 enzymes leading to the formation of the 
proximate carcinogenen, the 1′-hydroxy metabolite, which is further bioactivated to 
the ultimate carcinogenen, the 1′-sulfooxy metabolite (Miller et al., 1983; Phillips et 
al., 1984; Randerath et al., 1984; Smith et al., 2010). The 1′-sulfooxy metabolite is 
unstable and binds via a presumed reactive carbocation intermediate covalently to 
different endogenous nucleophiles including DNA (Phillips et al., 1981; Boberg et al., 
1983; Miller et al., 1983; Phillips et al., 1984; Randerath et al., 1984; Fennell et al., 
1985; Wiseman et al., 1987; Smith et al., 2002). 
Because of their genotoxicity and carcinogenicity, the addition of estragole and 
methyleugenol as pure substances to foodstuffs has been prohibited within the 
European Union since September 2008 (European Commission, 2008). In 2008, the 
Joint FAO/WHO Expert Committee on Food Additives (JECFA) re-evaluated the safety 
of alkenylbenzenes and indicated that although evidence of carcinogenicity to rodents 
given high doses of alkenylbenzenes exists, further research is needed to assess the 
potential risk to human health at relevant dietary exposure levels (JECFA, 2008). 
A significant difficulty in evaluating the toxicological data for alkenylbenzenes is 
that human exposure to these substances results from exposure to a complex mixture 
of food, spice, and spice oil constituents which may influence the biochemical fate and 
toxicological risk of the alkenylbenzenes. In this regard, it was shown that a methanolic 
extract of basil inhibited the formation of estragole DNA adducts in human HepG2 
cells exposed to the proximate carcinogen 1′-hydroxyestragole (Jeurissen et al., 2008). 
This inhibition occurred at the level of sulfotransferase (SULT)-mediated bioactivation 
of 1′-hydroxyestragole into 1′-sulfooxyestragole (Jeurissen et al., 2008). 
The objective of this PhD research was to study the inhibitory action of components 
in alkenylbenzene-containing herbs and spices on SULT-mediated alkenylbenzene DNA 
adduct formation and the consequences of this combination effect for risk assessment using 
estragole and methyleugenol as the model alkenylbenzenes. To achieve this objective, 
an integrated approach of in vitro, in vivo and physiologically based biokinetic (PBBK) 
models was applied to investigate how the SULT inhibition influences the bioactivation 
and thus potentially also the toxicity and risk assessment of estragole and methyleugenol. 
Chapter 1 of the thesis presents an introduction to the bioactivation, detoxification, 
genotoxicity and carcinogenicity of the alkenylbenzenes estragole and methyleugenol 
as well as a short introduction to PBBK modeling and the state-of-the-art knowledge 
on risk assessment strategies and regulatory status for alkenylbenzenes. 
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Chapter 2 of the thesis identifies nevadensin as a basil constituent able to inhibit 
SULT-mediated DNA adduct formation in rat hepatocytes exposed to the proximate 
carcinogen 1′-hydroxyestragole and nevadensin. The type of inhibition by nevadensin 
was shown to be non-competitive with an inhibition constant (Ki) of 4 nM. Furthermore, 
nevadensin up to 20 μM did not inhibit 1′-hydroxyestragole detoxification by 
glucuronidation and oxidation. The inhibition of SULT by nevadensin was incorporated 
into the PBBK models describing bioactivation and detoxification of estragole in male 
rat and human. The models thus obtained predict that co-administration of estragole at 
a level inducing hepatic tumours in vivo (50 mg/kg bw) with nevadensin at a molar ratio 
to estragole representing the molar ratio of their occurrence in basil, results in more than 
83% inhibition of the formation of the carcinogenic metabolite, 1′-sulfooxyestragole, in 
the liver of male rat and human even at 1% uptake of nevadensin. 
To extend the work to other alkenylbenzene-containing herbs and spices than 
basil chapter 3  presents data showing that methanolic extracts from different 
alkenylbenzene-containing herbs and spices such as nutmeg, mace, anise and 
others are able to inhibit the SULT enzyme activity. Flavonoids including nevadensin, 
quercetin, kaempferol, myricetin, luteolin and apigenin were the major constituents 
responsible for this inhibition of SULT activity with Ki values in the nano to sub-
micromolar range. Also, the various flavonoids individually or in mixtures were able 
to inhibit estragole DNA adduct formation in human HepG2 cells exposed to the 
proximate carcinogen 1′-hydroxyestragole, and to shift metabolism in favour of 
detoxification (e.g. glucuronidation) at the cost of bioactivation (e.g. sulfonation). 
In a next step, the kinetics for SULT inhibition were incorporated in PBBK models 
for estragole in rat and human to predict the effect of co-exposure to estragole and 
(mixtures of) the different flavonoids on the bioactivation in vivo. The PBBK-model-
based predictions indicate that the reduction of estragole bioactivation in rat and 
human by co-administration of the flavonoids is dependent on whether the intracellular 
liver concentrations of the flavonoids can reach their Ki values. Finally, we concluded 
that it is expected that this is most easily achieved for nevadensin which has a Ki value 
in the nanomolar range and is, due to its methylation, more metabolically stable and 
bioavailable than the other flavonoids.
Chapter 4 of the thesis investigates whether the previous observation that 
nevadensin is able to inhibit SULT-mediated estragole DNA adduct formation in primary 
rat hepatocytes could be validated in vivo. Moreover, the previously developed PBBK 
models to study this inhibition in rat and in human liver was refined by including a 
sub-model describing nevadensin kinetics. Nevadensin resulted in a significant reduction 
in the levels of estragole DNA adducts formed in the liver of Sprague–Dawley rats orally 
dosed with estragole and nevadensin simultaneously at a ratio reflecting their presence 
in basil. Moreover, the refined PBBK model predicted the formation of estragole DNA 
adducts in the liver of rat with less than 2-fold difference compared to in vivo data 
and suggests more potent inhibition in the liver of human compared to rat due to less 
efficient metabolism of nevadensin in human liver and intestine. 
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Also, an updated risk assessment for estragole was presented taking into account 
the matrix effect and this revealed that the BMDL10 and the resulting MOE for estragole 
increase substantially when they would be derived from rodent bioassays in which the 
animals would be exposed to estragole in the presence of nevadensin instead of to 
pure estragole.
To extend the work to other alkenylbenzenes than estragole chapter 5 of the thesis 
investigates the potential of nevadensin to inhibit the SULT-mediated bioactivation and 
subsequent DNA adduct formation of methyleugenol using human HepG2 cells as an 
in vitro model. Nevadensin was able to inhibit SULT-mediated DNA adduct formation 
in HepG2 cells exposed to the proximate carcinogen 1′-hydroxymethyleugenol in the 
presence of nevadensin. To investigate possible in vivo implications for SULT inhibition 
by nevadensin on methyleugenol bioactivation, the rat PBBK model developed in 
our previous work to describe the dose-dependent bioactivation and detoxification 
of methyleugenol in male rat was combined with the recently developed PBBK 
model describing the dose-dependent kinetics of nevadensin in male rat. Similar to 
what was presented for estragole in chapter 4, chapter 5 presents an updated risk 
assessment for methyleugenol taking the matrix effect into account. This revealed 
that the BMDL10 and the resulting MOE for methyleugenol increase substantially when 
they would be derived from rodent bioassays in which the animals would be exposed 
to methyleugenol in the presence of nevadensin instead of to pure methyleugenol.
In a next step, we aimed at moving one step forward towards endpoints that are 
closer to initiation of carcinogenesis than DNA adduct formation, namely, formation of 
hepatocellular altered foci (HAF). Chapter 6 presents data showing that the potent in 
vivo inhibitory activity of nevadensin on SULT enzyme activity and on alkenylbenzene 
DNA adduct formation is accompanied by a potent in vivo reduction in early markers 
of carcinogenesis such as HAF. This also suggests that a reduction in the incidence of 
hepatocarcinogenicity is expected in liver of rodents when alkenylbenzenes would be 
dosed simultaneously with nevadensin.
Chapter 7 presents a discussion on the in vitro and in vivo activity of dietary SULT 
inhibitors and their potential in reducing the cancer risk associated with alkenylbenzene 
consumption. This chapter also presents some future perspectives based on the major 
issues raised by our research.  
Altogether, the results of the present thesis indicate that the likelihood of 
bioactivation and subsequent adverse effects may be lower when alkenylbenzenes 
are consumed in a matrix containing SULT inhibitors such as nevadensin compared 
to experiments using pure alkenylbenzenes as single compounds. Also, the 
consequences of the in vivo matrix effect were shown to be significant when estragole 
or methyleugenol was tested in rodent bioassays in the presence of nevadensin at 
ratios detected in basil, thereby likely increasing BMDL10 and resulting  MOE values 
substantially in a subsequent risk assessment. However, the results also indicate that 
matrix effects may be lower at daily human dietary exposure levels of estragole or 
methyleugenol and nevadensin resulting from basil consumption. Also, matrix effects 
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seem to be limited in the presence of other SULT inhibiting dietary flavonoids even at 
high exposure levels of these flavonoids coming from supplements. This indicates that 
the importance of a matrix effect for risk assessment of individual compounds requires 
analysis of dose dependent effects on the interactions detected, an objective that can 
be achieved by using PBBK modeling. 
Overall, the present study provides an example of an approach that can be used 
to characterise dose- species- and inter-individual differences as well as matrix effects 
in the risk assessment of food-borne toxicants present (e.g. alkenylbenzenes). In 
this approach the most important toxicokinetic interactions are addressed using an 
integrated strategy of in vitro, in vivo and PBBK modeling approaches.  
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9 Samenvatting

SAMENVATTING
Alkenylbenzenen zoals estragole en methyleugenol zijn normale bestanddelen van 
specerijen en kruiden zoals dragon, basilicum, venkel, foelie, piment, steranijs en anijs 
en de essentiële oliën daarvan (Smith et al., 2002). Er bestaat belangstelling voor 
de veiligheidsevaluatie van alkenylbenzenen omdat deze verbindingen levertumoren 
veroorzaken in knaagdieren als ze in hoge doses oraal worden toegediend (Miller et 
al., 1983; NTP, 2000). Gebaseerd op deze dierstudies met estragole, methyleugenol 
en structureel verwante alkenylbenzenen zoals safrole, wordt de levercarcinogeniciteit 
toegeschreven aan de bioactivering van deze stoffen door cytochroom P450-enzymen 
resulterend in de vorming van de proximale carcinogene 1’-hydroxymetaboliet, 
die verder wordt geactiveerd tot de ultieme carcinogene 1’-sulfooxymetaboliet 
(Miller et al., 1983; Philips et al., Randerath et al., 1984; Smith et al., 2010). De 
1’-sulfooxymetaboliet is instabiel en bindt via een veronderstelde reactieve carbocation 
intermediair covalent aan verschillende endogene nucleofielen waaronder ook DNA 
(Philips et al., 1981; Boberg et al.,; Miller et al., 1983; Philips et al., 1984; Randerath et 
al., 1984; Fennel et al., 1985; Wiseman et al., 1987; Smith et al., 2002).
Vanwege hun genotoxiciteit en carcinogeniciteit is het toevoegen van estragole en 
methyleugenol als pure stoffen aan voedingsmiddelen binnen de Europese Gemeenschap 
sinds september 2008 (European Commission (EC), 2008) verboden. In 2008 heeft 
the Joint FAO/WHO Expert Committee on Food Additives (JECFA) de veiligheid van 
alkenylbenzenen opnieuw geëvalueerd en aangegeven dat, ondanks het feit dat bewijs 
bestaat van carcinogeniciteit voor knaagdieren die hoge doses toegediend kregen, verder 
onderzoek noodzakelijk is om het potentiële risico voor de gezondheid van mensen te 
bepalen bij relatieve lage blootstellingsniveaus via het dieet (JECFA, 2008).
Een belangrijk probleem bij de evaluatie van de betekenis van de toxicologische 
data voor alkenylbenzenen uit dierstudies voor de mens is, dat menselijke blootstelling 
aan deze stoffen het resultaat is van blootstelling aan een complex mengsel van 
voeding, specerijen and specerij-oliebestanddelen die het biochemische lot en 
het toxicologische risico van de alkenylbenzenen zouden kunnen beïnvloeden. In 
dit verband is aangetoond dat een methanolextract van basilicum de vorming van 
estragole DNA-adducten remde in humane HepG2 cellen die waren blootgesteld aan 
het proximale carcinogene 1’-hydroxyestragole (Jeurissen et al., 2008). Deze remming 
deed zich voor op het niveau van de sulfotransferase (SULT)-gemedieerde bioactivering 
van 1’-hydroxyestragole naar 1’-sulfooxyestragole (Jeurissen et al., 2008).
Het doel van dit PhD-onderzoek was de remmende invloed te bestuderen van 
bestanddelen in alkenylbenzeen bevattende kruiden en specerijen op SULT-gemedieerde 
alkenylbenzeen DNA-adductvorming en de gevolgen van deze combinatie-effecten voor 
de risico-evaluatie waarbij estragole en methyleugenol als de model-alkenylbenzenen 
zijn gebruikt. Om dit doel te bereiken is een geïntegreerde benadering toegepast van 
in vitro, in vivo en fysiologisch gebaseerde biokinetische (PBBK) modellering, om te 
onderzoeken hoe de SULT-remming de bioactivering en zodoende in potentie ook de 
toxiciteit en risicoschatting van estragole en methyleugenol beïnvloedt.
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Hoofdstuk 1 van dit proefschrift presenteert zowel een inleiding over de 
bioactivering, detoxificatie, genotoxiciteit en carcinogeniciteit van de alkenylbenzenen 
estragole en methyleugenol als ook een korte introductie van PBBK modellering en de 
state-of-the-art met betrekking tot strategieën voor risicoschatting en de regelgeving 
voor alkenlylbenzenen.
Hoofdstuk 2 van het proefschrift identificeert nevadensin als een bestanddeel van 
basilicum dat in staat is SULT-gemedieerde estragole DNA-adductvorming te remmen 
in hepatocyten van ratten die zijn blootgesteld aan het proximale carcinogeen 
1’-hydroxyestragole en nevadensin. Het type remming door nevadensin bleek non-
competitief te zijn met een remmingsconstante (Ki) van 4 nM. Bovendien remde 
nevadensin tot 20 μM niet 1’-hydroxyestragole detoxificatie via glucuronidering en 
oxidatie. De remming van SULT door nevadensin werd opgenomen in de PBBK-
modellen die bioactivering en detoxificatie van estragole in de mannelijke rat en in de 
mens beschrijven. De op deze manier verkregen modellen voorspellen dat gelijktijdige 
toediening van estragole op een niveau dat hepatische tumoren in vivo veroorzaakt(50 
mg/kg bw) met nevadensin gedoseerd in een molaire ratio ten opzichte van estragole 
van 0.06 (de molaire ratio van het voorkomen in basilicum), resulteert in meer dan 83% 
remming van de vorming van de carcinogene metaboliet, 1’-sulfooxyestrageole, in de 
lever van de mannelijke rat en de mens zelfs bij 1% opname van nevadensin.
Om het werk uit te breiden naar andere alkenylbenzeen-bevattende kruiden en 
specerijen dan basilicum presenteert hoofdstuk 3 data die aantonen dat methanolextracten 
van verschillende alkenylbenzeen-bevattende kruiden en specerijen zoals nootmuskaat, 
foelie, anijs en andere, in staat zijn de SULT-enzymactiviteit te remmen. Flavonoïden, inclusief 
nevadensin, quercetin, kaempferol, myricetin, luteolin en apigenin, waren de belangrijkste 
bestanddelen die verantwoordelijk waren voor deze remming van SULT-activiteit met 
Ki-waarden in het nano- tot sub-micromolaire gebied. Tevens waren de verschillende 
flavonoïden, individueel of in mengsels, in staat estragole DNA-adductvorming te 
remmen in humane HepG2-cellen die waren blootgesteld aan het proximale carcinogeen 
1’-hydroxyestragole, en verschoof metabolisme in het voordeel van detoxificatie (b.v. 
glucuronidering) ten koste van bioactivering (sulfonering). In een volgende stap werd de 
kinetiek voor SULT-remming geïncorporeerd in PBBK-modellen voor estragole in rat en 
mens om het effect te voorspellen van gelijktijdige blootstelling aan estragole en (mengsels 
van) de verschillende flavonoïden op de bioactivering in vivo. De op het PBBK-model 
gebaseerde voorspellingen wijzen er op dat de reductie van estragole bioactivering in 
rat en mens door gelijktijdige toediening van de flavonoïden afhankelijk is van de vaag of 
de intracellulaire leverconcentraties van de flavonoïden hun Ki-waarden kunnen bereiken. 
Tot slot concludeerden we dat het te verwachten is dat dit het gemakkelijkst te bereiken 
is voor nevadensin die een Ki-waarde heeft in het nanomolaire gebied en, dank zij zijn 
methylering, metabolisch stabieler is en meer biobeschikbaar dan de andere flavonoïden.
Hoofdstuk 4 van het proefschrift onderzocht of de eerdere observatie dat nevadensin 
in staat is SULT-gemedieerde estragole DNA-adductvorming te remmen in primaire rat-
hepatocyten ook in vivo kon worden gevalideerd. De experimenten werden ook gebruikt 
186
9
om de voorheen ontwikkelde PBBK-modellen om deze remming te bestuderen in ratte- 
en in humane lever te verbeteren door een sub-model toe te voegen dat nevadensin-
kinetiek beschrijft. Nevadensin resulteerde in een aanzienlijke reductie in de niveaus 
van estragole DNA-adducten in de lever van Sprague-Dawley ratten wanneer de ratten 
oraal tegelijkertijd estragole en nevadensin kregen toegediend in een ratio die gelijk 
was aan de aanwezigheid ervan in basilicum. Het verfijnde PBBK-model voorspelde 
de vorming van estragole DNA-adducten in de lever van de rat met minder dan een 
tweevoudig verschil, vergeleken met in vivo data. De modellen voorspelden ook een 
potentere remming in de lever van de mens dan van de rat, dankzij het minder efficiënte 
metabolisme van nevadensin in humane lever en darm.
Er werd ook een verfijnde risicoschatting voor estragole gepresenteerd waarbij 
rekening werd gehouden met het matrixeffect en dit toonde aan dat de BMDL10 en de 
daaruit resulterende MOE voor estragole aanzienlijk zouden toenemen als zij zouden 
worden bepaald op basis van bioassays waarin de dieren zouden zijn blootgesteld aan 
estragole tegelijk met nevadensin in plaats van aan pure estragole. 
Om het werk uit te breiden naar andere alkenylbenzenen dan alleen estragole, 
onderzoekt hoofdstuk 5 van het proefschrift het vermogen van nevadensin om de 
SULT- gemedieerde bioactivering van methyleugenol te remmen en daardoor de 
DNA-adductvorming van methyleugenol in humane HepG2-cellen in vitro. nevadensin 
bleek in staat te zijn SULT-gemedieerde methyleugenol DNA-adductvorming te 
remmen in HepG2-cellen die waren blootgesteld aan het proximale carcinogene 
1’-hydroxymethyleugenol tegelijk met nevadensin. Om mogelijke in vivo implicaties 
te onderzoeken voor SULT-remming door nevadensin op methyleugenol-bioactivering, 
werd het rat PBBK-model dat in ons eerdere werk was ontwikkeld om de dosis-afhankelijke 
bioactivering en detoxificatie van methyleugenol te beschrijven, gecombineerd met het 
recent ontwikkelde PBBK-model dat de dosis-afhankelijke kinetiek van nevadensin in 
de mannelijke rat beschrijft. Net als voor estragole in hoofdstuk 4, laat hoofdstuk 5 een 
aangepaste risicoschatting zien voor methyleugenol, waarbij rekening wordt gehouden 
met het matrixeffect. Dit toonde aan dat de BMDL10 en de daarvan afgeleide MOE 
voor methyleugenol aanzienlijk toenemen wanneer zij zouden worden ontleend aan 
knaagdier-bioassays waarin de dieren zouden zijn blootgesteld aan methyleugenol 
tegelijk met nevadensin in plaats van aan zuivere methyleugenol.
In een volgende fase van het onderzoek werd geprobeerd een stap verder te 
zetten naar eindpunten die dichter bij de initiatie van carcinogenese komen dan DNA-
adductvorming, namelijk vorming van zogenoemde hepatocellulaire altered foci (HAF). 
Hoofdstuk 6 toont data waaruit blijkt dat de in vivo remmende activiteit van nevadensin 
op SULT-enzymactiviteit en op alkenylbenzeen DNA-adductvorming, samengaat met 
een in vivo reductie in vroege markers van carcinogenese zoals HAF. Dit suggereert 
dat een reductie in incidentie van hepatocarcinogeniciteit kan optreden in de lever van 
knaagdieren als nevadensin tegelijk met alkenylbenzenen zou zijn gedoseerd.
Hoofdstuk 7 presenteert een discussie van de in vitro en in vivo activiteit van dieet 
SULT-remmers en hun vermogen om het risico op kanker te reduceren, dat wordt 
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geassocieerd met consumptie van alkenylbenzenen. Dit hoofdstuk beschrijft ook 
enkele toekomstige perspectieven gebaseerd op de voornaamste onderwerpen die 
voortvloeiden uit ons onderzoek.
Alles bijeen tonen de resultaten van dit proefschrift aan dat de waarschijnlijkheid 
van bioactivering en daarop volgende nadelige effecten, mogelijk lager zijn wanneer 
alkenylbenzenen worden geconsumeerd in een matrix die SULT-remmers bevat, zoals 
nevadensin, vergeleken met experimenten die zuivere alkenylbenzenen als enige 
stof gebruiken. Tevens bleken de gevolgen van het in vivo matrixeffect aanzienlijk 
te zijn wanneer estragole of methyleugenol werd getest in knaagdier-bioassays met 
nevadensin in ratio’s die in basilicum zijn gedetecteerd, resulterend in hogere BMDL10 en 
bijbehorende MOE-waarden. De resultaten wijzen er echter ook op dat matrixeffecten 
lager zijn bij blootstellingsniveaus representatief voor een dagelijks humaan dieet van 
estragole of methyleugenol en nevadensin door basilicumconsumptie. Tevens lijken 
matrixeffecten beperkt te zijn bij andere SULT-remmende dieetflavonoïden, zelfs bij 
hoge blootstellingsniveaus aan deze flavonoïden die in supplementen voorkomen. 
Dit toont aan dat het belang van een matrixeffect voor risicoschatting van individuele 
stoffen een analyse vergt van dosis-afhankelijke effecten op de gedetecteerde 
interacties, een doel dat kan worden bereikt door PBBK-modellering te gebruiken. De 
huidige studie geeft een voorbeeld van een benadering die kan worden gebruikt bij 
risicoschatting van botanische toxinen (zoals alkenylbenzenen). In deze benadering 
worden de belangrijkste toxico-kinetische interacties in planten behandeld door 
gebruik van een integrale benadering van in vitro, in vivo en PBBK-modellering.
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